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Abstract                                                                   
 
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase 
(NOS) which is metabolised by two isoforms of the enzyme dimethylarginine 
dimethylaminohydrolase (DDAH). Inhibition of DDAH has been shown to increase ADMA 
concentrations both in vitro and in vivo.  Clinically, high concentrations of ADMA have been 
associated with a range of diseases, particularly cardiovascular disease and more recently 
obesity.  
The role of the NO-ADMA-DDAH pathway has not yet been studied in adipose tissue. This 
thesis sets out to investigate the effects of pathological ADMA exposure firstly on adipocytes 
in vitro and secondly, on whole adipose physiology in vivo.  
In vitro the existence of the NO-ADMA-DDAH pathway was established in the 3T3-L1 cell 
line before investigating the effect of chronic ADMA exposure of their biology. ADMA was 
found to cause adipocyte hypertrophy through mTOR signalling in an NO independent 
manner. 
The effect of elevated ADMA on adipocytes in vivo was investigated through an adipocyte 
specific DDAH1 knockout. These mice developed visceral obesity with adipocyte 
hypertrophy with an increase in mTOR signalling. On a high fat diet there is a large increase 
in intracellular adipocyte ADMA in both knockout and control mice.  
Adipose vasculature is an important regulator of adipose expansion; to investigate the role of 
ADMA in this process an endothelial specific DDAH1 knockout mouse was developed. 
Angiogenesis in these mice is reduced restricting adipose growth in obesity.  
This thesis establishes that the NO-ADMA-DDAH1 pathway to be important in adipose 
physiology. Elevated ADMA in adipocytes and endothelial cells is detrimental to their 
function and increases various factors associated with the metabolic syndrome. 
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Chapter 1: General Introduction                                                 
 
1.1 Adipose Tissue 
1.1.1 Anatomy 
Adipose tissue has long been thought of as a simple storage depot for energy in the 
form of lipids, and as a by product a useful method of insulation in colder climes. 
However, more recently adipose tissue has been identified as a major endocrine 
organ secreting a number of specialised hormones termed “adipokines”. As a result, 
it is now thought that adipose may play a much larger role in energy homeostasis 
and whole body metabolism much of which is still being investigated and is yet to be 
discovered.  
Adipose tissue is made up of approximately 80% adipocytes, specialist fat storage 
cells, which are connected together by a network of collagen and elastin; as a result 
adipose is often described as a connective tissue. The remaining 20% of the tissue 
is predominantly made up of fibroblasts and tissue resident immune cells (figure 1.1). 
Adipose is serviced by an extensive network of capillaries and it is thought that 
almost every adipocyte is in direct contact with a blood vessel (Gersh and Still, 
1945). A limited number of nerve innervations have also been identified as a method 
of centrally regulating adipose homeostasis (Youngstrom and Bartness, 1995). 
Collectively, non-adipocyte adipose resident cells are known as the stromal-vascular 
fraction.  
Two types of adipose tissue exist within mammals, brown adipose and white 
adipose. White adipose tissue (WAT), the focus of this thesis, is the dominant lipid 
store but has further functions affecting energy homeostasis. WAT can be further 
subdivided into two distinct subgroups visceral fat and subcutaneous fat. Visceral fat 
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is found within the peritoneal cavity surrounding organs and includes mesenteric 
(around the intestines), retro-peritoneal (around the kidneys), and epididymal or 
gonadal fat. In extreme obesity epicardial fat is also found in the thorax. Carrying 
large amounts of visceral fat has been linked to an increased risk of developing type 
II diabetes and cardiovascular disease. Subcutaneous fat is found in a layer beneath 
the skin particularly on the limbs and acts as an insulator in cold temperatures. 
 
 
Figure 1.1 :  Histological section demonstrating the microscopic structure of 
adipose tissue.  A: Adipocytes, lipids are lost during fixation leaving a large empty 
space surrounded by a small ring of cytoplasm. BV: A large blood vessel still 
containing circulating blood cells. C: A small capillary travelling between two 




Brown adipose tissue (BAT), a tissue unique to mammals, is so named due to the 
large number of mitochondria found in the cytoplasm giving a brown tinge to the 
cells. In contrast to white adipocytes, brown adipocytes store lipids in multiple 
droplets; however, rather than lipid storage heat production is now thought of as 
brown fats major function. Heat is generated by the mitochondrial protein Uncoupling 
protein-1 (UCP-1) disrupting the electron chain to release energy as heat rather than 
storing it as ATP (Fedorenko et al., 2012). Brown adipocytes are found in much 
smaller depots than white fat with the dominant sites within rodents being the 
interscapular and perirenal areas. Rodents exhibit brown fat throughout development 
and in adulthood; however, in humans brown fat deposits are thought to reduce 
through development although active tissue around the spine has been shown in 
adults (Heaton, 1972; Nedergaard et al., 2007). As the main role of brown adipose is 
thermogenesis and not lipid storage it will not be discussed further in this thesis. 
1.1.2 Differentiation 
Pre-adipocytes reside in adipose depots and differentiate to mature lipid laden 
adipocytes when stimulated, normally in response to increased dietary lipids (Zuk et 
al., 2002). Early in differentiation the CCAAT/enhancer-binding proteins C/EBPβ and 
C/EBPδ are activated and start the transcription of adipocyte related genes (Yeh et 
al., 1995). Next C/EBPα and peroxisome proliferator-activated receptor γ (PPARγ) 
provide a positive feedback loop that supports and maintains differentiation (Wu et 
al., 1996), by targeting a number of specialist adipocyte genes including a glucose 
transporter (Glut4), adipocyte-selective fatty acid binding protein (aP2), fatty acid 
synthase (FASN) and acetyl CoA carboxylase (ACC) (Spiegelman et al., 1993).  A 
fully differentiated white adipocyte contains a large single lipid droplet in its centre 
surrounded by a thin layer of cytoplasm and a very small nucleus.  
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1.1.3 Lipid uptake and storage 
Fat predominantly in the form of triglycerides (TAG) is transported in the blood 
attached to a variety of lipoproteins or in larger chylomicrons. A proportion of lipid 
and glucose intake is utilised immediately by energy hungry cells to produce ATP; 
however, if energy intake outweights energy expenditure excess lipids are 
transported to adipose tissue for storage.  
As TAG-rich lipoproteins and chylomicrons reach adipose tissue they come in 
contact with lipoprotein lipase (LPL, figure 1.2). LPL is generated by adipocytes 
before being transported to the lumen walls of surrounding blood vessels; here LPL 
hydrolises triglycerides to free fatty acids (FA) which then enter the adipocyte 
(Goldberg, 1996; Wang and Eckel, 2009).  Once inside the adipocyte FA’s are 
converted to FA-acetyl CoA by Aceyl-coA synthetase (Kornberg and Pricer, 1953b; 
Weiss et al., 1960).    
Glucose enters the cell by way of a glucose transporter, specifically the GLUT4 
transporter in adipocytes (James et al., 1989). Upon entering the cell glucose is 
converted to glycerol-3-phosphate. FA’s and glycerol-3-phosphate are brought 
together though esterification to form first diacylglycerol before finally being 
converted into triacylglycerol (Kornberg and Pricer, 1953a). TAG then enters the lipid 
droplet, which is contained by a single layer of phospholipids around its outside 
supported by a number a proteins from the PAT family predominantly perilipin but 
also ADRP and TIP47 (Greenberg et al., 1991). By sequestering TAG in adipocytes 
this provides not only an energy store but also a protective mechanism bypreventing 







Figure 1.2: Glucose and fatty acids are taken up into the adipocyte and 
combine to form triglycerides; these are moved into the lipid droplet for 
storage. Lipid droplets are surrounded by scaffolding proteins from the PAT 
family. Triglyceride storage is upregulated through the insulin receptor. LPL – 




Fatty acid and glucose storage are regulated by a number of pathways and 
signalling molecules, the most prominent of which is insulin. Insulin acts via the 
insulin receptor signalling to increase Glut4 translocation to the membrane thereby 
increasing glucose uptake (Suzuki and Kono, 1980). It also increases fatty acid 
uptake by upregulating LPL transcription (Semenkovich et al., 1989), and activity 
(Raynolds et al., 1990).  
Other hormones such as thyroid, growth and sex steroids are all also thought to play 
a regulatory role in TAG synthesis and circulating catecholamines are known to 
down-regulate LPL activity reducing fatty acid production (Raynolds et al., 1990). 
Environmental factors can also regulate lipid storage including whether the individual 
is in a fed or fasted state. A stress environment is also thought to down-regulate LPL 
activity through the upregulation of catecholamines (Ricart-Jane et al., 2005). 
 
1.1.4 Lipolysis and release 
In a fasted or nutrient poor environment lipolysis, the breakdown of triglycerides, is a 
major regulator of lipid storage and maintains a supply of energy to actively 
metabolising cells (figure 1.3). Hormone-sensitive lipase (HSL) is considered the 
instigator of lipolysis as it starts the process of breaking TAG back into fatty acids 
and glycerol (Vaughan et al., 1964). It is known as ‘hormone sensitive’ as 
catecholamines stimulate its translocation to the lipid droplet through 
phosphorylation by protein kinase A (PKA).  However, PKA must also phosphorylate 
residues on perilipin, the lipid droplet scaffolding protein, before HSL can dock 
(Zhang et al., 2003). On lipolysis free fatty acids go on to provide energy for any cell 
type but predominantly to skeletal muscles, the heart and the liver. Glycerol is moved 






Figure 1.3:  Lipolysis of triglycerides is stimulated by catecholamines at 
adrenoceptors stimulating cAMP production and protein kinase A (PKA) 
activity. PKA phosphorylates perillipin and hormone sensitive lipase (HSL) 




Insulin is a major regulator of lipolysis, where in the fed state it inhibits cAMP 
production and therefore blocks HSL phosphorylation (Choi et al., 2006). In contrast 
the cytokine TNFα increases lipolysis, one of the mechanisms through which it does 
this is by the degradation of perilipin thereby increasing HSL access to TAG 
(Rosenbaum and Greenberg, 1998). 
 
1.1.5 Adipokines 
Adipose tissue has always been thought of as a lipid storage tissue, but more 
recently it has also been described as an endocrine organ producing a number of 
specialised “adipokines”.  
Leptin, originally known as the OB protein (Halaas et al., 1995), is an important 
regulator of energy intake, and therefore body composition, and was the first 
adipokine to be identified. Leptin is transcribed from the obese (ob) gene  which is 
expressed only in adipocytes (Zhang et al., 1994). When the ob gene is mutated as 
in the ob/ob mouse a phenotype of massive obesity is observed, which can be 
reversed by infusing leptin (Halaas et al., 1995). A second mouse model the db/db 
mouse develops a very similar level of obesity but one that cannot be reversed by 
leptin. This is due to a mutation in the leptin receptor that inhibits all downstream 
signalling of leptin secretion (Chen et al., 1996; Lee et al., 1996).   
Leptin is released from adipocytes as a long-term regulator of energy storage rather 
than in the short-term after nutrient intake. When released leptin binds to leptin 
receptors predominantly in the hypothalamus but also in vascular endothelial cells 
(Lee et al., 1996). In the hypothalamus leptin promotes a feeling of satiety, reducing 
nutrient consumption predominantly through the regulation of neuropeptides and 
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pituitary hormones (Friedman and Halaas, 1998); while in blood vessels it affects 
vasodilation and angiogenesis (Lembo et al., 2000; Park et al., 2001).     
 The adipoQ gene was also discovered to be specifically expressed in adipocytes 
and again produces a circulating protein, originally termed the adipoQ product (Hu et 
al., 1996) or Acrp30 (Scherer et al., 1995), but now known as adiponectin (Arita et 
al., 1999). Adiponectin is the most abundant hormone secreted by white adipocytes 
and makes up about 0.01% of all circulating proteins (Vaiopoulos et al., 2012). 
Adiponectin receptors are expressed on adipocytes suggesting paracrine signalling 
but also widely expressed in the liver, skeletal muscles and blood vessels. 
Adiponectin sensitises tissues to insulin through AMPK and PI3K signalling (Deepa 
and Dong, 2009) and therefore is thought to be anti-diabetic. In the liver this pathway 
stimulates fatty acid oxidation and a decrease in fatty acid and glucose synthesis 
(Brochu-Gaudreau et al., 2010). In the cardiovascular system adiponectin is thought 
to improve vascular reactivity and act an anti-atherosclerotic agent inhibiting smooth 
muscle proliferation (Matsuda et al., 2002) and reducing endothelial inflammation 
(Ouchi et al., 2003). 
A number of other adipokines have been identified including resistin (Steppan et al., 
2001), adipsin (Cook et al., 1987) and vaspin (Hida et al., 2005). However, at 
present their importance in adipose physiology is unknown. As well as adipocyte-
specific hormones adipocytes also produce a number of cytokines, inflammatory 
signalling molecules produced by a wide range of cell types, including Interleukins -6 
and -8 (Bruun et al., 2001; Mohamed-Ali et al., 1997), transforming growth factor – β 
(TGF-β)  and tumour necrosis factor- α (TNF-α) (Hotamisligil et al., 1993). The action 
of TNF-α is the most studied of these cytokines and is thought to have negative 
effects on insulin resistance. Although adipocytes themselves produce TNFα the 
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stromal-vascular fraction is thought to be the major contributor to adipose TNFα 
production (Weisberg et al., 2003). TNFα signalling in adipocytes causes 
transcriptional changes altering lipolysis, insulin signalling and adipokines production 
(Cawthorn and Sethi, 2008). 
 
1.1.6 Methods for studying adipocyte physiology   
The study of molecular mechanisms in adipocytes has been hampered by the fact 
that mature primary adipocytes are difficult to culture; as they are full of lipid they 
float above any culture media rather than being maintained as suspension or 
adherence cultures. One method to work around this is the ‘ceiling culture’ of primary 
adipocytes, where culture flasks are filled with media and turned upside down so the 
adipocytes adhere to the treated side of the flask (Sugihara et al., 1986; Zhang et al., 
2000). Although this method allows for microscopy analysis of primary cells they are 
thought to regress towards a fibroblast phenotype and therefore may not display 
‘normal’ adipocyte physiology.  
Due to the difficulties with primary cells a number of alternative methods have been 
developed including the culture and differentiation of pre-adipocytes and 
mesenchymal stem cells (Bennett et al., 1991). These adipocytes can grow adhered 
to culture plates and resemble primary adipocytes in their biology; however their use 
has been limited by the need to isolate these cells from bone marrow.  
The third method to investigate adipocytes in vitro is through the use of the 3T3-L1 
cell line. First isolated by Green and Kehinde in 1974 from a 3T3 culture the 3T3-L1 
cell line spontaneously accumulates lipids over a number of weeks turning into an 
adipocyte-like cell. If treated with a mix of insulin, glucocorticoids, and a cAMP 
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elevator the duration of differentiation is decreased dramatically to a two week period 
(Green and Meuth, 1974). Although mature 3T3-L1 cells develop many intracellular 
lipid droplets rather than a single droplet, they have been extensively characterised 
and have very similar biology to primary adipocytes. As a result they are widely used 




1.2 Nitric oxide in adipose physiology 
1.2.1 Discovery 
In 1980 Furchgott and Zawadzki accidently discovered that the presence of 
endothelial cells in the aorta was necessary for its relaxation in response to 
acetylcholine (Ach). Vessels where the endothelium was unintentionally removed did 
not respond to Ach as expected and could not maintain the same level of relaxation 
as when it was still present. It was therefore assumed that endothelial cells produced 
a substance that in turn acted on smooth muscle cells propagating Ach signalling. As 
the identity of this substance was unknown they named it endothelium derived 
relaxing factor (EDRF) (Furchgott, 1983). 
At the same time both Ferid Murad’s and Louis Ignarro’s laboratories showed that 
the gas nitric oxide (NO) relaxed vascular smooth muscle by the upregulation of 
cyclic guanoside monophosphate (cGMP) production (Gruetter et al., 1979; Gruetter 
et al., 1981; Murad et al., 1978). Furthermore, Rapoport and Murad (1983) indicated 
that treatment with Ach elicited an increase in smooth muscle cGMP via action on 
the endothelium in the same way that nitrogenous compounds did. 
It was not until 1987 however, that these two facts were connected when Salvador 
Moncarda’s lab demonstrated that EDRF and nitric oxide were one and the same 
(Hutchinson et al., 1987). Nitric oxide release from endothelial cells was stimulated 
by bradykinin to the same degree as EDRF had been previously. Further evidence 
for this theory was provided by Ignarro’s lab (Chaudhuri et al., 1988) who 
demonstrated that NO reacted with haemoglobin in the same fashion as EDRF. 
Thereafter it was identified that a wide range of vasodilators act through the release 
of NO in endothelial cells which diffuses to the smooth muscle where it upregulates 
of cGMP signalling and muscle relaxation.  
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1.2.2  Production 
The production of NO is catalysed by the nitric oxide synthase (NOS) family of 
enzymes. The enzymes modulate the oxidation of L-arginine in the presence of 
NADPH to release NO and L-citrulline (Palacios et al., 1989; Vallance et al., 1989). 
L-citrulline can then be recycled back to L-arginine via argininosuccinate synthase 
and argininosuccinate lysase thereby providing further substrate for NO production.  
Three isoforms of NOS have been identified and vary by tissue specificity and 
activation and are encoded by three different genes. Endothelial (eNOS/NOS3) and 
neuronal (nNOS/NOS1) isoforms, named after the tissue in which they were first 
identified, are both constitutively expressed (Lamas et al., 1992; Nishida et al., 
1992). They have a wide tissue distribution and are thought to provide basal NO 
production in physiological signalling pathways.  
The third inducible isoform (iNOS/NOS2) is found predominantly in immune cells but 
is also found in other cell types in response to an inflammatory stimulus. The 
transcription of iNOS is strongly upregulated in an immune response allowing for a 
rapid increase in NO production (Xie et al., 1992). 
1.2.3 Signalling 
The most extensively studied role of NO is in the relaxation of blood vessels as this 
is where it was first discovered. Here NO is generated in the endothelium before it 
diffuses into smooth muscle cells. Within the smooth muscle NO reacts with haem 
molecules soluble guanylyl cyclase thereby activating the protein and increasing 
cGMP production (Murad et al., 1978). Elevated concentrations of cGMP activate 
protein kinase G (PKG) which has a number of downstream targets which control 
muscle relaxation (Rapoport and Murad, 1983). It is this pathway that is considered 
to be canonical, although NO signals via a number of different mechanisms in many 
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cell types (figure 1.4); and this list was added to further by the generation of NOS 
knockout mice.   
When eNOS knockout mice were developed they were found, as expected, to have 
hypertension with an increase in blood pressure of approximately 20mmHG (Huang 
et al., 1995; Shesely et al., 1996).  But these mice also had more subtle phenotypes 
for example in the cardiovascular system regulation of muscle proliferation and 
endothelial permeability (Moroi et al., 1998).  
Neuronal NOS (nNOS) is found predominantly within neurons and glial cells, 
although it is also present within the heart and skeletal muscle (Knott and Bossy-
Wetzel, 2009). NO in the brain is thought to act as a neurotransmitter and nNOS 
knockout mice have been found to have deficient memory and cognitive 
performance (Weitzdoerfer et al, 2004). However, the most noticeable phenotype 
found in these mice were enlarged stomachs due to the lack of nNOS in the gut 
sphincter and therefore an inability to correctly control muscle relaxation in the 
digestive tract (Huang et al., 1993).  
Nitric oxide is also a powerful molecule in the immune system where it is produced 
by iNOS. Circulating leukocytes express iNOS as part of the innate immune system 
where large quantities of NO are produced quickly to act as a bactericidal and anti-
viral; iNOS-/- mice are particularly susceptible to infection (Wei et al., 1995). NO also 






Figure 1.4:  Nitric Oxide is produced by three nitric oxide synthase enzymes: 
eNOS, nNOS and iNOS. These generate NO in a wide range of cell types and 
allow NO to regulate a large number of physiological pathways including those 
in the cardiovascular, immune and nervous systems 
 
When triple NOS knockout mice were developed it was expected to be lethal in 
utero. However, offspring are born although 80% have died by around 10 months of 
age. They show a general increase in age-related phenotypes compared to single 
NOS knockouts and death is mainly caused through spontaneous myocardial 
infarction and diabetes insipidus (Tsutsui et al., 2006). 
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1.2.2 NO in adipocytes 
Nitric oxide is produced in adipocytes predominantly by eNOS but also by iNOS 
during adipose inflammation.  NOS expression was first demonstrated in rat followed 
by human isolated white adipocytes (Andersson et al., 1999; Engeli et al., 2004; 
Ribiere et al., 1996). The 3T3-L1 cell model also expresses eNOS (Tanaka et al., 
2003), but reports on iNOS seem to be variable and is likely to depend on the 
inflammatory state of the cells.  Neuronal NOS expression has not been detected in 
any white adipose depot (Engeli et al., 2004). The downstream signalling enzymes 
soluble guanylyl cyclase and Protein Kinase G are both expressed adipocytes.  
Mature adipocytes differentiate from pre-adipocytes both in adipose tissue depots 
and in 3T3-L1 cultures. Yan et al (2002) suggest that both exogenous NO and the 
NOS substrate L-arginine increase pre-adipocyte differentiation to mature adipocytes 
with no effect on proliferation and causes a corresponding increase in triglycerides 
and lipoprotein lipase activity. NO has also been shown to increase brown fat 
differentiation (Nisoli et al., 1998). In contrast Kawachi et al (2007) suggest that NO 
suppresses differentiation in 3T3-L1 cells in a dose dependent manner; with a 
corresponding decrease in triglycerides and staining with the lipid dye oil red O.   
The role of NO in lipid metabolism has not been intensively investigated and is 
currently confused. Gaudiot et al (1998) found that nitrosothiol NO donors but not 
other NO donors increase the rate of basal lipolysis in isolated rat adipocytes. They 
suggest that this effect is not through cGMP signalling but rather through the S-
nitrosylation of phosphodiesterase and an increase in intracellular cAMP 
concentrations. In contrast Andersson et al (1999) found NOS inhibition increased 
lipolysis in human adipose tissue while NO gas and the NO donor nitroglycerine 
reduced basal and adrenergic stimulated lipolysis respectively. Klatt et al. (2000) 
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also report a decrease in adrenergic stimulated lipolysis in the presence of the NO 
donor DEA/NO with no effect on basal lipolysis. Again they suggest that NO’s effect 
was not via cGMP but rather interferes with isoproterenol binding at the β3-
adrenoceptor by direct oxidation of the compound. All these results must be 
interpreted carefully as both high concentrations of NO and total NOS inhibition are 
unlikely to reflect physiologically relevant regulation of lipolysis. Further work is 
necessary to determine the physiological consequences on NO on lipid mobilisation 
in vivo.  
Nitric oxide is thought to affect adipokine production and function. Adiponectin 
secretion is decreased in both 3T3-L1 cells transfected with eNOS siRNA and in 
eNOS-/- knockout mice (Lee et al., 2010a). Adiponectin synthesis requires large 
amounts of energy and NO inhibition is thought to down-regulate mitochondrial 
biogenesis and activity (Nisoli et al., 2003) therefore limiting the amount of 
adiponectin that can be produced. Reduced adiponectin secretion in eNOS-/- mice 
has been confirmed by Nakata et al. (2008). Adiponectin itself also affects eNOS 
activity through the phosphorylation of serine 1177 via AMPK signalling (Ouchi et al., 
2004). Furthermore adiponectin-/- mice have reduced expression of eNOS in 
endothelial cells (Ohashi et al., 2006).   
Nitric oxide is also thought to regulate leptin secretion (Unno et al., 2006). The 
exogenous NO donor NOC 7 decreased leptin secretion in a dose dependent 
fashion. Endogenous NO produced by iNOS in response to LPS stimulation has a 
similar effect which can be reversed with NOS inhibitors. This suggests that during 
adipose inflammation leptin secretion may be decreased due to the increased 
activity of the NO pathway. 
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1.3 Nitric Oxide Regulation 
 
As discussed above NO is an important signalling molecule with a wide range of 
physiological targets. Due to this complicated biology the production of NO needs to 
be highly regulated. As a result NOS has a large number of enzymatic co-factors as 
well as a range of regulatory pathways.   
1.3.1 Cofactors 
Each NOS isoform has a number of enzymatic co-factors that are necessary for 
maximal activity (figure 1.4). Early studies of NO and smooth muscle relaxation 
indicated that Ca2+ was necessary for NO action (Singer and Peach, 1982). When 
Ca2+ enters a cell it can bind to calmodulin (calcium-modulated protein), this 
propagates Ca2+ signalling by interacting with a wide range of protein molecules 
(Chin and Means, 2000). It was found that calmodulin binding to NOS was an 
intermediate step between calcium signalling and NO release (Bredt and Snyder, 
1990). As these early studies often isolated NOS from the endothelium or brain the 
action of calmodulin was found to be important eNOS and nNOS regulation. 
However, iNOS does not rely on calcium signalling as calmodulin is permanently 
bound to the enzyme allowing NO to be produced immediately (Cho et al., 1992).   
A second cofactor for NOS activity was identified as tetrahydrobiopterin (BH4) which 
is thought to mediate the n-hydroxylation of L-arginine, an early step in the 
conversion of arginine to citrulline (Tayeh and Marletta, 1989). The production of NO 
relies on a five-step electron chain relying on a number of other cofactors. Electrons 
moving from nicotinamide adenine dinucleotide phosphate (NADPH) to flavin 
adenine dinucleotide (FAD) to flavin mononucleotide (FMN) to haem which 
encourages the recruitment of O2 to the enzyme, which acts as the final electron 
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acceptor (Liu and Gross, 1996). NOS activity can also be negatively regulated 
through the interaction of zinc or copper at the active site and inhibiting enzyme 
action (Perry et al., 2000; Persechini et al., 1995). 
 
 
Figure 1.5:  Nitric Oxide Synthase activity is regulated by a number of 
cofactors including haem molecules, tetrahydrobiopterin (BH4), zinc, and Ca2+-
Calmodulin. Adapted from Vallance and Leiper, 2004.  
1.3.2 Methylarginines 
Although the activity of the NOS enzymes relies on the involvement of co-factors as 
described above NO production is also regulated by a number of other mechanisms. 
The extent of enzyme expression is controlled by both transcription and translation, 
while phosphorylation and cellular location are important for enzyme activity. 
However, the regulatory mechanism focussed on in this thesis is through the 
competitive inhibition of L-arginine binding by structurally similar molecules, the 
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endogenously produced methylarginines. The action of methylarginines on NOS is 
particularly interesting as currently no other endogenous inhibitors of any enzyme 
are known to exist. Furthermore, methylarginine concentrations have been found to 
correlate with cardiovascular disease and are independent risk factors for disease 
progression; therefore understanding their mechanism of action and their role in 
physiology and pathology is important. (Leiper and Nandi, 2011). 
The addition of methyl groups to the guanidino residues of arginine is a common 
post-translational modification and epigenetic marker (Pahlich et al., 2006). Arginines 
can be either mono-methylated (L-NMMA, figure 1.6) or di-methylated on either the 
same guanidino group (asymmetric dimethylarginine, ADMA) or one on both 
guandino group (symmetric dimethylarginine, SDMA) with the reactions catalysed by 
the protein arginine methyltransferase (PRMT) family of enzymes (Bedford and 
Clarke, 2009).  
 The PRMT family of enzymes is sub-divided into two groups - type I and type II. 
Both groups catalyse the formation of L-NMMA which is thought to be an 
intermediate product for further methylation. Type I PRMT’s include PRMT 1, 3 and 4 
(also known as CARM 1) and produce ADMA via a second methylation step; 
whereas type II enzymes, of which PRMT 5 and 7 are the major isoforms, produce 
SDMA. Given that all methylarginines are produced in this way levels of PRMT 
expression and activity are important determinants of methylarginine concentrations.  
There is no known enzyme for the demethylation of arginine within proteins and as a 
result after proteolysis free methylarginines are found within the cytoplasm and 
blood. L-NMMA was first noted to inhibit NO production and vascular relaxation by 
Salvador Moncada’s lab in the late 1980’s (Palmer et al., 1988; Rees et al., 1989) 
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who suggested that due to L-NMMA’s structural similarity to L-arginine, there might 
be competitive inhibition occurring.  Following this ADMA was also identified as an 
inhibitor of NO production and as it occurs at higher concentrations in plasma is 
thought to be the more important isoform (Vallance et al., 1992b). In contrast SDMA 
has no effect of NO production, although cannot be utilised by NOS as a substrate 
for NO.   
Through biochemical experiments the asymmetric methylarginines have been shown 
to be competitive inhibitors for all NOS enzymes. The Ki of both ADMA and L-NMMA 
against eNOS has been calculated as 0.9μM and 1.1μM respectively while the K i for 
nNOS is lower at 0.67μM and 0.5μM (Cardounel et al., 2007; Cardounel and Zweier, 
2002). L-NMMA has been shown to have a much higher Ki for iNOS at 3.9μM (Reif 
and McCreedy, 1995). Although the concentrations needed for inhibition are higher 
than plasma concentrations in healthy humans at 0.5μM for ADMA (Teerlink, 2007), 
intracellular concentrations of methylarginines are thought to be much higher and 
therefore capable of blocking NO production (Cardounel and Zweier, 2002; Teerlink 
et al., 2009). However, due to the competitive nature of the antagonism by ADMA 
and L-NMMA inhibition can be overcome by the addition of excess L-arginine 
(Böger, 2007). 
Blockade of NOS by ADMA is also thought to increase the production of reactive 
oxygen species (ROS). When concentrations of L-arginine are low NOS can catalyse 
the production of superoxide (O2-) rather than NO, and this process is known as 
NOS uncoupling (Pou et al., 1992). Furthermore O2- is capable of reacting with NO 
itself producing peroxynitrite (ONOO-). Both O2- and ONOO- are ROS thought to play 
important roles in cell damage and disease. High concentrations of ADMA are 
thought to promote NOS uncoupling as increasing concentrations of ADMA correlate 
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with superoxide production (Boger et al., 2000). ADMA has been shown to uncouple 
all three isoforms of NOS, eNOS, nNOS and iNOS; and perhaps be important in 
atherosclerosis and lung injury (Antoniades et al., 2009; Cardounel et al., 2005; 
Sharma et al., 2010; Wells and Holian, 2007). 
 
Figure 1.6:  The chemical structures of L-arginine and its methylated 
isoforms; L-Ng mono-methylated arginine (L-NMMA), symmetric dimethylated 
arginine (SDMA) and asymmetric dimethylated arginine (ADMA). Figure adapted 





1.3.4 DDAH  
Arginine methylation and protein degradation are constitutive processes; therefore 
intracellular ADMA concentrations would become toxic if allowed to accumulate. As 
a result, ADMA concentrations are kept constant by a combination of renal excretion 
and enzymatic breakdown. ADMA can be transported into the blood by a number of 
membrane proteins including cationic amino acid (CAT) and y+LAT transporters 
(Closs et al., 2012; Strobel et al., 2013) before approximately 15% of it is removed 
by the kidney (Achan et al., 2003). However, the majority of ADMA is metabolised 
within cells by dimethylarginine dimethylaminohydrolase (DDAH, figure 1.7). 
ADMA and L-NMMA, but not SDMA, were first noted to be broken down in rats to L-
citrulline and dimethylamine by Ogawa et al. (1987b), and it was later recognised 
that this reaction was metabolised by DDAH with a Km of 0.18mM (Ogawa et al., 
1987a). However, it was not until after ADMA’s role in NO synthesis became 
apparent that further investigation into the enzyme occurred showing it too was an 
important regulator of NOS (MacAllister et al., 1996). A second isoform of DDAH, 
DDAH2, was later identified (Leiper et al., 1999) and the two isoforms are widely 
expressed in vivo (Tran et al., 2000). Although the expression pattern has not been 
fully characterised at present DDAH1 is thought to be the predominant form in the 
vasculature, liver and kidney, while DDAH2 is found in the immune system. 
A third enzyme alanine-glycoxylate amino transferase (AGXT-2) which is thought to 
be expressed only in the kidney converts ADMA to α-keto-δ-(NG,NG-
dimethylguanidino) valeric acid (DMGV) (Martens-Lobenhoffer et al., 2011; Rodionov 
et al., 2010). Originally it was thought to be of lesser importance than DDAH 
however, recent genetic studies have shown that AGXT-2 knockouts have raised 




Figure 1.7:  The NOS-ADMA-DDAH pathway. Methylation of arginine is 
catalysed by PRMT enzymes, which are then released into cytoplasm and 
plasma after proteolysis. Assymetric dimethylarginine (ADMA) and 
monomethyl arginine (L-NMMA) can competitively inhibit NO production and 
therefore concentrations are regulated by the enzymes DDAH1 and 2. 
 
1.3.3 ADMA and DDAH in adipocyte function 
PRMT expression in adipocytes has been identified at the RNA level with PRMT4 
suggested to be the most abundant isoform although PRMT1, 2 and 3 mRNA has 
also been identified (Spoto et al., 2007). At a functional level only PRMT1 in adipose 
and PRMT4 (CARM1) in 3T3-L1 cells have been shown to be present by western 
blotting (Iwasaki, 2012; Yadav et al., 2008). PRMT4 knockdown decreases 3T3-L1 
cell differentiation and it is thought to act as a co-activator at sites of PPARγ 
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transcriptional regulation (Yadav et al., 2008). As of yet the expression of PRMT’s in 
isolated primary adipocytes have not been investigated.  
The presence of PRMT’s in adipocytes suggests that ADMA is synthesised in this 
cell type. At present it has been shown that ADMA interrupts glucose uptake and 
Glut4 translocation at the super-physiological concentration of 100μM in 3T3-L1 cells 
(Yang et al., 2009) through the production of ROS that disrupt insulin signalling. It 
has also been suggested that ADMA increases lipolysis and cytokine production in 
3T3-L1 cells (Zhou et al., 2009) by causing endoplasmic stress. 
Recently it has been suggested that DDAH is present within white adipose tissue 
(Spoto et al., 2007), with both DDAH isoforms expressed as mRNA transcripts. 
Currently, it is unknown what role DDAH has in adipocyte physiology and one of the 
main aims of this thesis is to investigate its expression and activity in normal healthy 
adipocytes and adipose tissue. Further to this there is also relatively little known 
about the effects of ADMA on adipocyte function and whether increasing 
concentrations of ADMA can alter normal metabolic processes. Therefore, 





As with any system or tissue, adipose function can undergo pathological changes. 
Although diseases where adipose tissue wastes away, ‘lipidystophies’, do occur this 
thesis will focus on obesity, the increased storage of fat and the resultant expansion 
of adipose tissue.  
Obesity occurs when the balance between energy intake and expenditure shifts in 
favour of energy intake. As an excessive amount of fat and sugar is taken in from the 
diet it cannot be utilised immediately and is therefore stored for a future when 
nutrients may not be as accessible. However, in the modern western world there is 
rarely a shortage of nutrients and therefore energy storage continues.  
In obesity adipose tissue expands to accommodate fat intake in two ways. Firstly, 
existing adipocytes undergo hypertrophy increasing the fat stored in each individual 
cell. Secondly, pre-adipocytes proliferate and differentiate to mature lipid laden cells. 
However, although the tissue adapts to store increasing amounts of lipid, very large 
adipocytes do not function as normal and adipose tissue does not remain healthy. 
Globally the World Health Organisation considered 21% of the adult population to be 
obese as of 2008 (WHO, 2013). As a result, obesity and its associated diseases 
costs the British National Health Service approximately £5 billion a year (DoH, 2013). 
To aid public understanding of when an individual becomes overweight or obese a 
number of simplistic measures have been introduced. The Body Mass Index (BMI) 
considers an individual’s mass (kg) divided by their height (m) squared. Individuals 
with a BMI >25 are considered to be overweight while those >30 are clinically obese. 
However, BMI is over simplistic relying too heavily on an individual’s height and not 
taking into account where the fat is being deposited. Subcutaneous fat stored 
particularly on the hips and limbs is not thought to be a predictor for diabetes and 
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cardiovascular disease; in contrast and increase in visceral fat stored around organs 
within the abdomen is considered far more dangerous. As a result a second 
measure was developed measuring the hip-to-waist ratio. In women a ratio above 
0.85 and in men above 1.0 is considered to put the individual at risk.   
1.4.1 Altered Adipokine Secretion 
In obese adipose tissue Hu et al. (1996) established that the amount of adiponectin 
mRNA in rodents and humans was significantly less than in healthy subjects. 
Following this it was confirmed that circulating concentrations of adiponectin were 
also lower in obese individuals (Arita et al., 1999). The mechanism through which 
adiponectin production and secretion is reduced is not currently understood although 
it is closely correlated with insulin resistance; therefore, it has been hypothesised 
that insulin signalling alters adiponectin production (Weyer et al., 2001). Low 
adiponectin concentrations have a range of consequences including poor endothelial 
function (Tan et al., 2004), and increased inflammation (Engeli et al., 2003) and is 
therefore thought to be a major factor in the development of cardiovascular disease. 
 Plasma leptin concentrations increase in correlation with fat mass (Frederich et al., 
1995) due to its involvement in regulating energy intake.  Leptin is regulated by both 
insulin and glucocorticoids both of which are increased in obesity and therefore may 
be behind leptin upregulation (Guerre-Millo, 1997).  Although leptin secretion 
increases it does not stop food intake as adipose expansion continues and obese 
individuals are often thought of as ‘leptin resistant’.  
1.4.2 Inflammation 
Obesity is associated with chronic inflammation including an influx of macrophages 
into the visceral adipose (Weisberg et al., 2003; Xu et al., 2003). Large adipocytes 
produce monocyte chemoattractant protein-1 (MCP-1) and other cytokines that 
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signal to macrophages to infiltrate the tissue. Altered metabolic signalling in obesity 
increases free fatty acid concentrations in adipose tissue again acting as a 
chemoattractant (Kosteli et al., 2010). As adipose expands there is considerable 
tissue remodelling which leads to adipocyte death (Strissel et al., 2007); 
macrophages surround dead and dying cells clearing both lipids and cellular 
material. Here they form areas known as ‘crown-like structures’ where many immune 
cells merge to become a many-nucleated cell (Cinti et al., 2005). Finally, adipose 
tissue becomes hypoxic due to a combination of poor vascularisation and overly 
large adipocytes; this upregulates HIF-1 signalling again increasing macrophage 
motility. 
As well as macrophages the adipocytes themselves become increasingly 
inflammatory producing high concentrations of cytokines including TNFα, IL-6 and 
MCP-1.  Increased cytokine production is thought to contribute to chronic adipose 
inflammation and be a major driver in the development of obesity-associated insulin 
resistance. At high concentrations TNFα alone can reduce adipocyte glucose uptake 
by inhibiting insulin signalling and Glut-4 expression (Feinstein et al., 1993; 
Hotamisligil et al., 1993).  
It is important to note that only some adipose depots are thought to be involved in 
insulin resistance. The enlargement and inflammation of visceral fat (Gastaldelli et 
al., 2002) is a greater risk factor for insulin resistance than the expansion of 
subcutaneous fat. In fact some studies report that very little inflammation occurs in 
subcutaneous fat at all (Xu et al., 2003).  
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1.4.3 Plasma Lipids 
As obese individuals tend to consume a diet rich in fat they have higher circulating 
concentrations of triglycerides and free fatty acids (FFA); furthermore enlarged 
adipocytes also release high concentrations of FFA contributing to concentrations in 
the blood stream (Bjorntorp et al., 1969; Reaven and Chen, 1988). An excess of FFA 
results in ectopic lipid storage either in cells other than adipocytes or by the 
differentiation of adipocytes at sites were they are not normally found. Skeletal 
muscle, liver and the heart all take up fatty acids to use as energy via β-oxidation. 
However, when this process becomes overloaded lipid is stored within these cells 
and disrupts insulin signalling, reducing peripheral glucose uptake and metabolism 
(Boden et al., 1994; Boden et al., 2002; Snel et al., 2012).    
1.4.4 Metabolic syndrome  
Visceral obesity, due to metabolic changes in adipokine secretion, inflammation and 
circulating lipids, rarely occurs alone. Rather it is normally associated with a number 
of other pathologies including dyslipidemia, high triglycerides or a poor cholesterol 
profile, insulin resistance and cardiovascular disease. Together these are known as 
the metabolic syndrome (Alberti et al., 2005).  
The increase in inflammation and fatty acids discussed above leads to poor insulin 
signalling in skeletal muscle, liver and adipose tissue and therefore glucose uptake 
and handling in these tissues becomes diminished causing individuals to develop 
insulin resistance.  
Increased inflammation and fatty acids also play a major role in the development of 
obesity related cardiovascular disease. Raised circulating lipids result in fatty 
depositions within blood vessel walls which can develop into atherosclerotic plaques 
leading to a risk of blot clot formation.   
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1.5 NO and ADMA in pathology 
1.5.1 Nitric Oxide in pathology 
As nitric oxide is necessary in many signalling pathways its dysregulation, either over 
or under production, have pathological consequences. As a result NOS dysfunction 
has been implicated in a many diseases.  
Reduced eNOS signalling in blood vessels is often thought to be a major factor in 
endothelial dysfunction. Consistent with this overexpression of eNOS has been 
shown to protect against myocardial and hepatic reperfusion injury (Duranski et al., 
2006; Jones et al., 2004), and vascular lesions (Kawashima et al., 2001). 
1.5.2 Nitric Oxide in obesity 
A systemic reduction in NO signalling is thought to be a symptom of human obesity, 
particularly in the vasculature where increased inflammation, plasma lipids and 
decreased adiponectin secretion down regulate NO production (Kim et al., 2008; 
Ohashi et al., 2006; Rizzo et al., 2010). It is this endothelial dysfunction that is 
thought to be a major cause of obesity related cardiovascular disease. However, NO 
signalling is also reduced in other tissues such as skeletal muscle (Hickner et al., 
2006) and the kidney (Li et al., 2005). 
The role of NO in obese adipose tissue itself is more confused. In human obesity 
eNOS expression in adipose tissue is upregulated (Elizalde et al., 2000; Engeli et al., 
2004; Galvin et al., 2005) although it is unknown whether this is associated with an 
increase in local NO production. In contrast, rodent models of diet induced obesity 
show a significant reduction in eNOS expression and phosphorylation in visceral fat 
(Handa et al., 2011; Moraes et al., 2003; Sansbury et al., 2012). Interestingly eNOS 
expression is also reduced in other models of obesity including db/db mice 
(Sansbury et al., 2012). The mechanism by which eNOS expression is upregulated 
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in human, or down-regulated in mouse adipose has not yet been fully investigated 
although TNFα has been implicated in reducing eNOS activity (Valerio et al., 2006).  
By studying eNOS knockout mice a number of consequences of disrupted NO 
signalling in adipose have been established. Nakata et al (2008) found that on a 
normal chow diet eNOS-/- mice have visceral obesity with increased epididymal and 
retro-peritoneal depots. On further investigation adipocytes from eNOS-/- animals 
were found to be significantly larger than controls. Interestingly, neither nNOS or 
iNOS knockouts replicated this phenotype but all three knockout strains do have 
increased plasma triglycerides and reduced adiponectin secretion suggesting that 
other NOS isoforms can play a role in adipocyte function.    
As discussed previously inflammation is an important consequence of obesity. 
Handa et al (2011) identified increased inflammation and adipocyte cytokine 
production including MCP-1, TNFα and IL-6 on both normal and high fat diets in the 
adipose tissue of eNOS-/- mice. Insulin resistance has also been identified in these 
mice (Duplain et al., 2001; Nakata et al., 2008).  
Overexpression of eNOS within the vasculature inhibited weight gain after high fat 
feeding with lower levels of adiposity and less adipocyte hypertrophy (Sansbury et 
al., 2012). Their metabolic profile was also improved, all thought to be due to 
increased mitochondrial activity.  
Within obese human adipose tissue increased iNOS expression has also been 
established (Elizalde et al., 2000; Engeli et al., 2004). The same has been detected 
in mice (Weisberg et al., 2003) however, it is though that this is predominantly 
through iNOS expression in macrophages rather than adipocytes. Increased iNOS 
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activity can lead to increased concentrations of plasma nitrites and nitrates even 
though vascular eNOS activity is reduced (Noronha et al., 2005).  
1.5.3 ADMA and DDAH1 in pathology 
Elevated plasma ADMA concentrations have been negatively associated with a wide 
range of diseases. The definition of ‘elevated’ plasma ADMA varies greatly between 
clinical studies and often largely depends on the method of measurement used; 
however, healthy ADMA concentrations are maintained at around 0.5μM, an 
increase towards 1μM is considered pathological with a possibility of effecting NO 
production (Teerlink et al., 2009).  
A brief summary of diseases which are correlated with increased plasma ADMA are 
shown in table 1.1.  Raised ADMA was first identified in renal failure (Vallance et al., 
1992a) which is unsurprising due to the role the kidney play in methylarginine 
excretion. As a result L-NMMA and SDMA concentrations also increase with SDMA 
levels exceeding those of ADMA as it lacks any other route of degradation.  
As expected due to the role of NO in cardiovascular function high plasma ADMA 
correlates with a number of cardiovascular diseases and is now thought of as an 
independent marker of cardiovascular risk. However, raised ADMA is only an 
association and it is not known whether increased ADMA is a causal factor in the 
development of these diseases, whether it aids disease progression or is an 












Ito et al, 2001; Achan et al, 
2003 
 Coronary heart disease Mugge et al, 2003;  
 Stroke Yoo and Lee, 2001 
 Atherosclerosis Eid et al, 2003; Maas et al, 
2009 
 Pre-eclampsia Maas et al, 2004 
   
Metabolic Obesity McLaughlin et al, 2006 
 Diabetes Asagami et al, 2002;  
Mittenmayer et al, 2005 
 Hypercholesterolemia Boger et al, 1998 
   
Neuronal Alzheimer’s Selley, 2003 
 Depression McEvoy et al, 2013 
   
Other Renal Failure Vallance et al, 1992; 
Osanai et al, 2002 
 Asthma Scott et al, 2011 
Table 1.1: A summary of diseases where elevated ADMA has been correlated 
with increased risk, negative disease progression and outcome.  
 
An increase in plasma ADMA suggests that DDAH dysregulation may be a factor in 
many of these disease states. DDAH activity is thought to be reduced through 
exposure to TNFα, and oxidised lipoproteins  (Ito et al., 1999), while DDAH2 
expression is reduced by high concentrations of glucose (Sorrenti et al., 2006).   
Furthermore, in human studies a number of polymorphisms in either DDAH1 or 
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DDAH2 have been associated with increased ADMA and the outcome of a number 
of diseases including pre-eclampsia (Akbar et al., 2005), cardiovascular disease 
(Valkonen et al., 2005), septic shock (O'Dwyer et al., 2006), diabetes (Abhary et al., 
2010; Fogarty et al., 2012) and renal function (Caplin et al., 2010).  
To explore the effects of DDAH dysregulation DDAH1 knockout mice have been 
developed. The first global DDAH1 deletion was found to be foetal lethal (Leiper et 
al., 2007), but work on the heterozygous mice confirmed that a reduction in DDAH1 
activity and the resultant increase in ADMA concentrations caused hypertension due 
to a reduction in vascular activity. This has since been repeated by Hu et al (2011) 
where homozygous DDAH1 knockout mice were indeed viable but again had 
increased cardiovascular disease.   
Increased plasma or cellular ADMA concentrations are not always considered to be 
detrimental. The diseases shown in table 1.2 are associated with an upregulation of 
NO production through iNOS to an extent which causes detrimental side effects. As 
a result increasing ADMA concentrations have been shown to improve disease 
outcome. Genetic and pharmacological disruption of DDAH1, using the compound L- 
257 (Leiper et al., 2007), in sepsis improves outcomes by improving haemodynamic 
function in animals undergoing endotoxic shock (Nandi et al., 2012).   
Disease Mechanism Reference  
Heart Failure Combats the increased 
iNOS in myocytes 
Usui et al, 1998 
    
Sepsis Prevents sepsis related 
hypotension 
Leiper et al, 2007; Nandi et al, 
2012 
Table 1.2: Elevated ADMA has been implicated to be of benefit in a small 
number of disease states. 
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1.5.1 ADMA and DDAH in obesity 
Human clinical studies of obesity have associated a BMI >30 with increased 
circulating ADMA (Eid et al., 2004; Koc et al., 2010; Marliss et al., 2006). In these 
studies ADMA also correlates with a number of other markers of obesity including 
total body weight, fat mass, and waist circumference. Eid et al. (2004) suggest that 
the largest difference in ADMA concentrations are between normal and overweight 
individuals with only a further modest increase in those considered to be obese. 
Other studies suggest that within obese individuals those who display the full 
metabolic syndrome have higher ADMA concentrations than those who are only 
obese (McLaughlin et al., 2006; Palomo et al., 2011; Siervo et al., 2011). It has been 
suggested that the increase in ADMA is due to an increase in protein turnover in 
obesity and that this is seen more in male subjects than female with the association 
between ADMA and obesity stronger in men (Marliss et al, 2006).  
If obese individuals undergo weight loss then ADMA concentrations decrease with 
no change seen in SDMA concentrations (Krzyzanowska et al., 2004; McLaughlin et 
al., 2006). A fall in ADMA is also seen in individuals who lose weight via bariatric 
surgery (Patle et al., 2012).  
The only mouse study investigating ADMA concentrations in metabolic syndrome 
looked at the development of diabetes in db/db mice. These mice develop obesity as 
well as diabetes and ADMA concentrations were found to rise as the mice became 
more insulin resistant (Lee et al., 2011).  
This introduction has shown the importance of adipose in physiology and pathology 
not only as a storage tissue for lipids but as a major endocrine organ that regulates 
whole body energy homeostasis. Nitric oxide is a major signalling molecule that has 
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a wide range of targets including many within adipose tissue; however the role of the 
NOS inhibitor ADMA has not yet been fully investigated. This project aims to 
investigate the role of ADMA and its metabolising enzymes DDAH in normal adipose 
function and determine whether elevated ADMA or DDAH dysregulation have 
negative any effects in adipocyte physiology.  
An unbalance in energy intake to energy expenditure results in obesity, the 
pathological storage of excess lipid. DDAH expression and activity have not yet been 
investigated in either mouse or human obesity. The second aim of this thesis is to 
determine what role DDAH dysregulation and therefore increased ADMA plays in 
obesity. This will be driven by in vivo investigations into adipose physiology and 
whether DDAH1 deletion effects the development of obesity and its associated 




1. DDAH1 and ADMA play a role in adipocyte physiology and high ADMA 
concentrations alter adipocyte metabolic pathways. 
 
2. DDAH1 activity is dysregulated in obesity which increases ADMA 
concentrations having a negative effect on disease progression and the 












Chapter 2: Methods                                                             
 
2.1 Chemicals 
All chemicals were obtained from Sigma-Aldrich (St. Louis, Missouri, USA) and all 
cell culture consumables were obtained from PAA (GE Healthcare, Amersham, UK) 
unless otherwise stated. 
 
2.2 In Vitro Methods 
2.2.1 3T3-L1 Cell Culture 
The 3T3-L1 cell line, a murine fibroblast line, was obtained from ATCC (Virginia, 
USA) and cultured as per their protocol. Cultures were maintained as fibroblasts in 
low glucose (1g/l) DMEM supplemented with 5% Donor Calf Serum, 4mM L-
glutamine and 1x Penicillin/Streptomycin. Cells were passaged every four days when 
they became 80% confluent, cells more confluent than 80% start to undergo 
differentiation and are no longer proliferative.  
To stimulate differentiation to mature adipocytes cells were grown to confluence and 
maintained in low glucose DMEM for two days. At day two the media was replaced 
with high glucose (4.5g/l) DMEM supplemented with 5% Foetal calf serum, 4mM L-
glutamine and 1x Penicillin/ streptomycin, cultures remained in this media for the 
duration of the differentiation (figure 2.1). At day four differentiation is induced by 
supplementation with 0.5mM 3-Isobutyl-1-methylxanthine, 10μg/ml human insulin 
and 1μM dexamethasone for a further two days. On day six the media is 
supplemented with only 10μg/ml insulin. At day eight cells were cultured in the high 
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glucose DMEM described above for a further four days when the cells reached full 
maturity and lipid droplets could be seen within the cytoplasm. 
Experimental treatments were carried out on the fully mature cells cultured in high 
glucose DMEM for 48 hours or for ten days as stated in the results. Treatments 
included 1μM, 3μM and 10μM ADMA (Merck Millipore, Darmstadt, Germany), 10μM 





Figure 2.1:  3T3-L1 cell differentiation. 3T3-L1 cells are maintained and 
passaged as fibroblasts in low glucose DMEM with donor calf serum. Differentiation 
is induced by the addition of high glucose DMEM supplemented with FBS, insulin, 




2.2.2 Oil Red O Staining 
Lipid droplets can be stained with the dye oil red O. Cells were fixed with 4% 
paraformaldehyde (PFA) for 30 minutes. Post fixation cells were washed with 60% 
isopropranol before staining with 3.4mM oil red O in isopropranol for 15 minutes. 
After staining cells were washed with water and pictures taken with the 
microinjection microscope (Zeiss, Oberkochen, Germany) and colour camera. 
2.2.3 BODIPY Staining 
Mature adipocytes were stained with the fluorescent neutral lipid dye 4,4-difluoro-4-
bora-3a, 4a-diaza-s-indacene-3-dodecanoic acid (BODIPY) 505/515 with a protocol 
adapted from Goattardi et al (2007). Cells were grown to maturity on glass coverslips 
and treated appropriately before being fixed in 4% PFA for 30 minutes. Coverslips 
were washed with phosphate buffered saline (PBS) before BODIPY was added at 
200nM in PBS for 15 minutes at room temperature in the dark. Coverslips were 
again washed before mounting on slides with Prolong Gold anti-fade (with nuclear 
stain DAPI) mounting media (Invitogen, Life Technologies, California, USA). Cells 
were visualised using a Leica SP5 confocal microscope with LAS software (Leica 
microsytstems, Wetzlar, Germany) with flurophores excited at 505nm and 405nm. 
 
2.3 Primary Cell Isolation 
2.3.1 Adipocytes 
Primary adipocytes were isolated based upon the method by Rodbell (1964). The 
epididymal fat pads were removed and washed in PBS. Larger blood vessels were 
dissected out before the remaining tissue was minced into small pieces. 
Approximately 1g of tissue was added to 3ml low-glucose DMEM with 100mM 
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HEPES, 1.5% BSA and 0.2% Collagenase II. Adipocytes were liberated through 
gentle shaking at 37°C before spinning for one minute at 400 rcf. Fat cells float while 
remaining vascular-stromal cells pellet. The adipocytes were washed twice with 
DMEM and centrifugation repeated. Cells were either collected in Trizol for RNA, 
RIPA buffer for protein analysis or cultured overnight for microscopy.  
For fluorescent microscopy primary adipocytes were cultured in T12.5’s using the 
ceiling culture method (Sugihara et al., 1986; Zhang et al., 2000). Cells were placed 
in culture flasks which were filled full with supplemented high-glucose DMEM leaving 
as few air bubbles as possible. The flask is then turned upside down allow the 
adipocytes to float to the ‘bottom’ of the flask where after a few days they adhere 
(figure 2.2).  
 
 
Figure 2.2:  Ceiling Culture of primary adipocytes. As adipocytes float they are 
cultured upside down to allow them to adhere to the surface of the cell culture plate 
or flask. 
 
2.3.2 Pulmonary Endothelial Cells 
Murine lungs were removed and the peripheral tissue used for pulmonary endothelial 
cell culture. The tissue was minced into 1mm2 pieces and plated on to 6 well plates. 
Approximately 20 pieces were used per a well and gently covered with high glucose 
DMEM supplemented with 10% FBS, 4mM L-glutamine and 1x Pen/Strep; media 
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was changed every two days. Cells started to grow out from the tissue after 4-5 days 
and were then allowed to grow for another 3 days.  
Pulmonary endothelial cells were isolated from other cell types by using an anti-
ICAM antibody attached to magnetic beads. Magnetic Dynabeads (Invitrogen) with 
sheep anti-rat IG antibodies bound to the surface were incubated with rat anti-ICAM 
antibodies overnight (Becton Dickinson, New Jersey, USA). Beads were then 
washed with PBS to remove excess antibody and incubated with supplemented 
media to block non-specific binding. Beads were added to the cells cultures for 30 
minutes before washing with PBS. Beads bound to the endothelial cells while other 
cell types remained untouched. Cultures were then trypsinised until most of the cells 
had come off the plate. Cell types were separated by a magnet with endothelial cells 
kept while other cell types were removed in the supernatant.  
 
2.4 Molecular Biology Methods  
2.4.1 End – point PCR for genotyping 
The polymerase chain reaction (PCR) is a technique designed for the amplification of 
specific regions of DNA. End-point PCR determines the quantity of DNA at the end 
of the amplification protocol, thereby making subtle differences in expression difficult 
to identify as the reaction can become saturated; however it is useful for determining 
the presence or absence of specific parts of DNA when generating transgenic mice. 
Tail clippings or tissue extracts were digested with proteinase K at 53°C overnight 
before deactivating the enzyme at 94°C for 10 minutes. DNA was amplified using a 
heat stable DNA polymerase, Taq. The PCR reaction was completed using 1x 
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Readymix Taq PCR reaction mix which contains the necessary polymerase, dNTPS 
and loading dye to which were added at 200nM. Cycling conditions for specific 
primer pairing are set out below; primer sequences are shown in table 2.1.  
 
DDAH 1 floxed Primer Protocol 
Hold  2 minutes 94°C 
40 Cycles: 20 seconds 94°C 
 40 seconds 60°C 
 1 minute  72°C 
Final extension 5 minutes 72°C 
 
 
Cre Primer Protocol 
Hold  2 minutes 94°C 
40 Cycles: 20 seconds 94°C 
 40 seconds 60°C 
 1 minute  72°C 
Final extension 5 minutes 72°C 
 
PCR products were separated by gel electrophoresis on a 1.5% agarose gel 
containing 0.01% ethidium bromide. DNA products were visualised under UV light.  
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2.4.2 RNA Extraction  
To analyse differences in mRNA transcript expression RNA was extracted from both 
3T3-L1 cells and animal tissue using the RNeasy plus universal mini kit (Qiagen, 
Venlo, Netherlands) following the manufacturers protocol. Adherent cells were 
scraped from culture plates and then added to trizol solution while isolated primary 
cells and tissue were added directly. The samples were homogenised mechanically 
with 5mM stainless steel beads using a Tissuelyser II (Qiagen) set at 25Hz for 5 
minutes. If any tissue remained intact the above was repeated. Qiagen gDNA 
eliminator was added post homogenisation to remove any gDNA contamination. 
RNA was extracted through the addition of chloroform, followed by centrifugation at 
12,000g for 15minutes at 4°C to allow phase separation. The clear upper aqueous 
phase containing RNA was removed and added to an equal volume of 70% ethanol. 
RNA was purified using the filter columns and buffers provided in the kit before 
elution from the filter membrane with RNAse free water. RNA concentrations were 
determined by absorbance at 260nm by a Nanodrop Spectrophotometer (Thermo 
Scientific, MA, USA). 
2.4.3 Reverse Transcription – quantitative PCR 
Relative mRNA expression was analysed through two-step real time PCR. Before 
analysis mRNA must first be converted to cDNA through reverse transcription. The 
iScript cDNA synthesis kit (Bio-rad, CA, USA) was used following the manufacturer’s 
instructions with cycling conditions set out below. 
PCR protocol (x1 cycle)  
Reverse transcription 30 min at 42°C 
RTase inactivation 5 min at 85°C 
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In contrast to end-point PCR qualitative real time PCR (Rt-qPCR) is capable of 
detecting subtle differences as it detects the quantity of product at the end of each 
PCR cycle before conditions become saturated. The fluorphore SYBR green binds to 
double stranded DNA and emits an amount of light relative to DNA concentration.  A 
ready mix (iTAQ fast sybr green supermix with ROX, Bio-rad) containing fluorophore, 
polymerase, dNTP’s and ROX (a fluorescent dye used to normalise any machine 
errors) was used following the manufacturers protocol. Primers (Table 2.1) were 
added at 200nM while cDNA was added to the mix at 10ng; following this PCR 
plates were run on Applied Biosytems (Life Technologies, CA, USA) 7900HT fast 
machine using the following cycling protocol.  
qPCR cycling protocol:  
Initial step 95°C   2min 
Thermal cycling x 40  
Denaturation 95°C   3 secs 
Annealing 60°C   30secs 
Disassociation step  
 
Amplification curves were generated through the detection of SYBR green 
fluorescence and a fluorescence threshold (Ct) set during the exponential phase of 
the curve. Experimental gene Ct values were normalised against a housekeeper 
gene, and then relative gene expression compared to the expression in the control 
sample, this is the ΔΔCt method. The full equation is as follows: 
Relative Expression = 2-((Ct Test Gene - Ct Housekeeper) – ΔCt Control Sample) 
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House-keeper genes were selected after testing in the biological samples for 
stability, for example through differentiation or altered by diet. Two house-keeper 
genes selected were ribosomal protein L13 (RPL13) and polymerase II (POL2) as 
these remained stable through 3T3-L1 differentiation. Structural house-keepers such 
as actin and tubulin altered in differentiation as cells changed morphology. 
Furthermore tubulin is not expressed in primary adipocytes.   
 
2.4.4 Protein Preparation 
 Cell cultures were prepared for protein analysis by scraping into RIPA lysis buffer 
(Thermo Scientific) while tissue samples were homogenised in PBS using the 
tissuelyser II. Protease inhibitors (Roche Applied Sciences, Germany) were added to 
both preparations above. After homogenisation samples were spun at 16,000rpm, 
4°C for 15 minutes to remove remaining cell debris. The lysates were retained for 
analysis.   
2.4.5 Bradford Assay 
Protein concentrations were quantified using the Bradford Assay as developed by 
Bradford in 1976. Briefly Coomassie blue dye (Quick start Bradford protein assay, 
Bio-rad) shifts from red to blue on the binding of protein; this shift can be quantified 
by a colorimetric assay at 595nm.  A standard curve of known bovine serum albumin 






Gene Primer Sequences 
Genotyping  
DDAH1 floxed CCTCCCATTGCTAATGAAACGG; TCAGTTGGAGTGTGAGTGAC 
Cre GCCTGCATTACCGGTCGATGCA; GTGGCACATGGCGCGGAAC 
  
Rt-qPCR  
DDAH1 CACAGAAGGCCCTCAAGATC; TCTCATAGACCTTTGCGCTTTC 
DDAH2 CCTGGTGCCACACCTTTC;  AGGGTGACATCAGAGAGCTTCTG 
eNOS AAGACAAGGCAGCGGTGG; GCAGGGGACAGGAAATAGTT 
iNOS CAGCTGGGCTGTACAAACG; ATGTGATGTTTGCTTCGGA 
  
mTOR GCCACATCTAGCAACGTGAG;  CTGGTCATAGAAGCGAGTAG 
IRS-1 CGATGGCTTCTCAGACGTG; CAGCCCGCTTGTTGATGTTG 
Glut4 GTGACTGGAACACTGGTCCTAG; CCAGCCACGTTGCATTGTAG 
ACC ATGGGCGGAATGGTCTCTTTC;  TGGGGACCTTGCTTTCATCAT 
FASN TGCTCCCAGCTGCAGGC;  GCCCGGTAGCTCTGGGTGTA 
Scd-1 CGAGAGAAGGTGAAGACGGT; GCAGCAGGACCATGAGAATG 
TNFα CAAACCACCAAGTGGAGGAG; GTGGGTGAGGAGCACGTACT 
IL-6 CCGGAGAGGAGACTTCACA; TTCTGCAAGTGCATCATCGT 
  
RPL13 CTCATCCTGTTCCCCAGGAA; TGGGTGGCCAGCTTAAGTTC 
POL2A CCGCTCATGAAATGCTCCTT; CGGGTCACTCTCCCCATGT 




2.4.6 Western Blotting 
Western blotting, first developed by Towbin et al (1979), is a method to detect 
relative amounts of a specific protein in cell or tissue homogenates.  Proteins are first 
separated by gel electrophoresis before being transferred to a membrane. Proteins 
are then probed by a specific primary antibody before the signal is amplified by a 
secondary antibody. Protein detection is performed by either a chemiluminescent or 
intrared method and relative expression analysed against house-keeper proteins – α-
Tubulin and β- actin.  
Protein lysates were prepared for western blotting by adding Laemlli buffer and 
heating to 94°C to break cysteine bonds in protein tertiary structures.  Protein 
separation is achieved on a resolving gel where the speed and level of separation is 
determined by the percentage of acrylamide present.  A 12% resolving gel was 
made with the following recipe: 4.35mL dH2O; 3mL 40% acrylamide/Bis 37.5:1; 
2.5mL 1.5M Tris-Hcl pH8.8; 100uL 10% SDS; 5uL TEMED; 50uL 10% APS (all from 
Biorad). The stacking gel as follows: (10mL of 4%); 6.32mL dH2O; 1mL 
acrylamide/Bis 37.5:1; 2.52mL 0.5M Tris-Hcl pH6.8; 100uL 10% SDS; 10uL TEMED; 
50uL 10% APS. The full protocol for western blotting is described below.  
 
Protein Separation SDS-PAGE gel run between 90-150V for up to 90 
minutes dependent on protein size (Bio-rad Mini 
Protean cell)  
 
Transfer Proteins transferred to Hypond-P (Millipore) PVDF 





Blocking 5% Milk or BSA  in PBS – 0.1% Tween  (PBS-T) 
for 1h 
 
Primary Incubation Overnight incubation at 4°C with gentle agitation, 
primary antibodies diluted to the necessary 
concentration in the above blocking buffer 
 
Washes 3 x 5 minute washes in PBS-T 
 
Secondary Incubation Incubation for 1h with secondary antibody (HRP 
conjugate for chemiluminescence detection, Infra-
red conjugate for Licor detection) in the above 
blocking agent 
 




15 minute incubation with Amersham ECL kit 




Licor Odyssey Detection and quantification 
system 
 
Antibodies for DDAH1 and DDAH2 were made for the laboratory by Sigma and used 
at 1:3000.  
The following antibodies were obtained from Cell Signalling (Massachusetts, USA) 
and used at 1:1000 dilutuion: eNOS (#9572), mTOR (#2972), Rictor (#2114), Raptor 
(#2280), Akt (#4691), Phospho-Akt (Ser473, #4060), 4E-BP1 (#9644), Phospho-4E-
BP1 (Thr37/46, #2855), S6 Kinase (#9202), phosphor-S6 Kinase (Thr389, #9205). 
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The following antibodies were obtained from Abcam (Cambridge, UK) and used at 
1:5000: β-actin (ab8227) and α-tubulin (ab7291). 
2.4.7 ELISA’s 
Enzyme-linked immunosorbent assays (ELISA’s) are used to assess the 
concentration of plasma proteins. The method is similar to that of western blotting in 
that proteins are detected with specific antibodies. However, in the case of an ELISA 
these antibodies are cross-linked with the enzyme strepavidin–peroxidase which 
reacts with a peroxidase substrate. This reaction results in a colour shift that can be 
detected by a colourimeter and quantified against a standard curve of known 
concentrations.  
ELISA’s were performed on plasma samples to detect adiponectin (Abcam) and 
leptin (Millipore) following the manufactures protocols.   
 
Figure 2.3: ELISA Standard Curves Representative standard curves for ELISA 
assays against (A) leptin and (B) adiponectin.  
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2.5 Chemical Analysis 
2.5.1 Methylarginine measurement 
The identification and quantification of methylarginines in cell and tissue extract and 
plasma were carried out using Liquid Chromatography-Mass Spectrometry (LC-
MS/MS). 
Firstly, samples were homogenised as described in section 2.4.4. above and an 
internal standard of 7-deuterated ADMA added to calculate the efficiency of 
methylarginine extraction. Methylarginines were prepared by adding 5x volumes of 
methanol to precipitate proteins which were then pelleted by centrifugation at 
16,000g for 30 minutes. The supernatant was collected and evaporated dry over a 
heat block before the sample was resuspended in mobile phase (0.1% formic acid) 
to run on the LC-MS/MS. 
High pressure liquid chromatography (HPLC) allows components of a sample to be 
separated based upon their binding affinity to a silica based column. The HPLC 
system (Agilent) injected 10μL of sample on to a Hypercarb chromatography column 
(Thermo Scientific), samples were eluted off the column using a mobile phase of 
0.1% formic acid, 1% acetonitrile with a gradient increasing to 50% acetonitrile 
between 5 and 10 minutes of a 15 minute run per a sample. A mobile phase 
consisting of 1% formic acid, 50% acetonitrile should wash the column clean 
preparing it for the next sample with no carryover of contamination.  
After elution samples passed into the Agilent 6400 series triple quadrupole LC-
MS/MS where they are vapourised and ionized. The MS parameters for detection 
were as follows: ADMA, mass-to-charge ratio (m/z): 203.3 to 46.0, collision energy 
(CE): 12; SDMA, m/z: 203.3 to 70.2, CE: 24; monomethylarginine, m/z: 189.3 to 
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70.2, CE: 24; arginine, m/z: 175.2 to 60.1, CE: 8; d7-ADMA, m/z: 210.0 to 46.0, CE: 
24. 
The data was acquired and analysed using Agilent’s Masshunter Qualitative analysis 
programme. Chromatograms (figure 2.4a) were acquired and the data extracted 
using the multiple reactions monitoring (MRM) method (figure 2.4b) and the amount 
of each methylarginine in the sample determined by the total ion count within the 
relevant peak. Concentrations of methylarginines were determined by running a 
standard curve within the sample run.   
2.5.2 NOx Quantification 
Nitric oxide is a reactive species and quickly oxidises to nitrite and nitrate making it 
very difficult to measure accurately. As a result NO production is deduced from the 
concentrations of both nitrite and nitrate combined (NOx). The Sievers Nitric oxide 
analyser (NOA, GE Analytical equipment) was used to measure total NOx 
concentration in tissue and cell lysates, cell media and plasma. The NOA is capable 
of detecting NOx within very small volumes of samples, down to 5µL with a lower 
limit of detection of 0.2µM. Nitrates and nitrites are reduced back to NO through a 
reaction with VCl2 in HCL before passing into the system to react with ozone 
producing a chemiluminescent signal that is quantified by a photo-multiplier system. 
The concentration of NOx is calculated by comparison to a calibration curve of 
known nitrate samples. Samples were prepared by protein precipitation with four 
volumes of methanol and centrifugation at 16,000 rpm for 30 minutes.  The 





Figure 2.4:  Methylarginines are identified and quantified by liquid-
chromatography mass spectrometry. (A) Chromatogram displaying methylargine 
peaks eluting off the HPLC column. (B) The chromatogram in (A) extracted to display 
the ionisation fragments 203.3>46.2 which equates to ADMA.  
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2.6 Animal Experiments 
2.6.1 Regulatory Approval 
All animal experimentation was conducted under the approval of a home office 
project and personal license. Animal experiments were only carried out if there was 
no other appropriate disease model and the principles of the 3R’s of replacement, 
refinement and reduction were used to design the best experiments possible with 
minimal use of animals.  
2.6.2 Mouse Strains 
All mouse strains were on a mixed C57/Bl6 background with littermate controls to 
reduce genetic variability. DDAH1 floxed mice were generatd by Genoway (Lyon, 
France) and received as heterozygous subjects. These were mated to obtain 
homozygous offspring. 
The adiponectin cre mouse was a gift from Dr Dominic Withers, the tie-2 cre mouse 
was a gift from Dr Manasi Nandi. DDAH1 floxed mice were mated with cre 
expressing mice to obtain 1:1 ratio of DDAH1 homozygous floxed cre +ve and 
DDAH1 homozygous floxed cre –ve. To reduce the chance of cre toxicity cre 
expression remained heterozygous. The YFP reporter mouse was a gift from Dr 
Graeme Williams and was mated with the tie-2 cre mouse to determine cre 
expression. 
2.6.3 Housing Conditions 
Animals were housed in groups of male or female littermates with behavioural 
enrichment such as tunnels and nesting material. Housing rooms were kept at a 
constant temperature and on a 12 hour light/dark cycle. All mice were fed ad libitum 
on standard rodent chow and water unless otherwise stated and is the normal chow 
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diet utilise in chapters five and six. Standard chow was supplied by the animal 
housing facility and obtained from Special Diet Services Rat (Rat and Mouse No.1 
Maintenance). This diet is predominantly carbohydrate with only 7% energy from fat.   
2.6.3 Genotyping and ear notch identification 
Mice were weaned at 3-4 weeks of age and ear notched for identification; a tail 
clipping was taken for genotyping. Tails clippings were digested overnight at 53°C in 
lysis buffer (Triz base 10mM; MgCl2 1.5mM; KCl 50mM; gelatin 0.01%; Igepal Ca-
630 0.45%; Tween 20 0.45%) with fungal proteinase K. After digestion the 
proteinase K was deactivated at 94°C for 10 minutes. To identify genotypes end-
point PCR was carried out as described above (section 2.4.1) and run on agarose 
gels.   
2.6.4 High Fat Diet  
Male mice were put on a high fat diet after genotyping at 5-6 weeks of age. The diet 
provides 60% energy from fat (Basal purified diet w/60% energy from fat, Blue 
(58G9), TestDiets, Richmond, Indianna). This diet provides the necessary protein, 
soluble and insoluble fibre to maintain healthy digestion therefore limiting detrimental 
effects to the gut. Control mice remained on normal chow. Both groups of mice 
continued the diet for 16 weeks.  Mice were weighed fortnightly to track the change 
in weight gain with high fat feeding, at the same time blood was collected and fat and 
lean body composition was analysed. At the end of the 16 weeks mice were killed by 
schedule one and plasma and tissue samples were collected for future analysis.  
2.6.5 Tail Vein Bleeds 
Before blood collection mice were warmed to 37°C for 10 minutes in a Thermacage 
warming chamber (Datesand technologies, Manchester). Mice were then placed in 
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conical restrainers to allow easy access to the tail. A small incision was made on the 
lateral tail vein and blood collected by capillary action into collection tubes coated in 
lithium-heparin. Blood volume was determined by the repeated collection limits in the 
project licence – 15% of blood volume in 28 day period, approximately 50μl per 
mouse per sample. Samples were kept on ice until centrifuged for 10 minutes at 
10,000g and 4°C, plasma was collected for analysis.  
2.6.6 Echo-MRI 
 The Echo-MRI (EchoMRI, Houston, Texas) measures fat and lean mass in 
conscious animals. NMR determines different proton spin speeds in different tissues 
therefore differentiating between fat and lean tissues and circulating water. Animals 
are restrained inside tubes and placed inside the machine. Three scans are 
performed before displaying a mean value for lean and fat (g).  
2.6.7 Glucose Tolerance Test  
Insulin resistance was investigated in mice on normal and high fat diets via a glucose 
tolerance test. Mice were fasted overnight before being given a bolus dose of 
glucose at 1mg/g via intraperitoneal injection. Blood glucose readings were taken 
from the tail vein using a glucometer (Bayer Contour, USA) at 0, 15, 30, 60, 90 and 
120 minutes.  
2.6.8 Immunohistochemistry 
Epididymal fat pads were removed at the end of the study for immunohistochemistry. 
Tissue was prepared for staining by washing in PBS and undergoing fixation with 4% 
paraformaldehyde overnight. Tissues were then placed in 50% ethanol until they 
could be processed.  
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Mounting, slide preparation and staining were carried out by Mahrokh Nohadani (C 
and C Services, Hammersmith Hospital). Briefly fat was mounted in paraffin blocks 
before sectioning and placing on slides. Slides were rehydrated with repeated 
incubations with xylene, increasing concentrations of alcohol and finally water.  
Basic adipose histology was assessed through Elastin van Gieson’s staining a 
haematoxylin-ferric chloride stain which is used widely for connective tissues. 
Adipocyte area was assessed using this stain; cross-sectional areas were 
determined using ImageJ image analysis software (National Institute of Health, US).      
If the samples were going forwards for antibody staining non-specific binding was 
blocked with rabbit or donkey serum before incubation with primary antibodies. To 
determine vessel density endothelial cells were stained with CD31 antibody (Merck- 
Millipore); while macrophages were stained with Mac 2 antibody (Becton-Dickinson) 
to assess inflammation. Samples were then incubated with a biotinylated secondary 
antibody followed by counter staining with haematoxylin.  
2.6.9 Myography 
Myography was performed with the assistance of Anna Slaviero who mounted the 
vessels and assisted in dose response curves. Aortas were mounted on the 
myograph as follows and subjected to pharmacological stimuli to determine both 
endothelial and smooth muscle responsiveness. Mice were sacrificed by cervical 
dislocation, the chest was opened and the heart and lungs removed. The aorta and 
surrounding tissue was cut away from the rib cage and placed in a petri dish with 
physiological saline solution. The surrounding connective tissue and fat was 
removed from the vessel and 2mm sections were taken from the centre of the 
vessel. Two sections were taken from each mouse and mounted in parallel on the 
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DMT vessel myograph (DMT, Aarchus, Denmark) using the pin mounting system for 
larger vessels. Vessels were allowed to warm to 37°C and then equilibrate in the 
physiological solution for 1 hour before the ‘wake up procedure’ was started. This 
consisted on repeated incubations with Potassium chloride solution and 10nM 
noradrenaline to stimulate muscle contraction (figure 2.4a)  
After the ‘wake up’ the vessel was then ready to test pharmacological stimuli. Vessel 
contraction was assessed with increasing doses (1nM -10μM) phenylephrine until a 
plateau is reached (figure 2.5b). Following stimulation the vessel was then washed to 
remove the agent until the vessel tension returned to baseline.  
Endothelial-dependent relaxation of the vessel was tested with increasing doses of 
acetylcholine (1pM - 10μM). The vessel was pre-contracted with 80% of maximal 
phenylephrine response before acetylcholine was added.  Endothelial-independent 
relaxation was tested through increasing doses of sodium nitroprusside (1nM-10μM) 






Figure 2.5  (Previous Page): Myography traces assessing aortic reactivity in 
response to pharmacological stimulation. (A) Prior to pharmacological stimulation 
aortic rings undergo a ‘wake-up’ procedure causing contraction with potassium 
chloride and noradrenaline. NAK: Noradrenaline +Potassium Chloride, NAPSS: 
Noradrenaline alone, KPSS: Potasium chloride alone (B) Vessel contractility is 
probed by increasing concentrations of phenylephrine. Vessel relaxation is probed 
through increasing concentrations of acetylcholine and sodium Nitroprusside. 
2.7 Data Analysis 
Data are presented as means ± standard error of the mean (SEM). All statistical 
tests were carried out in Prism (Graphpad Software Inc, CA, USA). When a single 
variable was being assessed a student’s t-test was used to look at two groups, while 
an ANOVA (one-way analysis of variance) was used for comparisons between three 
or more groups. When experiments were comprised of two variables for example 
time and diet a two-way ANOVA was used. P values of <0.05 were considered to be 













3. The NO – DDAH - ADMA Pathway in 3T3-L1 cells                 
 
3.1 Introduction  
Current knowledge of adipose physiology is that the nitric oxide synthase isoforms 
eNOS and iNOS are expressed in white adipocytes and play a role in adipocyte 
function. More recently DDAH1 and 2 have been detected by RT-qPCR in human 
white adipose tissue biopsies (Spoto et al., 2007) and cultured pre-adipocytes. As of 
yet it has not been ascertained to what extent either DDAH isoform is expressed at 
the protein level, how their expression may change during differentiation from pre to 
mature adipocyte  or what role ADMA and DDAH have in adipocyte physiology.   
The ideal cell in which to investigate the NO-DDAH-ADMA pathway in adipocytes 
would be isolated primary adipocytes. However these cells are known to be a difficult 
model to work with due to their fragile nature, and the fact that they float when in 
culture. As a result the 3T3-L1 cell line is widely used both in studies investigating 
adipocyte differentiation and in mature adipocyte physiology. The 3T3-L1 cell line 
was originally derived as a sub-population of 3T3 cells by Green and Kehinde in 
1974. These cells spontaneously accumulate lipid droplets in their cytoplasm over a 
number of weeks. This process can in accelerated by adding an induction cocktail 
containing insulin, dexamethasome and isobutyl methylxanthine over a differentiation 
period of two weeks, the timeline of which is shown in figure 2.1. The induction 
cocktail upregulates the expression of important adipose transcription factors 
particularly PPARγ, C/EBPb, C/EBPd and FOXO1. These drive the transcription of 
adipocyte specific genes including those for fatty acid synthesis, lipid binding 
proteins, glucose transporters and the adipokines adiponectin and leptin.    
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To be a useful model system to explore the effects of ADMA 3T3-L1 cells must 
express all the relevant parts of the pathway. Previously 3T3-L1 cells have been 
shown to express both eNOS and iNOS and that both have a functional role in 
adipocyte physiology. Nitric oxide production by eNOS has been shown to alter both 
adiponectin (Lee et al., 2010a) and leptin (Unno et al., 2006) production while iNOS 
expression is upregulated during inflammation. At present it is unknown which DDAH 
isoform is expressed in 3T3-L1 cells and how their expression may alter during 
differentiation from fibroblast to adipocyte. The initial part of this chapter 
characterises the NOS-DDAH-ADMA pathway in 3T3-L1 cells. 
Obesity is associated with many detrimental changes in metabolic function; however 
the mechanisms behind these changes are currently unknown. High concentrations 
of plasma ADMA have been correlated with obesity (Marliss et al., 2006; Siervo et 
al., 2011) but it is not known how this affects the physiology of adipose tissue. Using 
the 3T3-L1 cell line as a model adipocyte the second part of this chapter explores 
changes in adipocyte physiology that occur on exposure to ADMA.  
3.2 Aims 
 
1. To characterise the expression of the nitric oxide synthase and DDAH 
enzymes in 3T3-L1 cells. To assess the production of ADMA in these cells.  
 
2. To determine the effect of ADMA on the 3T3-L1 cell physiology and the 





3.3.1 Confirmation of 3T3-L1 differentiation 
3T3-L1 cells were differentiated from dividing fibroblasts (Figure 3.1a) to mature 
adipocytes (figure 3.1b). Adipocytes can be identified by the accumulation of lipid 
droplets within the cytoplasm; this was further confirmed using the fluorescent 
neutral dye BODIPY which accumulates with lipid vesicles (figure 3.1c). 
 
 
Figure 3.1:  3T3-L1 cells differentiate from fibroblasts to lipid laden 
adipocytes (A) 3T3-L1 fibroblasts differentiate to (B) mature adipocytes containing 
lipid droplets. (C) Fat accumulation was verified with BODIPY staining of lipid 
droplets (green) with nuclei stained with DAPI (blue).  
 
3.3.2 The NO-ADMA-DDAH pathway in 3T3-L1 differentiation 
To confirm DDAH and eNOS expression in 3T3-L1 cells rt-qPCR was performed on 
samples taken throughout the differentiation period.  Both DDAH1 and DDAH2 were 
found to be expressed in 3T3-L1 fibroblasts. On addition of the induction cocktail 
DDAH1 mRNA expression increased 3.9 fold (± 0.899, p<0.05) between fibroblasts 
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and mature adipocytes (figure 3.2a). DDAH2 in comparison remained relatively 
stable throughout differentiation (figure 3.2b).   
Endothelial NOS has previously been detected in 3T3-L1 cells. Here eNOS mRNA 
transcript was undetectable in the 3T3-L1 fibroblasts but increased dramatically in 
the later stages of differentiation (x321.2 ± 68.4 at day 10 post FBS, and x1729 ± 
378.5 in mature adipocytes, p<0.0.001, figure 3.2c). Neither iNOS nor nNOS 
expression could be detected at any stage of the differentiation.  
To confirm that changes in mRNA expression were reflected at protein level western 
blots were performed. As changes in expression predominantly occurs post induction 
it was decided to use only the fibroblast, post-insulin and mature adipocyte time-
points. DDAH1 protein expression again increased through differentiation resulting in 
a 6.6 fold increase (±1.9, p<0.05) in the mature adipocytes (figures 3.3a and b) 
compared to fibroblasts.  In contrast to mRNA expression where DDAH2 remained 
stable, protein expression increased greatly in the post-insulin and mature adipocyte 
stages (x27.7 ± 7.9, p<0.01, figures 3.33a and c). As with mRNA transcript eNOS 
protein remained undetectable in both fibroblasts and post-insulin. In mature 
adipocytes however an immunoreactive band of the expected size of eNOS protein 





Figure 3.2:  DDAH1 and eNOS mRNA increases through 3T3-L1 
differentiation. (A) DDAH1, (B) DDAH2 and (C) eNOS mRNA transcript levels 
through differentiation relative to the expression in fibroblasts. DDAH1 expression 
increases between fibroblasts and adipocytes (x3.9 ± 0.899), while DDAH2 
expression remains constant through differentiation. The expression of eNOS is 
increased dramatically in mature adipocytes compared to fibroblasts (x1729 ± 378.5, 




Figure 3.3:  DDAH1, DDAH2 and eNOS are all expressed as proteins within 
mature adipocytes. (A) Western blots of DDAH1 and DDAH2, with analysis of (B) 
DDAH1 and (C) DDAH2 expression relative to α-tubulin. DDAH1 expression 
increased throughout differentiation (x6.6 ± 1.9 in adipocytes compared to 
fibroblasts), while DDAH2 increased towards the end of differentiation (x27.7 ± 7.9, 




3.3.3 Methylarginines in 3T3-L1 cells 
Methylarginines are produced in all cells to a varying extent; however, at present it is 
unknown to what degree adipocytes produce methylarginines, whether they 
contribute to circulating plasma concentrations and how they affect NO production. 
Cytosolic lysates from 3T3-L1 cells were analysed by mass spectrometry to 
determine intracellular ADMA concentration through differentiation. The ADMA 
concentration in fibroblasts was 0.386µmol/mg ± 0.13 (figure 3.4a) increasing to 
1.85µmol/mg ± 0.64 in mature adipocytes. ADMA production reaches a peak of 
2.6µmol/mg ±0.44, p<0.05, at day 10 (post FBS). Neither L-NMMA nor SDMA were 
detected at quantifiable levels within the cytosolic lysates.  
 
3.3.4 Nitric Oxide in 3T3-L1 cells  
Mature 3T3-L1 cells have previously been shown to produce nitric oxide but again it 
is unknown how this alters through differentiation. As NO is a highly reactive 
molecule it is difficult to measure directly; as a result its oxidation products nitrite and 
nitrate, together known as NOx, are used as surrogate markers. Intracellular NOx 
was analysed and found that fibroblasts produced 9.07µmol/mg protein ± 0.15 of 
NOx which remains constant through differentiation where mature adipocytes 





Figure 3.4:  3T3-L1 cells produce ADMA and NO throughout differentiation.   
(A) ADMA production increased through differentiation from 0.386µmol/mg ± 0.13 in 
fibroblasts to a peak of 2.60µmol/mg ±0.44 (*p<0.05) at day 10 before a final 
concentration of 1.85µmol/mg ± 0.64 is reached in adipocytes.  (B) 3T3-L1 cells 
produce a constant amount of NOx throughout the differentiation period (fibroblasts 
9.077µmol/mg ±0.152, adipocytes 7.663µmol/mg ± 0.61), N=3.  
 
 3.3.5 ADMA and adipocyte hypertrophy  
Clinical studies of obese individuals indicate prolonged exposure to replicate this 
3T3-L1 cells were exposed to 10µM ADMA for 10 days post differentiation. At the 
end of the treatment cells were stained with Oil red O to highlight lipid accumulation. 
Cells treated with 10µM ADMA were larger control cells (figure 3.5a and b, control 
27.6µm2 ± 1.41, 10µM ADMA 33.8µm2± 1.6, p<0.01); in contrast 10µM SDMA, or 
other NOS inhibitors 1mM L-NAME and 20µM PB-ITU had no effect on the size of 







Figure 3.5: Exogenous ADMA causes adipocyte hypertrophy in 3T3-L1 cells 
which cannot be replicated with NOS inhibitors. (A)  The average area of 3T3-L1 
cells increases after 10 days of exposure to 10µM ADMA (33.85μm2 ± 1.62) 
compared to control cells (27.65μm2 ±1.41). SDMA (26.26μm2 ±0.53), L-NAME 
(28.02μm2 ± 1.52), and PB-ITU (25.73 μm2 ± 1.27) had no effect on cell size. (B) 
Representative images from each treatment group, lipid droplets are stained with oil 




3.3.6 ADMA and mTOR  
Increased lipid accumulation in 3T3-L1 cells mimicked that seen in DDAH-/- drosphila 
which have enlarged fat bodies (J.Jacobsob, L. Partridge, unpublished data). Lipid 
accumulation occurs through a number of mechanisms; In vivo hormones, such as 
insulin, and changes in plasma profiles, such as increased cholesterol, can trigger an 
increase in fatty acid uptake and triglyceride storage. However, in vitro ADMA cannot 
alter the composition of the culture media therefore we investigated the regulation of 
lipid synthesis and storage pathways at a transcriptional level to determine if ADMA 
affected these. The effect of ADMA on adipocyte hypertrophy occurred after 10 days 
of treatment; however it is likely that cellular pathways underlying hypertrophy 
precede morphological changes. To observe these mechanisms an earlier timepoint 
of 48 hours post treatment was used to analyse mRNA and protein synthesis.  
The mammalian target of rapamycin (mTOR) is an important regulator of cell growth, 
and the studies in DDAH-/- drosophila had identified the involvement of some 
member of the mTOR pathway. However, the full mechanism of how DDAH-/- causes 
enlarged fat bodies in flies has not been elicited. Therefore we wanted to determine 
whether these pathways were involved in 3T3-L1 hypertrophy.  Treatment of cells 
with ADMA increased mTOR mRNA levels in a dose-dependent manner (figure 
3.6a). SDMA had no effect on mTOR transcription. To determine whether the 
mechanism of increased mTOR transcript was through NO inhibition 3T3-L1 cells 
were treated with the NOS antagonists L-NAME and PB-ITU (figure3.6b). As with 
cell size the effect of ADMA could not be reproduced through NO blockade. 
To determine whether ADMA altered gene expression within the insulin signalling 
pathway IRS1 and Glut4 mRNAs were examined. The effect of ADMA on these 
genes was variable and did not reach significance (figure 3.6c and d), Furthermore 
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SDMA induced similar effects suggesting that regulation of insulin signalling did not 
underly the specific effects of ADMA on adipocyte lipid accumulation.  
The ADMA stimulated increase in mTOR transcript is also reflected by an increase in 
mTOR protein expression. The dose-dependent manner of this increase continued 
(figure 3.7a: 1µM x1.74 ± 0.19 3µM x2.53 ± 0.28, P<0.05) although 10µM ADMA had 
less of an effect than 3µM ADMA (x1.73 ± 0.22). As with mRNA expression NOS 
inhibitors had no effect on protein expression (figure 3.7b). 
As a signalling molecule mTOR forms two complexes which have differing 
downstream effects. Both complexes rely upon mammalian LST8/G-protein β-
subunit like protein (GβL) binding to the complex (figure 3.7c). The two complexes 
then become specific through the binding of cofactors raptor (mTORC1) or rictor 
(mTORC2). To determine whether ADMA favours the expression of a particular 
complex expression levels of raptor and rictor where both determined. Neither 
protein had altered expression with increasing ADMA treatment (Figure 3.7d and e). 
3.3.7 mTOR Complex 1 
Increased activation of mTORC1 can lead to increased protein and lipid synthesis 
(figure 3.8a). To investigate whether the increase in mTOR expression causes a 
corresponding increase in signalling downstream of mTORC1 western blots were 
performed on both 4e-BP1 and p70 S6 kinase to analyse whether their expression 
alters. Figure 3.8b and c shows that the protein level itself stays constant through 
ADMA treatment. However, mTOR regulates this pathway through the upregulation 
of Thr 37/46 phosphorylation on 4e-BP1 and Thr 389 phosphorylation on p70 S6 
kinase. Phosphorylation site specific antibodies showed no difference in the level of 





Figure 3.6:  ADMA increases mTOR transcription independent of the NO 
pathway. (A) ADMA treatment for 48h increased mTOR transcription in a dose 
dependent manner (1µM ADMA x1.48± 0.30, 3µM x2.21± 0.57, 10µM x2.49± 0.47, 
*p<0.05), while SDMA has no effect. (B) NOS inhibitors L-NAME and PB-ITU have 
no effect on mTOR transcription. ADMA has no significant effect on either (C) IRS1 




Figure 3.7:  ADMA increases mTOR protein expression independent of NO, 
neither mTOR complex was favoured by ADMA exposure (A) mTOR protein 
expression increases with dose dependent exposure to ADMA over 48h (1µM ADMA 
x1.74 ± 0.19, 3µM ADMA x2.53 ± 0.28, 10µM x1.73 ± 0.22, *p<0.05) with no effect of 
SDMA. (B) The NOS inhibitors L-NAME and PBITU had no effect on mTOR protein 
expression. (C) mTOR forms two complexes with differing cofactors. (D and E) The 




Figure 3.8:  ADMA does not alter 4e-BP1 and S6 kinase phosphorylation. (A) 
Signalling pathways downstream of mTORC1, (B) ADMA has no effect on 4e-BP1 
phosphorylation at Thr37 and Thr46 or (C) p70 S6 kinase phosphorylation at Thr389, 
N=3.   
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As well as protein synthesis mTORC1 also regulates lipid biosynthesis through the 
upregulation of SREBP1c controlled genes (figure 3.8a). These include acetyl 
coenzyme A (ACC), fatty acid synthase (FASN) and stearoyl-CoA desaturase (Scd-
1). The effect of 10µM ADMA on these three genes was investigated through rt-
qPCR (figure 3.9). ACC expression was upregulated 3.8 fold ± 0.67 (p<0.01) while 
FASN expression was upregulated from a relative expression of 0.84±0.07 to 
1.4±0.16 (p>0.05) upon ADMA treatment. Scd-1 expression increased slightly from 
0.98±0.07 to 1.27±0.18 but this was not statistically significant.  
Rapamycin is an inhibitor of mTOR activity with a higher affinity for mTORC1 than 
mTORC2. As the action of ADMA on cell size and lipid synthesis genes seems to be 
through mTOR signalling it should be blocked by rapamycin treatment. Mature 3T3-
L1 cells were exposed to 10nM rapamycin alone or treated with 10nM rapamycin 
and 10μM ADMA for 10 days. The increase in cell size seen with ADMA treatment 
was blocked by rapamycin while rapamycin alone had no effect on 3T3-L1 cell size 
(figure 3.11a).   
ADMA treatment of 3T3-L1 cells for 48h upregulated the lipid synthesis genes ACC 
and FASN. Treatment with 10nM rapamycin had no effect on the relative expression 
of either gene (figure 3.11b and c). When co-treated with both ADMA and rapamycin 
the upregulation by ADMA was blocked with the expression of both genes similar to 





Figure 3.9:  Exogenous ADMA increases lipid biosynthesis gene expression. 
(A) 10µM ADMA treatment over 48hours caused an increase in ACC – acetyl 
coenzyme A expression (x3.8 fold ± 0.67, p>0.01), FASN – fatty acid synthase 
expression (x1.4 fold ± 0.16, p<0.05) and Scd-1 – stearoyl coA desaturase 1 (x1.27± 





Figure 3.10:  The mTOR inhibitor rapamycin reverses the effects of ADMA 
on cell size and gene expression. (A) ADMA driven hypertrophy was blocked by 
co-treatment with rapamycin (Control 20.4μm2 ± 2.7, 10nM rapamycin and 10μM 
ADMA 18.38μm2 ± 3.8). (B- C) Upregulation of ACC and FASN was blocked by 
10nM rapamycin (ACC – control 1.07 ± 0.23, 10nM rapamycin + 10μM ADMA 0.566 
±0.15; FASN control 0.945 ± 0.31, 10nM rapamycin + 10μM ADMA 0.63 ± 0.35). 
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3.3.8 mTOR Complex 2 
The second mTOR complex has rictor as its determining cofactor (figure 3.11a) and 
can phosphorylate Akt at serine 473 which has a large number of targets including 
eNOS. mTORC2 is also involved in cytoskeletal reorganisation. Treatment with 
increasing doses of ADMA over 48 hours caused an increase in Akt phosphorylation 
with no change to total Akt. 1µM ADMA caused a 1.93 fold ± 0.10 increase in Akt 
phosphorylation with no further dose dependent increases seen with 3µM ADMA 
(x1.94± 0.26). 
A downstream target of Akt activation is the phosphorylation of eNOS at serine 1177. 
As with Akt phosphorylation 1µM ADMA caused a maximal increase in 
phosphorylation (6.43± 0.64, p<0.01), while both 3µM and 10µM ADMA caused 





Figure 3.11:  ADMA upregulates mTORC2 activity resulting in increased Akt 
and eNOS phosphorylation. (A) mTORC2 complex phosphorylates Akt which in 
turn phosphorylates eNOS. mTORC2 is also involved in cytoskeleton reorganisation. 
(B) The phosphorylation of Akt at ser473 increases with ADMA exposure (1µM 
ADMA x1.93 fold ± 0.10, 3µM ADMA, x1.94± 0.26, p<0.05). (C) ADMA treatment 
upregulates eNOS phosphorylation at ser 1177 (1µM 6.43± 0.64, 3µM 4.19± 0.95, 




3.4.1 The DDAH-ADMA-eNOS pathway in 3T3-L1 cells 
The 3T3-L1 cell line is a well characterised model of adipogenesis that after 
treatment with a cocktail of insulin, dexamethasome and IBMX differentiate into 
mature adipocytes (figure 3.1). Mature 3T3-L1 cells have previously been shown to 
express eNOS and to produce NO (Tanaka et al., 2003), which was again replicated 
here (figure 3.2, 3.3 and 3.4). In contrast iNOS has also been identified in 3T3-L1 
cells but could not be detected. The expression of iNOS relies heavily on the 
inflammatory state of cells and therefore may vary between cultures of 3T3-L1 cells, 
and was not stimulated during these experiments.  
Both DDAH1 and DDAH2 transcript have been detected in mature adipocytes in vivo 
(Sporto et al,2007), but have never been described in 3T3-L1 cells. Here it is shown 
that DDAH1 expression increases through differentiation at both mRNA (figure 3.2) 
and protein levels (figure 3.3) possibly suggesting an upregulation of promoter 
activity. DDAH2 mRNA expression remained unchanged throughout differentiation 
although protein levels increased significantly from the fibroblast to mature adipocyte 
(figure 3.3). This suggests that there is an upregulation in protein translation possibly 
due to increased mRNA translation, a decrease in DDAH2 proteolysis or due to the 
expression of necessary cofactors in the mature cell; but this would need further 
study to determine how DDAH2 expression is regulated.  
As 3T3-L1 cells express all parts of the NOS-ADMA-DDAH pathway they are a 
useful model for investigating any physiological changes that occur in adipocytes as 
a result of ADMA exposure. 
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3.4.2 Adipocyte hypertrophy  
In human studies of obesity higher than normal concentrations of ADMA have been 
detected in plasma (Koc et al., 2010; Palomo et al., 2011; Siervo et al., 2011). As 
obesity is a chronic condition the adipocytes of obese individuals may have been 
exposed to elevated ADMA for a prolonged period of time. To replicate this in vitro, 
3T3-L1 cells were exposed to 10µM ADMA for 10 days post differentiation. ADMA 
exposure caused a 22% increase in cell size compared to control cells (figure 3.5).  
Lipid accumulation within cells is normally regulated at an endocrine level by a 
cocktail of insulin, cholesterol and sterols. Insulin increases the uptake of fatty acids 
and glucose into adipocytes allowing increased triglyceride synthesis. Cholesterol 
and sterols stimulate their respective binding proteins (CHREBP and SREBP) which 
both stimulate the transcription of lipid biosynthesis genes. However, as 3T3-L1 cells 
exposed to ADMA underwent hypertrophy without any other alteration in external 
factors the transcriptional control of cell growth was investigated instead. Both IRS1 
and Glut4 are involved in the insulin signalling cascade and although normally 
stimulated by the binding of insulin their upregulation could increase signalling 
through this pathway. However, neither genes expression was effected by exposure 
to ADMA (figure 3.6a and b).  
The mammalian target of rapamycin (mTOR) is known as a major regulator of 
growth and therefore a likely candidate in the involvement of adipocyte hypertrophy. 
The activation of mTOR can occur through a number of mechanisms the best 
characterised of these being by insulin or growth factors via the PI3K pathway. 
Although amino acids are known to regulate mTOR activity through its translocation 
to the lysosome (Laplante and Sabatini, 2009; Settembre et al., 2012), the action of 
ADMA on mTOR transcription is a novel mechanism (figure 3.6). Direct action of 
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ADMA on promoter sites has not previously been reported and is currently being 
investigated through the use of a promoter reporter assay. To determine whether the 
upregulation in mTOR expression was coupled to an increase in activity and 
therefore contributes to adipocyte hypertrophy its downstream signalling targets 
were investigated.   
 
3.4.3 mTORC1 
To be functionally active mTOR must assemble into a complex with a number of 
cofactor proteins (Kim et al., 2002; Sarbassov et al., 2004). mTORC1 is best known 
for its involvement in protein synthesis through the phosphorylation of its 
downstream targets S6 kinase and 4e-BP1. After 48 hour treatment with ADMA 
neither protein expression nor phosphorylation was altered (figure 3.8). This may be 
due to their involvement in commitment and terminal differentiation to adipocytes 
rather than the expansion of mature cells. S6 kinase phosphorylation occurs early in 
adipocyte differentiation and is important in driving a number of adipogenic factors 
particularly C/EBPβ and C/EBPδ, as a result S6K knockouts are resistant to diet 
induced obesity as adipocyte hyperplasia does not occur (Carnevalli et al., 2010). 
These early markers of differentiation are also altered in 4e-BP-/- mice again 
suggesting a role in the very early stages of cellular commitment to an adipocyte 
phenotype (Le Bacquer et al., 2007), 
More recently mTORC1 has also been shown to be involved in the accumulation of 
lipids in both the liver and adipocytes (Laplante and Sabatini, 2009). mTORC1 
through an unknown pathway triggers the translocation of SREBP1c from the 
cytoplasm to the nucleus where it targets a number of genes including ACC, FASN 
and Scd-1. These three genes are all involved in lipid biogenesis and were therefore 
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candidates to be involved in adipocyte hypertrophy. ADMA at 10µM increased 
expression of both ACC and FASN, suggesting that adipocyte hypertrophy is due to 
an inappropriate increase in lipid synthesis. Hyperactive mTOR has been identified 
in obese fat tissue in rodents, (Khamzina et al., 2005; Um et al., 2004), and therefore 
may in part be due to the high ADMA concentrations associated with the disease. 
Interestingly SREBP1c has been suggested to downregulate DDAH1 expression 
(Ivashchenko et al., 2009) suggesting that excessive ADMA stimulates a cycle of 
increasing ADMA concentrations and adipocyte hypertrophy.  
To determine whether this mechanism is conserved in obesity ADMA signalling 
needs to be studied in vivo, this will be discussed in chapter five where a model of 
diet induced obesity in an adipocyte specific DDAH1 knockout is investigated. 
To confirm that increased adipocyte hypertrophy and lipid biosynthesis occur through 
mTOR signalling 3T3-L1 cells were treated rapamycin, an mTOR inhibitor. 
Rapamycin acts acutely on mTORC1 while needing more chronic exposure before 
inhibiting complex mTORC2.  Rapamycin reversed the effects of ADMA on adipocyte 
hypertrophy; furthermore, the upregulation of lipid biosynthesis genes were also 
overturned by rapamycin treatment (figure 3.11), thereby confirming the role of 
mTOR in ADMA-induced adipocyte hypertrophy.  
 
3.4.4 mTORC2 
The downstream signalling pathways of mTORC2 are less well known than those of 
complex 1 but mTORC2 has been identified as the enzyme involved in the primary 
phosphorylation of Akt at Ser473. ADMA increased phosphorylation at this site 
suggesting that the mechanism by which ADMA increases mTOR activity can work 
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on both complexes (figure 3.10). Interestingly, ADMA increased eNOS 
phosphorylation at ser1177, a target of Akt. This phosphorylation increases both the 
rate and maximal turnover of eNOS thereby introducing a possible pathway to 
increase NO production in the face of increasing ADMA concentrations. 
 
3.4.5 NO Independence 
At present all of ADMAs affects are thought to act through the inhibition of NO 
synthesis. Here the action of ADMA on cell size, mTOR expression and lipid 
synthesis gene transcription cannot be reproduced with the NOS inhibitors L-NAME 
and PB-ITU. As the effect of ADMA is not replicated by SDMA it is unique to ADMA 
rather than methylarginines in general. Early data not included here suggests that 
the application of the NO donor SNAP does not reverse the effects of ADMA, 
supporting an NO independent pathway although this needs to be investigated 
further. To determine how ADMA increases the transcription of mTOR further work 
on the mTOR promoter and whether ADMA can alter the expression of any 
transcription factors needs to be completed. 
 
3.5 Conclusion 
In summary, 3T3-L1 cells are a good model to study the actions of ADMA in obesity 
as they produce both ADMA and NO and express DDAH and NOS enzymes. 
Exposing these cells to chronic exogenous ADMA leads to cellular hypertrophy due 
to an increase in lipid synthesis. The mechanism by which this occurs is through the 
stimulation of mTOR transcription and in turn the upregulation of its signalling 
activity. ADMAs stimulation of mTOR transcription is novel as both a regulatory 


















The investigation of DDAH and ADMA in 3T3-L1 cells in the previous chapter found 
that exogenous ADMA cause adipocyte hypertrophy by increasing mTOR signalling 
and the expression of lipid synthesis genes. However, 3T3-L1 cells are derived from 
a cancerous cell line (Green and Kehinde, 1974) and may not be representative of 
the action of ADMA and DDAH1 in vivo. Therefore to investigate whether the 
changes seen in vitro are replicated in adipose tissue it is necessary to move into 
primary adipocytes.  
Adipocytes are not the only cell type that affects adipose function. Of particular 
interest with respect to the NO-ADMA-DDAH pathway is the interaction between 
adipose and the vasculature, due to the major role of NO in the endothelium. 
Adipocytes produce adipokines such as adiponectin and TNFa that can alter NO 
production within vessel walls effecting vessel tone and ultimately blood pressure 
responses (Chen et al., 2003; Cheng et al., 2007; Morikawa et al., 2000; Virdis et al., 
2011).  Equally, the vasculature can have lasting effects adipose tissue physiology. 
Blood vessels are the predominant source of lipids and glucose for triacylglyceride 
production as well as providing other nutrients and oxygen, and must continue to do 
this when adipose expands. Angiogenesis, of which NO and ADMA are known 
regulators (Wojciak-Stothard et al., 2007), is particularly important in adipose 
expansion and for maintaining healthy adipose in development and obesity (Rupnick 
et al., 2002; Voros et al., 2005). It is thought that adipocyte hypoxia promotes 
inflammation and insulin resistance (Hosogai et al., 2007; Ye et al., 2007). 
106 
 
To investigate DDAH1 and ADMA in adipose tissue, in both adipocytes and blood 
vessels, it is necessary to move away from the cell culture experiments described in 
chapter three and instead use whole body in vivo experiments. This chapter 
describes the production and characterisation of two murine model systems that will 
be used to explore the relationship between adipose tissue and blood vessels. The 
first model, an adipocyte specific DDAH1 knockout, was developed to replicate the 
work done in 3T3-L1 cells verifying that increased mTOR signalling is conserved in 
vivo and to further this by investigating how this affects whole body physiology. The 
second model, an endothelial specific deletion of DDAH1 was developed to explore 
the role of ADMA in blood vessels and to investigate how this affected adipose 
physiology.  
The genetic manipulation of mouse strains has long been used to explore particular 
phenotypes and the intracellular mechanisms that drive them. Early studies bred 
mice for a particular trait, for example the BPH/2 and BPL/1 strains which exhibit 
hyper and hypotension respectively (Schlager, 1974). More recently specific genes 
have been targeted through either global deletion or overexpression.  The global 
deletion of DDAH1 was first achieved through the replacement of exon one with a 
neomycin cassette through homologous recombination. However, as this led to 
foetal lethality the heterozygous deletion of DDAH1 was studied instead (Leiper et 
al., 2007). More recently a viable DDAH1 global knockout mouse has been 
developed (Hu et al., 2011) through the specific deletion of DDAH1 in sperm which 
then confers a heterozygous global deletion to the offspring. An overexpression 
model of DDAH1 has also been developed through the insertion of a human DDAH1 
construct driven by the β-actin promoter to achieve global expression (Dayoub et al., 
2003). Although both of these techniques have greatly expanded the knowledge of 
107 
 
DDAH1 function they are limited to the fact that the genetic manipulation is global 
and therefore subtle roles of DDAH1 in different systems and tissues cannot be 
determined.  
To achieve a targeted approach to gene manipulation the Cre-LoxP system was 
developed which can drive gene deletion in a site-specific manner, be under 
temporal control, or a combination of the two. The Cre-LoxP system was found in the 
P1 bacteriophage and drives the specific recombination of two DNA sequences 
(Sternberg and Hamilton, 1981); the cre recombinase enzyme cutting DNA 
specifically at the LoxP sequence (fig 4.1). This method was then developed for use 
in mammalian cells (Sauer and Henderson, 1988) adding LoxP sites either side of 
the sequence to be deleted, thereby developing a new method of genetic 
manipulation. To achieve tissue specificity cre recombinase expression is controlled 
by a promoter whose activity is restricted to the tissue of choice (Tsien et al., 1996). 
The recombinase is then switched on at the stage of development where the 




Figure 4.1:  The Cre-LoxP system. Cre recombinase expression is driven by a 
tissue specific promoter which cuts DNA at LoxP sites. In DDAH1 the LoxP sites are 
inserted around exon 1 which is deleted in the presence of Cre. 
 
Cre recombinase expression is driven by a tissue specific promoter to restrict 
recombinase activity to a specific cell type. Cre recombinase cuts at LoxP sites 
deleting the flanked region and allowing recombination of the two exposed ends. To 
generate a DDAH1 knockout LoxP sites were inserted around exon 1 which was 
109 
 
deleted upon cre expression. Adipocyte specific deletion has been achieved through 
the development of a number of cre lines. The first adipocyte specific cre line utilised 
the adipocyte protein-2 (aP2) gene promoter which drives fatty acid-binding protein-4 
expression (Barlow et al., 1997); this was followed by a further two strains developed 
independently using the same promoter to drive recombination (Abel et al., 2001; He 
et al., 2003). The aP2 lines achieve cre expression in both white and brown fat 
depots; however, in some cases activity in perigonadal tissue was less than in 
subcutaneous fat (Lee et al., 2013). Furthermore in some of these lines ectopic cre 
activity has been noted in the heart and skeletal muscle. To improve specificity a 
second adipocyte cre line was developed utilising the adiponectin (AdipoQ) gene to 
drive recombination (Eguchi et al., 2011; Wang et al., 2010). Both these lines lead to 
strong recombinase activity in all adipose tissue but little expression elsewhere (Lee 
et al., 2013).  The AdipoQ cre developed by Evan Rosens lab (Eguchi et al., 2011) 
was used in the development of the DDAH1 adipocyte specific deletion.  This line 
achieves equal expression of cre recombinase in different visceral adipose depots 
but has slightly lower expression in subcutaneous fat due to lower levels of 
adiponectin production.  
Endothelial specific cre recombinase expression has been driven by five different 
promoters. The first to be utilised was the PECAM-1 promoter (Terry et al., 1997) 
although this caused global deletion through germline expression. As a result further 
cre lines were developed including those driven by the Tie-1 and Tie-2 receptor 
promoters (Gustafsson et al., 2001; Kisanuki et al., 2001), the  VEGF receptor (Licht 
et al., 2004) and VE-cadherin (Alva et al., 2006). DDAH1 endothelial deletion (Hu et 
al., 2009) driven by a Tie-2 promoter (Koni et al., 2001) has previously been 
described. In these mice it was determined that almost all DDAH1 expression is 
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confined to the endothelium, with little expression elsewhere. However, this specific 
promoter can also drive cre expression in the germline therefore developing a global 
rather than specific knockout (JaxLab, 2013). To compare the endothelial deletion in 
here to that in Hu et al (2009) another Tie-2 driven DDAH1 deletion was developed 
using a construct that has been reported to be tissue specific (Alp et al., 2003), and 




1. To establish and characterise conditional deletion of DDAH1 within adipocytes 
and to determine any effects this has on the NO-ADMA-DDAH pathway. 
 
2. To establish and characterise the specificity of Tie-2 cre expression and to 




4.3 Results  
4.3.1 DDAH1 floxed mice 
DDAH1 heterozygous floxed mice were generayed by Genoway (Lyon, France) and 
mated to generate homozygous floxed progeny. The presence of floxed alleles was 
determined through genotyping of tail clippings. Figure 4.2a is a representative 
genotyping gel; a wildtype mouse (lane 1) produces a single band at 427 base pairs, 
a homozygous mouse (lane 3) produces a band at 568 base pairs, the centre lane 
shows a heterozygous subject with both bands visible. DDAH1 homozygous floxed 
mice were fertile and had no obvious phenotypic differences from wildtype mice. 
4.3.2 Cre recombinase 
DDAH1 homozygous floxed mice were mated with DDAH1 homozygous 
floxed/heterozygous cre mice to generate litters containing an approximate 1:1 ratio 
of DDAH1 homozygous floxed cre positive and cre negative mice. Cre negative mice 
were used as controls. Cre expression was verified through the appearance of a 





Figure 4.2:  Genotyping gels of DDAH1 floxed alleles and cre expression. (A) 
Lane 1: Wildtype DDAH1 subject, Lane 2: Heterozygous subject, Lane 3: 
Homozygous DDAH1 floxed subject. (B) Top row: DDAH1 floxed genotyping as in 
(a), Bottom row: Cre recombinase expression is verified through the presence of a 




4.3.3 Adipocyte DDAH1 deletion 
Primary adipocytes were isolated from floxed controls and adipocyte specific 
DDAH1-/- (DDAH1Ad-/-) mice. To verify that isolated cells were adipocytes intracellular 
lipids were stained with BODIPY (a green neutral lipid dye). Adipocytes (figure 4.3a) 
had a large cellular lipid droplet with small nuclei stained with DAPI (blue).  
DDAH1 mRNA concentrations was significantly reduced in DDAH1Ad-/- primary 
adipocytes (0.262 ± 0.07 in DDAH1Ad-/- ; 0.847 ± 0.133 in floxed mice, p<0.01, figure 
4.3b) but remained constant in other tissues including the kidney and lung. DDAH2 
expression was unaffected by DDAH1 deletion in adipocytes (figure4.3c) while 
eNOS expression increased from 0.698 ± 0.18 in controls to 1.741 ± 0.359 in 





Figure 4.3:  DDAH1 mRNA transcript is deleted specifically in DDAH1Ad-/- 
adipocytes and not in other tissues. (A) 1° adipocytes are stained with BODIPY 
(green) highlighting the lipid droplet and DAPI (blue) staining the nucleus. (B) 
DDAH1, (C) DDAH2 and (D) eNOS mRNA transcript levels from isolated adipocytes, 
lung and kidney from floxed (black) and DDAH1Ad-/- mice (grey). DDAH1 deletion 
occurs only in DDAH1Ad-/- adipocytes (floxed controls 0.847 ±0.133, DDAH1Ad-/- 
0.262 ± 0.07, * p<0.01), while DDAH2 expression remains unaltered. An increase in 
eNOS expression is seen in DDAH1Ad-/- adipocytes (0.698 ± 0.18) compared to 
floxed controls (1.741 ± 0.359),* p<0.05.  
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The deletion of DDAH1 in adipocytes was also confirmed by western blotting. 
DDAH1 protein fell to 0.197 ± 0.07 in DDAH1Ad-/- mice (p<0.001, figure4.4a and b). 
As with transcript DDAH1 protein remained constant in both lung and kidneys. 
DDAH2 protein expression remained unaltered in the DDAH1Ad-/- adipocytes (figure 
4.4a and c). Detection of an eNOS band in primary adipocytes was not possible.  
Deletion or inhibition of DDAH1 has previously been shown to increase ADMA 
concentrations with a corresponding decrease in NOx concentrations (Leiper et al, 
2007). To determine whether adipocyte derived DDAH1 has this affect,cytosolic 
lysates of isolated adipocytes were extracted and analysed by mass spectrometry to 
detect ADMA. There was a small but not statistically significant increase in 
intracellular ADMA in DDAH1Ad-/- mice (figure 4.5a, floxed 0.078μmol/mg protein ± 
0.012, DDAH1Ad-/- 0.108μmol/mg protein ± 0.033). However, when NOx 
concentrations were analysed there was a significant fall in total NOx production in 
DDAH1Ad-/- adipocytes (figure 4.5b, floxed controls 30.66μmol/mg ± 4.99, DDAH1Ad-/- 
18.22µmol/mg ± 3.87, p<0.05).  There was no difference in circulating ADMA or NOx 





Figure 4.4:  DDAH1 protein is deleted in DDAH1Ad-/- adipocytes.  (A) Western 
blotting of floxed and DDAH1Ad-/- adipocytes, lung and kidney probing for DDAH1 
and DDAH2 with β-actin as a loading control. Relative expression of (B) DDAH1 
showed a decrease to 0.197 ± 0.07, p<0.001, in DDAH1Ad-/- mice; while (C) DDAH2 





Figure 4.5: ADMA concentrations rose slightly in DDAH1Ad-/- adipocytes 
while NOx concentrations fell. There was no change in circulating 
concentrations of ADMA or NOx. (A) ADMA concentrations in isolated adipocytes 
increase from 0.078μmol/mg ± 0.012 in DDAH1 floxed mice to 0.108μmol/mg ± 
0.033 with DDAH1 adipocyte deletion (ns). (B) NOx concentrations fall in 1° 
adipocytes from 30.66μmol/mg ± 4.99 in controls to 18.22μmol/mg ± 3.87 in 
DDAH1Ad-/- subjects (*p<0.05). Circulating plasma concentrations of both ADMA (C) 
and NOx (D) were unaffected by adipocyte DDAH1 deletion. 
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4.3.4 Endothelial Cre expression 
To produce an endothelial specific DDAH1 deletion cre expression was driven by the 
tie-2 promoter. However, as not all lines driven by this promoter have been specific, 
confirmation that cre expression was confined to the endothelium was needed. This 
was achieved by crossing the tie-2 mouse strain to a yellow fluorescent protein 
(YFP) reporter mouse where YFP is only expressed in the presence of cre 
recombinase. Tissue sections from these mice were stained with CD31, an 
endothelial specific marker, to confirm colocalisation with YFP expression. 
Sectioning of the kidney (figure 4.6) identified a blood vessel with YFP and CD31 
colocalisation in the endothelial lining of the lumen. YFP expression does not occur 
elsewhere suggesting that cre activity is confined specifically to endothelial cells. 
Sectioning and staining were performed by Dr Lucy Colman.  
 
4.3.5 Endothelial DDAH1 deletion 
To confirm that DDAH1 deletion is achieved in endothelial cells lungs from DDAH1 
floxed and endothelial DDAH1 negative (DDAH1En-/-) mice were minced and then 
cultured to encourage outgrowth of primary cells (figure 4.7a). This was followed with 
an ICAM-antibody bead purification to isolate the endothelial cells (figure 4.7b). Upon 
purification of the endothelial cells PCR was performed on extracted DNA. 
Amplification of DDAH1 primers (figure 4.7c and d) only occurs after exon one 
deletion due to the large size of the product in control mice and therefore only occurs 





Figure 4.6:  Tie-2 cre expression is specific to the endothelium. A 
representative image taken from a tie-2 YFP mouse of a kidney blood vessel.  (A) 
DAPI staining of cell nuclei, (B) cre driven YFP expression, (C) CD31 staining of the 
endothelium, (D) The merge of all three channels shows colocalisation of CD31 with 






Figure 4.7:  Endothelial cells are purified from the outgrowth of lung 
fragments and show DDAH1 gene deletion only in DDAH1En-/- mice. (A) Lung 
fragments were cultured to encourage the outgrowth of new cells including 
endothelial cells. (B) Endothelial cells are isolated by endothelial specific ICAM 
antibodies bound to magnetic beads. (C-D) The amplification of DDAH1 primers 
situated either side of exon one only occurs in DDAH1En-/- endothelial cells and not in 
DDAH1 floxed mice where the product is too large to amplify. FP- forward primer, 
RP- reverse primer.  
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To ascertain that DDAH1 deletion in endothelial cells was maintained at protein level 
the pulmonary outgrowth was stained for DDAH1 and CD31. In DDAH1 floxed mice 
(figure 4.8a) DDAH1 staining colocalised with CD31 confirming DDAH1 expression 
in endothelial cells. When DDAH1En -/- cells (figure 4.8b) were stained CD31 staining 
was still present but no DDAH1 staining was visible confirming that DDAH1 had 
been knocked out in this cell type.  
Previously it has been suggested that endothelial cells account for almost all DDAH1 
expression in the kidney and liver. To determine whether this was the case western 
blots comparing floxed and DDAH1En -/- kidney and liver were performed (Figure 
4.9a). No detectable change in DDAH1 expression between the two groups was 
apparent in either tissue (Figure 4.9b).   
Plasma ADMA concentrations were analysed by mass spectrometry and found to be 
unaffected by endothelial DDAH1 deletion (figure 4.10a). Plasma NOx 
concentrations were also analysed and found to be significantly raised in DDAH1En -/- 






Figure 4.8:  DDAH1 colocalises with CD31 in DDAH1 floxed endothelial cells 
but is not expressed in DDAH1En-/- endothelial cells. Endothelial cells from (A) 
DDAH1 floxed and (B) DDAH1En-/- mice were stained with DAPI nuclear stain, 
endothelial specific CD31 and DDAH1. DDAH1 colocalised with CD31 in floxed mice 





Figure 4.9:  DDAH1 expression remains unaffected in DDAH1En-/- kidney and 
liver. (A) Western blotting of DDAH1 in kidney and liver taken from DDAH1 floxed 
and DDAH1En-/- mice. (B) Analysis of western blotting shows no difference in DDAH1 







Figure 4.10:  ADMA plasma concentrations were unaffected by endothelial 
DDAH1 deletion, however systemic NOx concentrations were increased in 
these mice. (A) Plasma ADMA concentrations were unaltered in DDAH1En-/- mice. 
(B) Circulating NOx concentrations were increased in DDAH1En-/- mice (46.24μM ± 





Adipose tissue is made up of a number of cell types, including adipocytes, blood 
vessels and inflammatory cells, which interact to complete the metabolic and 
endocrine functions of fat. As DDAH1 is expressed in both adipocytes and 
endothelial cells tissue specific knockouts were produced to dissect the role of the 
NO-ADMA-DDAH1 pathway in each cell type rather than the tissue as a whole.  The 
aim of this chapter was to establish that DDAH1 deletion occurs in these cell types 
while continuing to be expressed elsewhere.  
 
4.4.1 Adipocyte specific DDAH1 deletion  
Adipocyte specific deletion of DDAH1 was driven by the adiponectin promoter. Both 
DDAH1 mRNA (figure 4.3b) and protein (figure 4.4a and b) were absent from 
isolated primary adipocytes. A small amount of DDAH1 is still amplified by rt-qPCR 
and a small band still visible by western blotting; this is likely to be contamination 
from small fragments of blood vessels and fibroblasts present in adipose tissue that 
were not removed during the isolation procedure. DDAH1 expression was unaffected 
in both kidney and lung tissue suggesting that cre expression is specific to 
adipocytes.  DDAH2 expression was unaffected by DDAH1 deletion, although 
interestingly eNOS mRNA expression increased two fold in response. Due to the 
small amount of protein obtainable from primary adipocytes it was not possible to 
confirm whether this increase in eNOS was also seen at the protein level. The 
increase in eNOS may be a feedback mechanism to attenuate the effect of NOS 
inhibition in an ADMA rich environment. As ADMA in 3T3-L1 cells caused eNOS 
phosphorylation it would be interesting to probe whether this occurs in vivo. 
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To confirm that DDAH1 deletion in adipocytes did indeed cause an increase in 
ADMA both intracellular and circulating concentrations were determined. Plasma 
ADMA was not affected by DDAH1 deletion suggesting that under normal 
physiological conditions adipose is not a major source of circulating ADMA (figure 
5.4). A small increase is seen in intracellular ADMA, although due to sample 
variability this increase did not reach statistical significance, it did have a 
physiological downstream affect with a significant reduction in NOx production in 
adipocytes lacking DDAH1. These observations are consistent with accumulation of 
ADMA resulting in chronic inhibition of NOS. However the relatively modest increase 
in ADMA that we detected in DDAH1Ad-/- adipocytes is associated with a substantial 
reduction in NOx concentrations. As ADMA is a competitive inhibitor of NOS the 
degree of inhibition achieved by increasing ADMA is dependent on the prevailing 
arginine concentration. This data might suggest that arginine concentrations in 
adipocytes are relatively low, this could be measured by mass spectrometry, or that 
DDAH1 can influence NOS activity independent of ADMA.  There have been a 
number of studies suggesting that DDAH enzymes can influence NO production 
independent of changes in ADMA concentrations (Pope et al., 2009; Zhang et al., 
2011), however the biological significance of these observations is yet to be tested.   
 
4.4.2 Endothelial deletion of DDAH1  
DDAH1 endothelial negative mice have previously been generated by Hu et al 
(2009) who reported that DDAH activity is entirely confined to the endothelium and 
that it is the major tissue responsible for ADMA metabolism. However, other studies 
have shown that DDAH1 is expressed in a number of cell types including the kidney 
proximal tubule and hepatocytes where DDAH1 specific knockout have been made 
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(unpublished data). Furthermore the specific promoter cre used by Hu et al (2009) 
has been reported to express in both the male and female germline indicating that 
the promoter construct used to create this line does not retain an endothelium-
specific expression pattern in vivo and may cause a global deletion in some progeny. 
To investigate the expression of DDAH1 in endothelial cells and its role in global 
ADMA metabolism as well as adipose physiology, a second endothelial specific 
knockout mouse was developed.  
Here tie-2 promoter specificity was established using a YFP reporter mouse where 
YFP expression was confined to endothelial cells lining the lumen of blood vessels 
(figure 4.6). DDAH1 deletion was confirmed in primary pulmonary endothelial cells at 
both the DNA level through end-point PCR (figure 4.7 c) and at the protein level 
through immunofluorescent staining (figure 4.8). DDAH1 expression remained 
unaffected by endothelial deletion in the kidney and liver (figure 4.9). Therefore this 
mouse model has been established as an endothelial specific DDAH1 deletion, and 
it can be concluded that DDAH1 expression is not confined to endothelial cells and is 
strongly expressed in other cell types.  
As very little material was gathered from isolated pulmonary endothelial cells the 
effect of DDAH1 deletion on intracellular ADMA and NOx concentrations could not 
be determined.  An alternative would have been to measure secreted concentrations 
in the cell media but due to the mixed nature of primary cell outgrowth it would be 
difficult to determine the number of endothelial cells in these cultures relative to the 
amount of ADMA being produced. As a result ADMA and NOx could only be 
measured in the plasma of these mice (figure 4.10).  As with DDAH1Ad-/- mice 
systemic ADMA concentrations were unaffected by endothelial DDAH1 deletion. 
Converse to previous studies no one cell type seems to be responsible for global 
128 
 
ADMA concentrations; rather the additive effects of a global deletion alter systemic 
ADMA. When investigating NOx concentrations it was surprising to find that 
concentrations were actually increased in DDAH1En-/- mice compared to controls. As 
to why this occurs is further explored in chapter six.     
 
4.5 Conclusion 
Two novel murine models of DDAH1 deletion have been generated and verified for 
their tissue specificity. Both models are useful to investigate the specific roles of 
DDAH1 and ADMA in relevant cell types rather than the more difficult approach of 
determining their subtle roles in a global knockout. How these specific DDAH1 
deletions affect normal and obese adipose physiology will be investigated in the next 












Chapter 5: The DDAH1Ad-/- Mouse 
 
5.1 Introduction  
Adipocytes are major regulators of energy homeostasis through the regulation of lipid 
storage and  the release of adipokines that signal to other organs controlling nutrient 
intake. The DDAH-ADMA-NOS pathway has been identified in primary adipocytes; 
presently, it has been shown that DDAH1 and DDAH2 are both expressed in human 
(Spoto et al., 2007) and rat adipose tissue (Iwasaki, 2012). However, the role that the 
DDAH-ADMA-NOS pathway plays in vivo in the regulation of adipocyte metabolism is 
currently unknown. Overexpression of DDAH1 has been shown to improve the 
control of glucose handling in vivo; although it is unknown how much adipocyte 
DDAH1 is involved in this improvement (Sydow et al., 2008).  
To investigate the physiological role of DDAH1 and ADMA in adipocytes, an 
adipocyte specific DDAH1 knockout mouse (DDAH1Ad-/- ) described in chapter four, 
was developed. The phenotyping of this mouse aims to address questions relating to 
how DDAH1 and in consequence ADMA affect energy homeostasis including glucose 
handling and fat storage. Furthermore, this mouse model will allow us to investigate 
whether the major findings from in vitro experiments, described in chapter three, also 
occur in vivo. Exogenous ADMA caused adipocyte hypertrophy in 3T3-L1 cells 
through the upregulation of mTOR activity and lipid biosynthesis gene transcription. 
Overexpression of DDAH1 in vivo has previously been noted to down-regulate ACC 
and FASN expression in white adipose tissue which is an early indication that the 




In human obesity it has been observed that ADMA concentrations increase in relation 
to fat mass and BMI (Eid et al., 2004; Marliss et al., 2006; McLaughlin et al., 2006). 
At present it is unknown why this increase occurs and whether it is due to DDAH1 
dysfunction in obese adipocytes. This will be investigated by subjecting DDAH1Ad-/- 
mice to a high fat diet experimentally modelling human diet induced obesity (DIO). 
Furthermore, it has been suggested that mTOR activity is inappropriately high in 
obesity and that this contributes to insulin resistance (Khamzina et al., 2005); 
however whether this pathway is active in adipose is not fully understood. In the light 
of our observations that ADMA increased mTOR activity in 3T3-L1 cells it will be 
interesting to investigate whether any rise in ADMA during DIO is associated with a 
rise in mTOR expression.  
     
5.2 Aims 
 
1. To determine whether the affects of ADMA on adipocyte hypertrophy seen in 
3T3-L1 cells are conserved in DDAH1Ad-/- mice. 
 
2. To investigate whether increased mTOR expression and signalling is seen in 
DDAH deficient adipocytes in vivo. 
 
3. Does adipocyte hypertrophy have affects on adipokine secretion and glucose 
handling? 
 
4. To assess how DDAH1Ad-/- affects diet induced obesity in terms of glucose 




5.3  Results 
5.3.1 Body Composition 
DDAH1Ad-/- and DDAH1 floxed controls were maintained on a normal chow diet and 
monitored from six- weeks of age for a further 16 weeks. At the start of the study 
both groups weighed an average of 22g (figure 5.1a) and continue to gain weight at 
the same rate for a further six weeks. After six weeks the weight of control mice 
weight plateaued reaching 31g ± 1.09 after 16 weeks, whereas DDAH1Ad-/- mice 
continue to gain weight reaching 34.2g ± 0.77 at the end of the study (p<0.05, figure 
5.1b).  
Fat and lean mass were determined by echo-MRI. At the start of the study both 
cohorts had on average 2.2g fat per mouse which increased at a similar rate until 
about ten weeks into the study (figure 5.1c). Again control mice plateaued and 
remain at an average of 4.3g ± 0.69 fat per mouse while DDAH1Ad-/- mice continue to 
lay down fat stores reaching an average of 5.9g ± 1.0 fat per mouse; this 
represented on average a 36% increase in fat mass, however, due to a high level of 
variability between subjects this did not reach significance (figure 5.1d).  
 Lean mass, which is predominantly a measure of muscle mass, was 18.09g in 
controls and 19.09g in DDAH1Ad-/- at six-weeks of age. This increased rapidly in the 
first two weeks until the mice reached maturity (figure 5.1e). After this time gain of 
muscle mass slows considerably with both cohorts reaching similar final lean mass, 
controls 24.7g ± 0.98 and DDAH1Ad-/- 24.56g ± 1.31 per mouse (figure 5.1f). 
Together this data suggests that DDAH1Ad-/- mice store more fat which contributes to 






Figure 5.1  (Previous page): DDAH1Ad-/- mice have increased body mass after 
16 weeks due to an increase in fat deposition. DDAH1 floxed and DDAH1Ad-/- 
mice were observed from six-weeks old for 16 weeks.  (A-B) DDAH1 floxed (blue 
circles) and DDAH1Ad-/- (green triangles) mice weigh the same at six-weeks old 
(controls 22.17g ± 2.53, DDAH1Ad-/- 23.29 ± 2.47). After 16 weeks controls reach 
31.1g ± 1.0 while DDAH1Ad-/- have a higher mass at 34.3g ± 0.77 (* p>0.05). (C-D) 
Fat mass on both cohorts start at 2.2g per mouse which increases to 4.3g ± 0.69 in 
floxed controls and 5.9g ± 1.02 in DDAH1Ad-/-. (E-F) Lean mass (muscle) starts at 
18.09g in controls and 19.09g in DDAH1Ad-/- and increases steadily in both cohorts 




5.3.2 Adipocyte Hypertrophy 
To further investigate the apparent increase in fat mass seen in DDAH1Ad-/- mice, 
epididymal fat pads were removed at the end of the study. As with total fat mass 
DDAH1Ad-/- mice had slightly larger epididymal depots than control littermates (figure 
5.2a). On average this was a 14% increase in fat pad size but this did not reach 
significance due to a high level of variability. 
Chronic exposure to extracellular ADMA caused adipocyte hypertrophy in 3T3-L1 
cultures. To determine whether intracellular ADMA has the same affect in vivo 
epididymal fat was fixed and stained with Elastic Van Gieson’s (EVG) dye. The 
average area of adipocytes in each subject was determined and it was found that 
DDAH1Ad-/- mice had larger adipocytes (18.05μm2 ± 1.01) than control littermates 
(14.47μm2 ± 0.52, p>0.05, figure 5.2b and c).  
The mechanism underlying adipocyte hypertrophy in 3T3-L1 cells was an increase in 
lipid synthesis through the upregulation of mTOR signalling. To investigate this 
mechanism in vivo primary adipocytes were isolated and analysed by rt-qPCR. 
Figure 5.3a demonstrates an upregulation of mTOR transcription from 1.1 ± 0.1 in 
controls to 2.14 in DDAH1Ad-/- adipocytes (figure 5.3a, p<0.05). Furthermore, ACC 
increases from 1.93 ± 1.09 to 7.4 ± 2.20 and FASN from 0.82 ± 0.47 to 1.91 ± 0.31 





Figure 5.2:  DDAH1Ad-/- mice have larger adipocytes than their littermate 
controls. (A) Epididymal fat pad mass was not significantly different between 
DDAH1 floxed (0.346g ± 0.085) and DDAH1Ad-/- (0.397g ± 0.073) mice. (B) The 
average area of adipocytes was larger in DDAH1Ad-/- (18.05μm2 ± 1.01) than controls 
(14.47μm2 ± 0.52, *p<0.05). (C) Representative images of EVG staining of 





Figure 5.3:  mTOR, ACC and FASN upregulation is conserved in DDAH1Ad-/- 
primary adipocytes. (A) mTOR transcript is increased in DDAH1Ad-/- primary 
adipocytes (2.14 ± 0.61) compared to those extracted from floxed mice (1.11 ± 0.16, 
p<0.05). (B-C) Genes regulating lipid biosynthesis are upregulated in DDAH1Ad-/- 
adipocytes – ACC from 1.94 ± 1.10 to 7.48 ± 2.23 (p<0.05), FASN from 0.82 ± 0.47 






To investigate the physiological consequence of ADMA related adipocyte 
hypertrophy the plasma concentrations of the adipokines adiponectin and leptin were 
measured. Leptin increases slightly in DDAH1Ad-/- mice (Figure 5.4a) while there is a 
small corresponding decrease in adiponectin concentrations (Figure 5.4b, also not 
significant). These results are in keeping with an increase in fat mass but suggest 
the change is not great enough to affect adipokines production or secretion. 
5.3.4 Inflammation 
Increased inflammation is often associated with increased fat mass. DDAH1Ad-/- mice 
have increased macrophage infiltration into the adipose tissue (22.21 ± 1.29), as 
measured by the number of Mac2 stained cells, compared to floxed controls (17.96 ± 
0.99, p<0.05, figure 5.5a and b). To determine if increased macrophage infiltration 
correlates with an increased inflammatory response from the surrounding adipocytes 
Rt-qPCR analysis assessed TNFa expression. However, no difference between the 





Figure 5.4:  Adipokines remain unaltered in DDAH1Ad-/- mice compared to 
controls. (A) Leptin plasma concentrations show a non-significant increase from 
7.13ng/ml ± 1.04 in DDAH1 floxed mice to 8.25ng/ml ± 1.30 in DDAH1Ad-/- mice. (B) 
Adiponectin plasma concentrations fall slightly but not significantly to 12.87μg/ml ± 





Figure 5.5:  Macrophage infiltration into adipose tissue increases with 
DDAH1 deletion. (A) Epididymal fat was incubated with Mac2 antibodies and the 
average number of macrophages (brown stain) per an image was calculated. (B) 
Macrophage infiltration increases from 17.96 ± 0.99 in controls to 22.21 ± 1.29 in 
DDAH1Ad-/- mice. (C) TNFα transcript production in 1° adipocytes remains unaffected 
by DDAH1 deletion.  
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5.3.5 Adipocyte DDAH1 in obesity 
DDAH1 dysregulation in adipocytes causes hypertrophy in mice on a normal chow 
(NC) diet. To determine whether this affect is exacerbated in obesity DDAH1Ad-/- mice 
were put on a high fat diet (HFD), 60% energy from fat, for 16 weeks. As expected, 
mice on a HFD gained weight at a much faster rate and to a much larger degree 
compared to those on a NC diet (DDAH1 floxed – NC 31.1g ± 1.0, DDAH1 floxed – 
HFD 47.9g ± 2.1, figure 5.6a). However, there was no difference in either the rate of 
weight gain or the final weight between DDAH1 floxed or DDAH1Ad-/- mice (50.0g ± 
1.0, figure 5.6b) on a HFD.   
The increased weight gain in mice on a HFD is due to an increased deposition of fat 
(figure 5.6c and d) where both DDAH1 floxed (20.6g ± 2.5) and DDAH1Ad-/- mice 
(18.81g ± 3.16) have significantly more fat than control mice on a NC diet (4.34g ± 
0.70). Lean mass is unaffected by a HFD and all three groups end the study at 
around 23g (figure 5.6e and f).  The body composition differences between DDAH1 
floxed and DDAH1AD-/- seen on a normal diet no longer have any affect after the mice 
are placed on a HFD. 
As with total fat mass, there was no difference in the amount of epididymal fat 
between floxed and DDAH1Ad-/- mice; although the final mass was three times larger 
than mice on a normal chow diet (figure 5.7a). As a consequence of a HFD 
adipocytes store greater amounts of triglycerides; therefore adipocyte hypertrophy is 
an integral factor in obesity. A HFD caused the average cell size to increase from 
14.47µm2 ± 0.42 in floxed mice on NC to 46.76µm2 ± 8.22 after fat feeding. However, 
there was again no difference in adipocyte size between the two genotypes (figure 







Figure 5.6  (Previous Page): DDAH1 floxed and DDAH1Ad-/- mice gain equal 
amounts of weight and fat when on a high fat diet. Mice were placed on a high 
fat diet (HFD) with 60% energy from fat for 16 weeks. (A-B) Mice on a HFD gain 
more weight than those on a normal diet; however, there is no difference in the final 
weight of the two groups (control 47.97g ± 2.13, DDAH1Ad-/- 50.0g ± 1.02). Fat and 
lean mass was analysed by echo-MRI. (C-D) Floxed and DDAH1Ad-/- mice gain more 
fat mass then the control diet cohort although there is no difference between the two 
groups (floxed 20.6g ± 2.49, DDAH1Ad-/- 18.81 ± 3.16). (E-F) Lean mass is 
unaffected by a HFD with all groups reaching the same final weight (floxed 23.15g ± 






Figure 5.7:  Epididymal fat mass and adipocyte size are the same in floxed 
and DDAH1Ad-/- mice on a high fat diet. (A) On a high fat diet (HFD) epididymal fat 
pads are much larger than mice on normal chow (NC), however, there is no 
difference between DDAH1 floxed (1.34g ± 0.08) and DDAH1Ad-/- (1.53g ± 0.29) 
mice. (B) Adipocytes are enlarged after a HFD compared to NC mice, although 
unaffected by genotype (DDAH1 floxed mice 46.7µm2 ± 8.22 and DDAH1Ad-/- 
53.35µm2 ± 7.59). (C) Representative images of EVG stained epididymal fat pads. 
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To investigate why the genotypic effect of increased fat on a normal diet was not 
conserved after HF feeding ADMA concentrations were determined in both plasma 
and primary adipocytes. HF feeding did not affect circulating ADMA concentrations 
(figure 5.8a), but did increase intracellular ADMA in DDAH1 floxed and DDAH1Ad-/- to 
a similar extent (0.66µmol/mg ± 0.16 and 0.47µmol/mg ± 0.11 respectively, figure 
5.8b). 
Although plasma ADMA was unaffected plasma NOx concentrations increased in 
both cohorts after high fat feeding (figure 5.8c). Possibly due to an increase in 
systemic inflammation associated with obesity and an upregulation of macrophage 
iNOS activity. Intracellular NOx concentrations were inversely correlated with 
intracellular  ADMA and fell dramatically from 30.66µmol/mg protein ± 4.99 in 
DDAH1 floxed mice on a normal diet to 9.87µmol/mg protein ± 1.59 on a HFD. 
However there was no difference between the floxed and DDAH1Ad-/- mice (figure 
5.8d).   
As HFD raises ADMA concentrations, mTOR mRNA levels were measured to 
determine whether HFD induced mTOR via elevation of ADMA. In both floxed and 
DDAH1Ad-/- mTOR transcription was increased (figure 5.9a). The increase in both 
ADMA and mTOR due to a HFD were much larger than those caused by DDAH1 
deletion and therefore overrode the knockout phenotype seen on a normal diet. 
When the downstream lipid biosynthesis genes were investigated it was found that 
ACC upregulation by ADMA was completely inhibited by HFD and therefore ACC 
levels were the same as control animals (figure 5.9b). However FASN transcription 
was still upregulated in both DDAH1 floxed and DDAH1Ad-/- adipocytes after a HFD 




Figure 5.8:  Adipocyte ADMA is increased and NO production decreased 
after HF feeding. (A) Plasma ADMA concentrations are unaffected by a HFD. (B) 
Adipocyte intracellular ADMA concentrations increased after high fat compared to 
normal chow (NC) diet with no difference between DDAH1 floxed 
(0.66µmol/mg±0.16) and DDAH1Ad-/- (0.47µmol/mg ± 0.11). (C) Plasma NOx 
concentrations increase from 31.66µM ± 1.6 in DDAH1 floxed mice on a normal diet 
to 45.2µM ±6.23 on a HFD with no difference between cohorts. (D)  HFD reduced 
adipocyte NO production from 30.6µmol/mg ± 4.99 to 9.87µmol/mg ±1.59 in floxed 





Figure 5.9: (A) mTOR transcript expression increased after a HFD in DDAH1 
floxed (5.32 ± 0.84) and DDAH1Ad-/- (4.38 ± 1.50) mice compared to mice on normal 
chow (NC)(B) ACC transcription is shut off after a HFD and is not affected by 
DDAH1 deletion. (C) FASN transcription increased with HF feeding from 0.39 ± 0.22 
to 1.50 ± 0.60 in DDAH1 floxed mice and a slightly higher increase in DDAH1Ad-/- to 
2.87 ± 0.48. 
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5.3.6 Insulin Resistance 
Insulin resistance is often associated with increased weight and fat gain; therefore, 
as DDAH1 deletion caused an increase in weight and adipocyte size intraperitoneal 
glucose tolerance tests (ipGTT) were performed on all cohorts. Mice on a normal diet 
showed a typical response to the ipGTT  (figure 5.10a) with plasma glucose peaking 
just below 20mmol/l 15 minutes post injection. Both cohorts achieved a similar peak 
and recovered at the same rate returning to baseline at the end of the two hour 
period.  
The cohorts on a HFD both reached a higher peak of around 25mmol/l glucose 
concentrations 15 minutes post injection (figure 5.10b). Unlike mice on a normal diet 
this peak concentration remained for another 15 minutes before concentrations fell 
slowly. Neither cohorts plasma concentration returned to baseline within the two hour 





Figure 5.10:  High fat feeding causes insulin resistance, but DDAH1 deletion 
does not affect glucose tolerance. Insulin resistance was tested by the 
intraperitoneal glucose tolerance test. (A) On a normal diet peak plasma glucose 
concentrations are reached 15 minutes post injection (DDAH1 floxed 19.32mmol/l, 
DDAH1Ad-/- 17.53mmol/l) before concentrations return to baseline. (B) HFD mice 
become insulin resistance where plasma glucose peaks at a higher concentration 
(DDAH1 floxed 25.43mmol/l, DDAH1Ad-/- 25.03mmol/l) and does not return to 
baseline over a two hour period. There is no difference between DDAH1 floxed and 





Little is known about the role of DDAH1 and ADMA in adipocyte physiology or 
pathology. However, raised ADMA concentrations have been correlated with human 
obesity (Eid et al., 2004; Koc et al., 2010). To investigate the role of raised ADMA in 
adipocytes a mouse model was generated using the adiponectin promoter to drive 
DDAH1 deletion specifically in adipocytes. As discussed in chapter four DDAH1 was 
successfully deleted at both transcript and protein levels. DDAH1 deletion caused a 
small rise in intracellular ADMA concentrations which reduced nitric oxide production. 
With this mouse model the aim was to identify whether the effects of ADMA identified 
in 3T3-L1 cells are conserved in vivo and whether the same mechanism is involved. 
Furthermore this model aimed to interrogate the role of ADMA and DDAH1 in the 
development of obesity. 
 
5.4.1 Fat Deposition 
Exposure of 3T3-L1 cells to exogenous ADMA triggered the transcription of lipid 
biosynthesis genes which was associated with an increase in cell size. To see if this 
translates in vivo and leads to increased fat mass mice were monitored for 16 weeks 
from six weeks of age. DDAH1Ad-/- mice reached a higher total mass than their 
littermate controls due to an increase in fat mass (figure 5.1). The increase in total fat 
mass was 36% whereas the increase seen in epididymal fat pads was only 14%; this 
suggests that other adipose depots may play a more important role in the increase in 
total fat. It would be interesting to investigate this as discerning which depots are 
most affected may highlight where DDAH1 and ADMA activity is highest or show 
which depots respond most dramatically to changes in lipid storage.  
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When epididymal fat pads were sectioned it was again revealed that an increase in 
adipocyte ADMA caused adipocyte hypertrophy (figure 5.2). On average an 
epididymal adipocyte was 28% larger in DDAH1Ad-/- mice than control, however, this 
increase did not correlate with the total increase in the epididymal fat at 14% 
discussed above. This could suggest that size and mass do not relate directly to each 
other, or it may suggest that not all cells are affected by DDAH1 deletion. DDAH1 
deletion does not occur in pre-adipocytes as the adiponectin promoter is not switched 
on until an adipocyte reaches maturity. Therefore it is unknown whether increased 
adipose ADMA affects these cells as there is no change in their intracellular 
metabolism; therefore this section of fat depot may not contribute to the increased 
mass of the depot.    
A consequence of ADMA related fat gain was an increase in macrophage infiltration 
(figure 5.3). The increase in tissue resident macrophages in DDAH1Ad-/- led to an 
increase in the multinucleated cells known as crown-like structures suggestive of 
adipocyte cell death (Cinti et al., 2005). Although there was an increase in 
inflammation in terms of macrophages the adipocytes themselves did not seem to be 
more inflamed as TNFα transcription was unchanged in primary adipocytes. TNFα is 
one of the most important cytokines produced by adipocytes however, it is not the 
only cytokine produced (Hotamisligil et al., 1993). A limitation here in the assessment 
of inflammation is that other markers that have not been investigated and therefore 
changes may have occurred that have been overlooked.  
Inflammation related to increased fat storage is a chronic condition that develops 
over time perhaps leaving animals with DDAH1 dysregulation at greater risk of 
developing an inflamed adipose tissue. Furthermore, by the end of the study 
DDAH1Ad-/- mice had not reached a plateau in weight or fat gain and therefore could 
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change further. A longer term study would also help determine the long term effects 
of adipocyte derived ADMA on the development of the metabolic syndrome. 
 
5.4.2 Upregulation of mTOR Signalling   
The mechanism underlying adipocyte hypertrophy in 3T3-L1 cells was through the 
increased transcription and activity of mTOR which in turn upregulated lipid 
biosynthesis genes. However, the 3T3-L1 cell line is a cancerous line and therefore 
may not have ‘normal’ metabolic activity (Green and Kehinde, 1974). To investigate 
whether this mechanism is conserved in vivo primary adipocytes were isolated and 
mRNA expression probed. The expression of mTOR, ACC and FASN were all 
increased in DDAH1Ad-/- adipocytes to a similar level as that seen in 3T3-L1 cells on 
exposure to ADMA. This suggests that the concentration reached inside primary 
adipocytes is equivalent to that of 3T3-L1 cells when exogenous ADMA is applied. 
Furthermore, the ADMA involved is synthesised inside the cell and therefore it is 
unlikely that ADMA competing with arginine at transporters for entry into the cell is 
the cause of mTOR upregulation.   
The correlation in vivo of increased mTOR activity and enlarged visceral fat seen 
here agrees with the increased activity of mTOR previously reported in obesity which 
has been implicated in the development of insulin resistance (Khamzina et al., 2005). 
Whether this amplification of activity is due to increased ADMA alone in vivo will need 
further investigation, but work in the 3T3-L1 cells suggests that ADMA alone is 
efficient to drive this signalling mechanism.  
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5.4.3 Diet Induced Obesity  
Obesity is a growing problem worldwide due to the large number of associated 
diseases that individuals are at risk of. Although obesity is known to be due to altered 
energy balance the cellular pathways that alter in response are not well understood. 
To understand what role DDAH and ADMA have in the development of obesity 
DDAH1Ad-/- and floxed littermate controls were placed on a high fat diet (60% energy) 
for 16 weeks.  
Unlike the increased weight and fat gain in DDAH1Ad-/- mice on a normal diet there 
was no difference between the two cohorts on a HFD. In fact all differences between 
the two groups disappear after the full 16 weeks of high fat feeding. Importantly the 
difference in intracellular ADMA between the two groups disappears due to a 
massive increase in ADMA production by both wildtype and DDAH1Ad-/- adipocytes 
compared to mice on normal chow mice. This increase in ADMA correlates with an 
increase in mTOR therefore triggering mTOR signalling in both groups.  
Although murine diet induced obesity does not model human obesity exactly, as 
there is no increase in the circulating plasma ADMA that has previously reported, it 
does suggest that DDAH1 dysfunction is not the cause of high ADMA concentrations. 
Rather ADMA concentrations may rise in adipose tissue in response to the increased 
protein turnover associated with the breakdown of inflamed and dying cells that occur 
in obesity. If indeed this increased ADMA has a detrimental effect on the surrounding 




5.4.4 Insulin Resistance 
Obesity is a major risk factor for insulin resistance so glucose handling was accessed 
in DDAH1 knockout mice. Glucose handling as determined by the peak and decay of 
plasma glucose is very similar in both groups. In these two groups inflammation is 
low compared to that seen after high fat feeding, even in animals with adipocyte 
hypertrophy, and this may be why there is little difference between the two groups. 
As with inflammation the development of insulin resistance is chronic and therefore it 
would be interesting to see if this alters over time. By using long-term studies it would 
be interesting to discover whether the small increase in inflammation increases a 
later risk of developing insulin resistance in old age.  
As expected mice on a high fat diet developed insulin resistance but as with other 
results after high fat feeding glucose handling was the same in both groups. Global 
DDAH1 overexpression decreases circulating ADMA and improved insulin sensitivity 
on a normal chow diet. Although the authors attribute this to improved glucose 
handling in the liver and muscle they did not investigate adipose signalling. Therefore 
reducing ADMA in adipocytes may reduce mTOR signalling and play a role in 
improving glucose handling.    
5.4.5 Future Work 
In 3T3-L1 cells the action of ADMA on the mTOR signalling pathway is predominantly 
if not exclusively NO independent. However, increased ADMA also results in 
inhibition of NO synthesis in these cells (Chapter 4) and is this may well play a role in 
metabolic control. Previous studies have demonstrated that NO is required for 
mitochondrial biogenesis (in adipocytes) and that NO may compete with oxygen to 
limit mitochondrial respiration. Mitochondria biogenesis is known to be regulated by 
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NO (Nisoli et al., 2003) and therefore if reduced in DDAH1Ad-/- adipocytes may 
contribute to the hypertrophy phenotype.  
When DDAH1 is deleted in adipocytes the increase in intracellular ADMA is actually 
very small; however, there is a much larger fall in nitric oxide production. Other 
studies have suggested that ADMA metabolism does not account for all of the effects 
of DDAH (Pope et al., 2009) and therefore an interesting question to investigate is 
whether NOS inhibition by ADMA accounts for all the actions seen here in 
adipocytes.   
 
5.5 Conclusion 
In summary DDAH1 deletion in adipocytes increases intracellular ADMA with no 
affect on circulating concentrations. This increase in ADMA causes adipocyte 
hypertrophy which in turn contributes to an increase in total fat mass. The increase in 
fat is small however and although increases adipose resident macrophage numbers 
over this study period does not alter the inflammatory state of adipocytes themselves 
or alter adipokines production.  ADMA’s stimulation of the mTOR signalling, originally 
identified in the 3T3-L1 cells, is conserved in the primary adipocytes and seems to 
again contribute to hypertrophy by upregulating ACC and FASN transcription.  
On a high fat diet mice develop obesity and rapidly gain fat mass. This results in a 
massive increase in adipocyte ADMA production although still does not affect 
circulating concentrations. As a result of this increased ADMA any phenotypic 
differences between DDAH1 floxed and DDAH1Ad-/- mice disappears. All obese mice 
had increased mTOR transcription which further increased FASN transcription and 














Chapter 6: The DDAH1En-/- Mouse 
 
6.1 Introduction 
Adipose tissue has a dense capillary network, with almost every adipocyte in contact 
with a blood vessel (Gersh and Still, 1945). Blood not only maintains the oxygen 
tension of the tissue but is also the source of triglycerides, fatty acids and glucose 
that adipose tissue stores and therefore adequate perfusion is necessary for efficient 
lipid deposition and mobilisation. This is thought to be a problem as in human obesity 
adipose blood flow is impaired particularly after nutrient intake compared to lean 
individuals (Jansson et al., 1998).  
Adipose tissue is unique in that it can alter the extent of vascularisation throughout 
adulthood (Crandall et al., 1997). In obesity, as adipose tissue grows, blood vessel 
growth is also necessary to maintain a healthy oxygen environment and a lack of 
vessel growth restricts adipose expansion (Rupnick et al., 2002). As a result 
angiogenesis has been considered as a good drug target for the treatment of 
obesity. Initial studies were directed at the inhibition of vascular endothelial growth 
factor (VEGF) signalling as this had been a useful treatment in cancer. In obesity 
VEGF inhibition successfully retarded adipose expansion (Sung et al., 2013; Tam et 
al., 2009), and therefore led to a reduction in fat mass in animal models. However, 
an unwanted side effect is that the adipose tissue becomes hypoxic inducing 
adipose inflammation (Hosogai et al., 2007; Ye et al., 2007) which has been 
associated with insulin resistance.  
Nitric oxide is a known regulator of angiogenesis (Murohara et al., 1999; Ziche et al., 
1994) and it has previously been demonstrated that DDAH1 dysregulation and 
increased ADMA can inhibit the formation of endothelial tubules in vitro (Wojciak-
158 
 
Stothard et al., 2007). DDAH1 deletion and angiogenesis in vivo has not yet been 
investigated. By using the endothelial specific DDAH1 knockout mouse developed in 
chapter four, rather than a global deletion, the effects of endothelial derived ADMA 
on adipose angiogenesis can be determined.  
Previously it has been suggested that endothelial DDAH1 is important in maintaining 
blood vessel tone and responsiveness. Hu et al (2011) demonstrated that vascular 
reactivity was altered in DDAH1En-/- mice and that in particular endothelial response 
to acetylcholine is reduced due to a lack in NO signalling. However, as previously 
discussed in chapter four these mice had an increase in circulating ADMA which is 
likely to alter vascular reactivity in the same way that it is affected in heterozygous 
DDAH1 knockouts (Leiper et al., 2007) and or as in AGXT2 knockout mice where 
high ADMA improves vessel reactivity (Caplin et al., 2012). In contrast DDAH1En-/- 
mice described here does not have altered plasma ADMA and therefore can be used 
to investigate the role of endothelial derived ADMA in vascular reactivity.  
Finally, in the previous chapter it was demonstrated that adipocyte derived ADMA 
caused adipocyte hypertrophy and increased fat mass in vivo.  To determine 
whether endothelial derived ADMA affects neighbouring adipocytes in the same way 
the DDAH1En-/- mice were subjected to the same 16-week studies noting weight and 





1. To establish whether endothelial derived ADMA alters adipocyte physiology 
and causes adipocyte hypertrophy. 
 
2.  To investigate whether angiogenesis in a model of obesity is affected by 
endothelial DDAH1 deletion. 
 
3.  To determine whether endothelial derived ADMA alters vascular reactivity 






6.3.1 Body Mass 
From six-weeks of age DDAH1 floxed and DDAH1En-/- were monitored for 16 weeks 
on a normal chow diet. Body weight increased at a similar rate in both DDAH1En-/- 
and control littermates increasing form 20g to ~ 30g over the study period (figure 
6.1a and b).  Similarly, total fat mass in both controls and knockouts increased 
steadily over the 16 weeks from 1.8g to 3g (figure 1.6c and d). 
 In contrast DDAH1En-/- mice have less lean mass at the start of the study (16.4g) 
compare to controls (17.8g) although this is not significant at 6 weeks of age. Over 
the duration of the study DDAH1En-/- mice continue to have less lean mass and at 16 
weeks DDAH1En-/- mice have significantly less muscle (21.5g ± 0.19 at 16 weeks) 
than floxed controls (23.4g ± 0.08, p<0.05). 
A reduction in lean mass with no change in weight can be explained by a difference 
in water retention between the two cohorts. However, towards the end of the study 
there is a slight increase in fat mass in DDAH1En-/- mice that does not reach 
significance due to a high level of variability and small cohort size.  Furthermore, the 
fat mass in these mice is a very small percentage compared to total body mass and 
any small change here is unlikely to affect final weight. Therefore, to assess whether 
fat is affected by endothelial derived ADMA epididymal depots were removed and 







Figure 6.1  (Previous page): DDAH1En-/- mice reach the same total mass as 
floxed mice but have significantly less lean mass. DDAH1 floxed and DDAH1En-/-
were observed from six weeks of age for a further 16 weeks. (A-B) Both cohorts put 
on weight at a similar rate growing from 20g to 30.23g ± 0.145 in DDAH1 floxed mice 
and 31.45g ± 1.06 in DDAH1En-/- after 16 weeks. (C-D) Control and DDAH1En-/- mice 
gain fat mass at similar rates reaching a total of 3.30g ± 0.29 and 3.95g ± 0.05 
respectively after 16 weeks. (E-F) DDAH1En-/- mice had less lean mass throughout 
the 16 week period. At the end of the study DDAH1En-/- (21.50g ± 0.19) had 
significantly less lean mass than controls (23.4g ± 0.08, * P<0.05). 
 
 
6.3.2 Adipocyte hypertrophy 
 Epididymal fat mass and adipocyte size are affected by ADMA exposure as seen in 
chapters three and five with other sources of ADMA. Upon dissection epididymal fat 
pads were noticeably larger than floxed controls and this was confirmed after 
weighting the tissue. DDAH1En-/- epididymal depots were twice as large (0.487g ± 
0.05) as DDAH1 floxed depots (0.267g ± 0.06, p<0.05, figure 6.2a). After sectioning 
and staining adipocyte cross-sectional area was determined. Adipocytes in floxed 
mice had an average adipocyte area of 20.2µm2 ± 2.84 at the end of the study, in 
contrast to DDAH1En-/- mice adipocytes were larger with an average area of 36.0µm2 





Figure 6.2:  DDAH1En-/- mice have larger epididymal fat depots and larger 
adipocytes than controls. (A) On dissection epididymal fat pads were removed and 
weighed. DDAH1En-/- mice had significantly larger fat depots (0.487g ± 0.05) than 
floxed controls (0.267g ± 0.06, * p<0.05). (B) Epididymal pads were fixed, sectioned 
and stained with EVG. The cross-sectional area of adipocytes was analysed and 
found that DDAH1En-/- mice had significantly larger adipocytes (36.9µm2 ± 3.36) 
compared to floxed mice (20.2µm2 ± 2.84, **<0.01). (C) Representative images of 




Plasma samples were taken at the end of the 16-week study to determine circulating 
adipokine concentrations. Adiponectin concentrations fell from 3.2µg/ml ± 0.22 in 
control mice to 1.55µg/ml ± 0.38 in DDAH1En-/- mice (p<0.01, figure 6.3a). There is a 
corresponding increase in leptin concentrations in DDAH1En-/- mice (15.91ng/ml ± 
2.1) when compared to floxed mice (4.31ng/ml ± 0.7, p<0.01, figure 6.3b). Both of 
these changes are in line with an increase in fat deposition. 
 
6.3.4 Adipose Inflammation 
Epididymal fat was stained with Mac2 antibody to determine the extent of 
macrophage infiltration. Very few macrophages are visible in DDAH1 floxed adipose 
tissue (9.43 ±1.09) whereas more macrophages are seen in DDAH1En-/- tissue (17.68 
± 0.6, figure 6.4a and b) although this doesn’t reach significance. However, in 
DDAH1En-/- fat crown-like structures, congregations of macrophages around dying 
adipocytes as in figure 6.4a, start to appear suggestive of inflammation.   
Expression of TNFα and iNOS mRNA in primary adipocytes was analysed by rt-
qPCR. There was a trend towards increased TNFα expression in DDAH1En-/- 
adipocytes although expression levels were very variable (figure 6.4c). Very little 
iNOS could be detected in either floxed or DDAH1En-/- adipocytes but there was little 




Figure 6.3:  Adiponectin is decreased and leptin increased in DDAH1En-/- 
mice. (A) Plasma adiponectin concentrations were lower in DDAH1En-/- (1.55µg/ml ± 
0.38) than DDAH1 floxed mice (3.2µg/ml ± 0.22, **p<0.01). (B) Leptin concentrations 
in DDAH1En-/- plasma (4.31ng/ml ± 0.7) were higher than the control group 







Figure 6.4  (Previous page): Infiltration by macrophages into adipose tissues 
increases slightly in DDAH1En-/- mice with a corresponding increase in 
adipocyte TNFα expression.  (A-B) Epididymal fat was stained with Mac2 antibody 
and the number of macrophages per image counted. DDAH1En-/- fat had a slight 
increase in macrophages (17.68 ± 0.6) compared to controls (9.43 ± 1.09, ns). (C-D) 
RNA from primary adipocytes was analysed for TNFα and iNOS expression. TNFα 
transcript rose slightly from 1.48 ± 2.79 to 2.79 ± 1.1 in DDAH1En-/- mice, while iNOS 




6.3.5 Diet Induced Obesity 
To model diet induced obesity DDAH1 floxed and DDAH1En-/- mice were placed on a 
60% energy from fat diet from six-weeks of age for a further 16 weeks. On a HFD 
both groups put on more weight than mice on the normal chow diet. However, weight 
gain in DDAH1En-/- mice lags behind DDAH1 floxed mice (p<0.01, figure 6.5a) 
although there is no significant difference between the two groups by week 16 
(DDAH1 floxed 50.0g ± 1.12, DDAH1En-/- 45.25g ± 2.04, figure 6.5b). 
As with total mass the increase in fat mass is slower in DDAH1En-/- than in controls 
(p<0.05, figure 6.5c) have slightly less fat mass at the end of the 16-week period 
(DDAH1 floxed 19.29g ± 1,68, DDAH1En-/- 15.44g ± 1.07, ns, figure 6.5d). 
Lean muscle mass is unaffected by high fat feeding but as with DDAH1En-/- mice on a 
normal diet those on a HFD have less muscle mass than floxed controls (p<0.05, 
figure 6.5e). As with fat mass, lean mass  the DDAH1En-/-  do reach a similar end 
mass after the full 16 weeks (DDAH1 floxed 23.4g ± 1.3, DDAH1En-/- 22.1g ± 0.69, 
ns). 
Upon dissection after 16-weeks of HF feeding visceral fat had very noticeably 
increased in both floxed and knockout mice. Epididymal fat pads were weighed and 
were found to be the same in both cohorts (figure 6.6a). After sectioning and staining 
adipocyte size was assessed and found to have expanded significantly in both 
groups. However, DDAH1En-/- mice continue to have significantly larger adipocytes 








Figure 6.5  (Previous page): DDAH1En-/- mice on a high fat diet gain less 
weight which is due to both a decrease in fat and lean mass. (A-B) DDAH1 
floxed and DDAH1En-/- both gain weight on a high fat diet compared to mice on 
normal chow (NC). DDAH1En-/- mice gain weight at a significantly slower rate than 
floxed mice (**p<0.01) and still have slightly less mass by week 16 (50.0g ± 1.12 
floxed, 45.25g ± 2.04 DDAH1En-/- p=0.07). (C-D) Fat expansion occurs at a slower 
rate in DDAH1En-/- mice than controls (*p<0.01) and remains lower at 16 weeks 
(19.29g ± 1.68 floxed, 15.44g ± 1.07 DDAH1En-/-, p=0.08). (E-F) Lean mass is 
unaffected by HF feeding but DDAH1En-/- have significantly less muscle mass 
(*p<0.01). Lean mass of the two groups comes together by week 16 (23.4g ± 1.3 





Figure 6.6:  High fat feeding increases epididymal fat pad weight and 
adipocyte size. DDAH1En-/- mice have increased adipocyte hypertrophy. (A) 
Epididymal fat mass increased after high fat feeding but was the same in both 
cohorts. (B) Adipocytes are enlarged after a HFD (compared to normal chow mice, 
NC) but DDAH1En-/- have significantly larger adipocytes (85.7µm2 ±2.86) than 
controls (67.42µm2 ±6.74). (C) Representative images of EVG stained enlarged 
adipocytes surrounded by macrophages.  
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In models of DIO it is has previously been demonstrated that adiponectin plasma 
concentrations fall while leptin concentrations rise (Arita et al, 1999; Frederich et al, 
1995) when compared to mice on normal chow diets. This pattern was repeated in 
DDAH1 floxed and DDAH1En-/- mice after high fat feeding (figure 6.7a and b). 
However, there was no difference in either adiponectin or leptin plasma 
concentrations between the two groups.  
The extent of adipose tissue inflammation was again determined through 
macrophage infiltration. After HF feeding the number of tissue resident macrophages 
was increased in DDAH1 floxed mice (17.13 ± 1.62, figure 6.8a and b), furthermore 
crown-like structures had started to appear. DDAH1En-/- mice also showed increased 
macrophage infiltration in DIO but there were significantly more macrophages in the 
fat tissue of these mice compared to controls (22.4 ± 1.4, p<0.05).  In DDAH1En-/- 






Figure 6.7:  Adiponectin falls and leptin increases after HF feeding. There is 
no difference between DDAH1 floxed and DDAH1En-/- mice. (A) Plasma 
adiponectin falls in both DDAH1 floxed (0.59µg/ml ± 0.39) and DDAH1En-/- (0.57µg/ml 
± 0.26). (B) Leptin concentrations rise in response to HFD in both DDAH1 floxed 







Figure 6.8:  (Previous Page) Markers of inflammation are higher in DDAH1En-/- 
mice after high fat feeding than in controls. (A-B) Mac2 staining in epididymal 
pads increases after HF feeding. DDAH1En-/- have increased macrophage infiltration 
(22.4 ± 1.4) compared to controls (17.13 ± 1.62). (C-D) TNFα and iNOS expression 
in primary adipocytes after HFD and is slightly increased in DDAH1En-/- mice (TNFα – 
floxed 4.80 ± 2.1, DDAH1En-/- 8.71± 2.5; iNOS – floxed 2.18 ± 0.26, DDAH1En-/- 3.49 




6.3.6 Blood Vessel Density 
In high fat feeding adipose expansion in DDAH1En-/- mice was retarded as shown by 
the body composition scanning in figure 6.5. As discussed in the introduction to this 
chapter DDAH1 and ADMA play important roles in angiogenesis and therefore a 
possible mechanism behind underlying adipose expansion could be a reduction in 
capillary growth.  
This was investigated through epididymal fat pad staining with antibodies against 
CD31 (PECAM-1), an endothelial cell marker, and the number and cross-sectional 
area of blood vessels was analysed. On a normal chow diet the number of blood 
vessels with a cross-sectional area greater than 20µm2 was the same in both 
DDAH1 floxed and DDAH1En-/- mice (figure 6.9a and b). However, when the smallest 
capillaries were considered there were statistically fewer in DDAH1En-/- mice than in 
the floxed controls.    
When the mice were placed on a HFD the number of the smallest capillaries fell in 
both floxed and DDAH1En-/- compared to their littermates on a normal diet.  The 
difference between DDAH1 floxed and DDAH1En-/- mice remained with DDAH1En-/- 
mice having the fewest capillaries of any group. As with mice on a normal diet larger 








Figure 6.9:  (Previous Page) DDAH1En-/- mice have reduced capillary density 
in epididymal fat pads. (A) Representative images of CD31, an endothelial marker, 
staining of epididymal fat from DDAH1 floxed and DDAH1En-/- mice on normal and 
high fat diets. Large arrows: vessels over 20µm2 in area. Small arrows: vessels 
<20µm2 in area. (B) The cross sectional area of each blood vessel was analysed and 
the number of vessels counted.  There was no effect of genotype or diet on the 
number of vessels over 20µm2 in cross-sectional area. In contrast vessels under 
20µm2 are significantly decreased in DDAH1En-/- mice (10.17 per slide ± 1.0.) 
compared to DDAH1 floxed mice (15.79 per slide ±1.89, p<0.05) on a normal diet. 
Vessel density reduces further after a HFD to 11.75 per slide ± 2.3 in DDAH1 floxed 
mice and 6.16 per slide ± 0.79 in DDAH1En-/-. 
 
 
As the capillary density of adipose tissue is not a standard angiogenesis assay, to 
confirm that vessel growth is impaired in these mice we also ran an aortic ring 
sprouting assay. Aortic rings from control and DDAH1En-/- mice were cultured in 
matrigel supplemented with fibroblast growth factor over seven days. Aortic rings 
taken from DDAH1 floxed mice have an average of 24.8 ± 4.4 vessel sprouts per a 
ring in contrast to DDAH1En-/- which have significantly fewer with an average of 10.9 
± 2.4 sprouts per a ring (p<0.05) 
Many sprouts also contain branches; again DDAH1 floxed mice showed on average 
significantly more branches per a sprout (0.87 ±0.1) compared to DDAH1En-/- mice 






Figure 6.10: DDAH1En-/- shows significantly less cellular outgrowth from 
culture aortic rings. (A) Representative images of cultured aortic rings. (B) The 
average number of vessel sprout from a DDAH1En-/- aorta is significantly fewer (10.9 
± 2.4) than a DDAH1 floxed (24.8 ± 4.4, p<0.05). (C) The number of branches per a 
new sprout is also significantly fewer in DDAH1En-/- cultures (0.38 ± 0.06) in 
comparison to DDAH1 floxed mice (0.87 ± 0.1, P<0.01).   
 
6.3.7 DDAH1 and hypoxia 
Fat pads with a reduced capillary network are likely to be a hypoxic, and therefore 
DDAH1En-/- mice possibly have more hypoxic fat stores than their littermate controls. 
Previous studies have demonstrated that DDAH1 expression is down-regulated in 
hypoxic environments (Jacobi et al, 2005; Millatt et al, 2003) due to miRNA-21 
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mediated degradation of DDAH1 mRNA (Chen et al, 2013; and unpublished data 
from L. Iannone and B. Wojciak-Stothard). DDAH1 expression in primary adipocytes 
was determined by Rt-qPCR and found to be reduced in DDAH1En-/- mice (0.269 ± 
0.15) compared to floxed mice (0.733 ± 0.16, figure 6.10a) when on a normal chow 
diet. This led to a small but non-significant increase in intracellular ADMA 
concentration in the DDAH1En-/- adipocytes (0.42μmol/mg ± 0.19, DDAH1 floxed 
0.30μmol/mg ± 0.14, ns , figure 6.10 b). 
 
 
Figure 6.11: DDAH1 expression is decreased in DDAH1En-/- primary 
adipocytes and corresponds with increased in intracellular ADMA.  (A) 
DDAH1 RNA expression is reduced in DDAH1En-/- primary adipocytes (0.269 ± 0.15) 
in contrast to DDAH1 floxed mice (0.733 ± 0.16, ns). (B) Intracellular ADMA 
increases slightly in DDAH1En-/- (0.42μmol/mg ± 0.19, DDAH1 floxed 0.30μmol/mg ± 
0.14, ns).   
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6.3.8 Insulin Resistance 
Insulin resistance was assessed by an intraperitoneal glucose tolerance test in 
DDAH1 floxed and DDAH1En-/- mice on both normal and high fat diets. Mice on a 
normal diet reach peak plasma glucose concentrations 15 minutes post injection. 
DDAH1 floxed mice peak at 21.1mmol/l ± 1.3 which quickly falls back towards 
baseline (figure 6.11a). DDAH1En-/- mice start at the same baseline glucose 
concentrations but peak at a much lower 16.8mmol/l ± 1.3 before returning towards 
baseline (p<0.05). Both groups reach a final concentration of around 10mmol/l 
glucose two hours after injection.  
After a high fat diet peak plasma glucose is still reached 15 minutes post injection, 
however, the peak is higher than a mouse on a chow diet (25.0mmol/l and 
20.3mmol/l for DDAH1 floxed and DDAH1En-/- mice respectively, figure 6.11b). These 
mice have developed insulin resistance as plasma concentrations only start to fall 
back towards baseline at 60 minutes post injection. Neither DDAH1 floxed or 
DDAH1En-/- plasma concentration return to baseline and remain 50% higher than the 





Figure 6.12:  DDAH1En-/- mice have reduced peak plasma glucose after an 
intraperitoneal glucose tolerance test. (A) On a chow diet DDAH1 floxed and 
DDAH1En-/- have a baseline fasting plasma glucose concentrations of 7.5mmol/l and 
7.0mmol/l respectively. After an ip injection of glucose circulating plasma reaches a 
peak concentration of 21.1mmol/l and 16.3mmol/l respectively (*p<0.05) before 
concentrations fall back towards baseline. (B)  After high fat feeding the peak plasma 
glucose reached is 25mmol/l and 20.3mmol/l in DDAH1 floxed and DDAH1En-/- 




6.3.9 Vessel Reactivity 
Previous studies have demonstrated the importance of DDAH1 in vascular reactivity 
(Leiper et al, 2007). However, it is not yet well understood the role of endothelial 
DDAH1 in vessel relaxation therefore vessels from DDAH1En-/- mice were 
investigated using myography. A high fat diet has previously been shown to cause 
endothelial cell damage and reduce vessel responsiveness to circulating signalling 
molecules such as acetylcholine. To investigate the extent to which DDAH1 and 
ADMA play a role in endothelial damage myography was also performed after HF 
feeding.  
Isolated sections of aorta were subjected to increasing doses of phenylephrine (PE) 
and the contractile response recorded. The logEC50 for PE was -7.1 for DDAH1 
floxed and DDAH1En-/- mice whether fed normal chow or a HFD.  The maximal 
contraction elicited by PE was the same in cohorts on a chow diet reaching 
4.6mmHg ± 0.28 in floxed animals and 4.8mmHg ± 0.41 in DDAH1En-/- . However, 
after a HFD the maximal response increases in DDAH1En-/- to 6.3mmHg ± 0.41, and 
further still in DDAH1 floxed mice to 7.9mmHg ± 0.53 (figure 6.12a, p<0.0001).  
To test endothelial cell responsiveness to acetylcholine (Ach) vessels were first sub-
maximally (80%) contracted with PE before investigating the dose response to Ach. 
On a chow diet DDAH1 floxed and DDAH1En-/- have similar logEC50 and maximal 
relaxation values (DDAH1 floxed -8.04 ± 0.25 and 68% ±4.21 respectively;  
DDAH1En-/-  -8.2 ± 0.12 and 70.0% ± 2.67). After HF feeding vessels become less 
responsive to Ach and the logEC50 shifts to -7.4 ± 0.19 in DDAH1 floxed and -7.7 ± 
0.25 in DDAH1En-/-. The maximal response also decreases to around 50% in both 
groups (figure 6.11b, p<0.0001). 
184 
 
 To investigate whether smooth muscle NO signalling is altered vessels were again 
pre-contracted with PE before treating with sodium nitroprusside (SNP). The SNP 
response was not affected by either DDAH1 endothelial deletion or high fat diet 
consumption with a logEC50 between -6.8 and -7.4 for all groups and with 90% 
relaxation reached in all cases (figure 6.11c).   
 
 
Figure 6.13:  (Following Page) DDAH1 endothelial deletion does not alter 
vascular reactivity but a high fat diet affects phenylephrine and acetylcholine 
responses. (A) Aortic contraction in response to increasing phenylephrine doses. A 
LogEC50 of -7.1 was unaffected by genotype or diet however the maximum response 
was increased after high fat feeding from  4.6mmHg ± 0.28 in floxed animals and 
4.8mmHg ± 0.41 in DDAH1En-/- to 7.9mmHg ± 0.53 and 6.3mmHg ± 0.41 respectively 
(*p<0.0001). (B) Dose dependent relaxation to acetylcholine. Endothelial deletion 
does not affect Ach responses with both cohorts having a LogEC50 of -8.1 and a 
maximal relaxation of 70%. After HF feeding Ach responsiveness shifted to a 
LogEc50 of between -7.4 and -7.7 for both groups with a reduced maximal response 
at 50%. (C) Sodium nitroprusside relaxation is unaffected by genotype or diet with a 









Specific deletion of DDAH1 was developed to investigate the role of ADMA and NO 
in adipose vasculature particularly in obesity. Deletion of DDAH1 inhibited 
angiogenesis restricting adipose expansion in obesity. Surprisingly although total fat 
was reduced in these mice, visceral fat as assessed by epididymal fat mass was 
increased and the adipocytes themselves again enlarged. 
 
6.4.1 Angiogenesis 
DDAH1 deletion delayed adipose expansion on a high fat diet (figure 6.5) which is 
probably due to a reduction in blood vessel growth (figure 6.9). A reduction in 
angiogenic potential in DDAH1En-/- was confirmed through reduced vessel outgrowth 
from cultured aortic rings.  NO is thought to be an important signalling molecule in 
the development of new blood vessels. Vascular endothelial growth factor (VEGF), 
the major modulator of angiogenesis, triggers NO production in endothelial cells (van 
der Zee et al., 1997). The NO released can then go on to complete the loop 
triggering more VEGF release. Once made however NO has a number of roles that 
are beneficial to a growing vessel including endothelial proliferation and migration 
(Murohara et al., 1999). 
 As NO is involved in angiogenesis it would be expected that both ADMA and DDAH 
also regulate vessel growth. When the mechanism by which ADMA inhibits 
angiogenesis was investigated in vitro it was confirmed that it blocked endothelial 
tubule growth in matrigel (Smith et al., 2003) and that much of this was through an 
NO-dependent pathway regulating endothelial migration (Wojciak-Stothard et al., 
2007) through the inhibition of Rho-GTPases and an impairment of the cytoskeletal 
re-organisation (Fiedler et al., 2009).  A number of studies in vivo have shown that a 
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reduction in ADMA following DDAH1 overexpression improves angiogenesis; tumour 
growth is enhanced (Kostourou et al., 2002) and revascularisation after ischemia 
(Achan et al., 2005) and injury are both improved (Konishi et al., 2007).  
This is the first study to investigate the effect of DDAH1 deletion on angiogenesis in 
vivo and here it is demonstrated that this alone is sufficient to inhibit vessel growth in 
expanding adipose tissue. As ADMA concentrations could not be measured in 
isolated endothelial cells it can only be assumed that it is endothelial derived ADMA 
that is inhibiting vessel growth as has previously been discussed but it cannot be 
ruled out that DDAH1 has actions independent to that of ADMA metabolism. To 
determine whether vessels from DDAH1En-/- mice do produce more ADMA a future 
experiment would be to culture aortic rings in Krebs solution and determine the 
amount of ADMA release from the vessel. 
As with previous studies investigating the effect inhibition of angiogenesis on 
adipose expansion, the deletion of DDAH1 slows adipose growth (Rupnick et al., 
2002; Sung et al., 2013). However, this inhibition is not maintained and DDAH1En-/- 
mice reach a similar weight and fat mass as controls by the end of the study 
suggesting this would be a poor target for therapy. Furthermore, as with other 
studies inhibiting angiogenesis, the hypoxic environment that this creates 
encourages macrophage infiltration and an increase in inflammation that is thought 
to be detrimental to adipose health.  
 
6.4.2 Adipocyte Hypertrophy 
In previous chapters, exogenous and intracellular ADMA have been shown to cause 
adipocyte hypertrophy in 3T3-L1 cells in culture and primary adipocytes in vivo. 
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Therefore, in this chapter the effect of endothelial derived ADMA on fat storage and 
adipocyte hypertrophy was investigated. 
DDAH1En-/- mice had increased epididymal fat mass and adipocyte size on a normal 
chow diet (figure 6.2) which led to changes in adipokine plasma concentrations and 
levels of inflammation (figure 6.3 And 6.4). After high fat feeding DDAH1En-/- still had 
larger adipocyte than DDAH1 floxed mice (figure 6.6 and 6.8).  
The fact that adipocyte hypertrophy was identified in these mice suggested that 
endothelial derived ADMA was sufficient to alter lipid synthesis, in the same way that 
adipocyte derived ADMA was sufficient to cause hypertrophy in the DDAH1Ad-/- mice. 
However, this seemed surprising as endothelial derived ADMA had not altered 
circulating concentrations of ADMA or changed vascular reactivity suggesting that 
the endothelium is not a major source of ADMA.  
After high fat feeding DDAH1En-/- fat expansion was retarded due to reduce vessel 
density. It is likely that as a result of this the adipose tissue becomes hypoxic, this 
could be confirmed through probing HIF-1 signalling in these cells a pathway that is 
upregulated in low oxygen environments. Previously, it has been reported that 
DDAH1 expression is decreased in oxygen deprived environments. Rats exposed to 
hypoxic conditions show reduced pulmonary DDAH1 expression compared to 
rodents in a normoxic environment leading to increased pulmonary ADMA 
concentrations (Millatt et al., 2003). Furthermore, in a model of hind-limb ischemia 
DDAH1 expression quickly fell in response to reduced oxygen leading to a 
corresponding rise in local ADMA concentrations (Achan et al, 2005).  
In primary adipocytes isolated from DDAH1En-/- mice DDAH1 expression was 
reduced compared to controls suggesting that these cells are hypoxic.  This led to a 
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small increase in ADMA inside the adipocytes themselves which may contribute to 
adipocyte hypertrophy (figure 6.10).  
Therefore elevating endothelial derived ADMA has two outcomes within adipose 
tissue. Firstly, ADMA inhibits angiogenesis through a NO dependent mechanism 
restriction adipose expansion early in obesity. Secondly, ADMA causes a down-
regulation of DDAH1 expression in neighbouring cells in this case the adipocyte, 
causing adipocyte hypertrophy and increased fat mass.  
 
6.4.3 Glucose Handling 
Enlarged adipocytes, tissue hypoxia and increased inflammation are all thought to be 
detrimental to glucose handling. However, although DDAH1En-/- mice display these 
risk factors on a normal chow diet DDAH1En-/- mice surprisingly had lower peak 
plasma glucose concentration than control mice although both have returned to 
similar concentrations by the end of the two hour period (figure 6.11). Furthermore, 
DDAH1En-/- mice had less muscle which is the major site of glucose uptake, again 
making this result surprising.  
DDAH1En-/- may have poorer vascular perfusion than control mice due to NO’s role in 
vascular reactivity. Poorer perfusion could explain a reduced peak at 15 minutes 
post-injection but a delay or shift in this peak may be expected in response. The fact 
this shift does not occur and that myography experiments do not show a difference in 
vascular reactivity cannot explain this reduction in peak values.  A second 
determinant of peak glucose is whether rate at which gluconeogensis in the liver is 
stopped in response to plasma glucose concentrations. A lower peak here may 
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suggest that liver function in the DDAH1En-/- is improved; although the mechanism 
through which this occurs will need further investigation.   
Situations of increased visceral obesity and improved glucose tolerance have been 
seen previously. The VEGFb knockout mouse (Hagberg et al., 2012) shifts lipid 
storage away from skeletal muscle resulting in increased storage in adipose tissue. 
However, as a result of reduced muscle lipid storage they have improved glucose 
handling. This suggests that there may be more complicated mechanisms involved 
in DDAH1 involvement with glucose handling that need further investigation.  
 
6.4.4 Vascular Reactivity 
DDAH1 deletion in endothelial cells did not alter vascular reactivity in the aorta 
(figure 6.12). This is in contrast to Hu et. al. (2009) who reported that endothelial 
deletion alone was sufficient to decrease vessel responsiveness to acetylcholine. 
However, in that study there was also a lifelong increase in circulating ADMA 
concentrations which led to hypertension and would therefore have consequences 
on vascular signalling and perhaps remodelling. This is further supported by other 
studies where there is a correlation between increased circulating ADMA and 
impairment in relaxation. The DDAH1 heterozygous knockout mouse (Leiper et al, 
2007) and the AGXT2 knockout mouse (Caplin et al. 2012) both have systemic 
increases in ADMA and altered vascular reactivity. 
There are a number of possibilities as to why endothelial deletion in this model did 
not alter the acetylcholine response. The deletion of endothelial DDAH1 does not 
seem to alter circulating ADMA concentrations (chapter 4) and therefore it may be 
that the increase in intracellular ADMA in endothelial cells is not enough to 
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completely block the nitric oxide response to acetylcholine. Secondly, DDAH2 is also 
expressed in endothelial cells (Arrigoni et al., 2003) and in some cases thought of as 
the predominant isoform in this cell type (Wang et al., 2007). Therefore DDAH2, 
through either an increase in activity or expression, may be able to overcome any 
increase in intracellular ADMA concentrations due to DDAH1 deletion keeping the 
level of vascular reactivity constant. Finally, there are many regulators of vessel tone 
which may have been upregulated in DDAH1En-/- mice as a result of reduced NO 
signalling.     
Although there was no change in systemic ADMA and aortic responses this does not 
preclude a vascular phenotype in smaller vessels particularly in the adipose where 
increased ADMA production also occurs in the adipocytes. Here DDAH1En-/- is shown 
to be important in angiogenesis but the combined local effect of endothelial and 
adipocyte ADMA may also lead to a reduction in  adipose perfusion and may be a 
further cause of hypoxic adipose tissue. Adipose perfusion could be investigated by 
imaging blood flow in the adipose tissue for which there are a number of techniques 
including microscanning, fluorescent dyes, and the use of microspheres.  
Vessel responsiveness to Ach is altered by a high fat diet, and the aorta becomes 
less responsive as a result. This is a difference in endothelial dependent relaxation 
but is not mimicked by DDAH1 deletion in mice on a normal diet. However, in obese 
adipocytes the concentration of intracellular ADMA rises far beyond that caused by 
DDAH1 deletion (chapters four and five) and the same may happen to the adipose 
depots that surround blood vessels affecting the vascular reactivity of wildtype and 




Previously, Hu et. al. (2009) had developed a DDAH1En-/- that demonstrated that 
DDAH1 expression and activity was confined to the endothelium. However, here and 
in other unpublished data DDAH1 has been showed to be widely expressed in a 
number of tissues and has a role in their physiology; as a result, a new DDAH1En-/- 
mouse line was developed here showing endothelial specificity.    
 Here DDAH1 deletion within endothelial cells inhibits angiogenesis limiting adipose 
expansion in mice placed on a high fat diet. Inhibition of angiogenesis caused 
adipose hypoxia decreasing DDAH1 expression in adipocytes. The increase in 
ADMA led to adipocyte hypertrophy, altered adipokine production and an increase in 














Chapter 7: General Discussion 
 
7.1 Summary of results 
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide 
production (Vallance et al., 1992b). Raised plasma concentrations of ADMA have 
been associated with a wide range of diseases, and as a result it and its 
metabolising enzymes DDAH1 and DDAH2 have become targets for the possible 
treatment and improvement of many disease states (Ghebremariam et al., 2012; 
Leiper and Nandi, 2011; Maas, 2005). 
Adipose tissue is the major storage site of energy in the form of triglycerides, but is 
also an important endocrine organ that secretes a wide range of circulating 
hormones and inflammatory markers. DDAH1 and DDAH2 were first identified in 
adipocytes by Spoto et al (2007); however, it was unknown what role these enzymes 
played in adipocyte physiology. A primary aim of this thesis was to determine the 
expression and roles of the DDAH enzymes in adipose tissue firstly using 3T3-L1 
cells in vitro and moving on to whole animal models.  
Obesity is an important risk factor in the development of number of diseases 
particularly hypertension and insulin resistance (Alberti et al., 2005). As a result 
treating obesity and its associated diseases takes large percentages of international 
health service budgets, amounts that are forecast to increase in the future. ADMA 
concentrations have been associated with obesity in humans but it was unknown 
what affect high ADMA concentrations had on the development of the disease. This 
thesis aimed to answer some of the questions surrounding ADMA in adipocytes 
particularly in relation to how it effects the development of obesity. 
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7.1.1 ADMA increases adipocyte size through an NO-independent upregulation 
of mTOR signalling 
The 3T3-L1 cell line is a widely used model for adipocyte differentiation and function. 
In Chapter three of this thesis it is shown that these cells when differentiated to 
mature adipocytes express both isoforms of DDAH and produce ADMA under 
normal conditions. To explore the effect of ADMA on 3T3-L1 function cells were 
exposed to a patho-physiological concentration (10μM) which after 10 days of 
treatment caused adipocyte hypertrophy.   
Hypertrophy seems to be driven by an increase in mTOR signalling (figure 7.1) 
particularly through an increased transcription of the lipid synthesis genes acetyl-
CoA carboxylase and fatty acid synthase. Equally ADMA increased the 
phosphorylation of both Akt and eNOS again a signalling pathway down-stream of 
mTOR.  
Interestingly, the action of ADMA on both cell size and mTOR expression was 
independent of NO inhibition and could not be reproduced with the NOS inhibitors L-
NAME and PB-ITU. Early evidence also suggests that NO donors can not reverse 
the effect of ADMA on mTOR transcription again indicating an independence from 
NO signalling (data not included) The mechanism by which ADMA upregulates 
mTOR transcription and activity is unknown and more work is needed to determine 





Figure 7.1:  DDAH1 dysregulation increases ADMA concentrations which 
upregulates mTOR transcription in adipocytes independent of nitric oxide 




7.1.2 Adipocyte and endothelial DDAH1 deletion do not alter plasma ADMA 
concentrations 
This thesis establishes two models of conditional DDAH1 deletion specifically in 
adipocytes (DDAH1Ad-/-) and endothelial cells (DDAH1En-/-). Both strains successfully 
limited DDAH1 deletion to the cell type of interest therefore providing two new 
models to explore elevated ADMA in adipose tissue and in obesity.   
An important step in the early phenotyping of these mice was to determine the effect 
of DDAH1 deletion on ADMA concentrations. In DDAH1Ad-/- intracellular ADMA was 
increased but systemic ADMA concentrations were unaffected. Furthermore, in 
DDAH1En-/-  circulating ADMA was again unaffected although intracellular ADMA 
could not be measured in isolated endothelial cells due to the low recovery of 
purified cells.  
These novel mouse strains were placed on a high fat diet to determine whether 
plasma ADMA concentrations increased as previously seen in human studies. 
However, although intracellular adipocyte concentrations are increased in both 
control and knockout strains there is still no change in plasma concentrations of 
ADMA indicating that relatively short term weight gain on its own does not lead to 
systemic increases in ADMA in rodents. In human obesity weight gain occurs over a 
prolonged period of time and is associated with a number of co-morbidities. Further 
studies will be need to resolve the differences between human studies and 





7.1.3 DDAH1Ad-/- causes adipocyte hypertrophy and increases fat mass 
The DDAH1Ad-/- strain was developed to investigate whether the affects of ADMA 
found in the 3T3-L1 cells was preserved in vivo. DDAH1Ad-/- mice have greater mass 
than controls at 22 weeks of age due to an increase in fat mass. When epididymal 
fat pads were removed DDAH1Ad-/- were identified as having increased adipocyte 
size mimicking the effects seen in 3T3-L1 cells.  
To confirm that the same mechanism was involved in vivo primary adipocytes were 
isolated and when probed by Rt-PCR showed increased concentrations of mTOR, 
ACC and FASN transcript suggesting that again inappropriate lipid synthesis is 
involved increasing fat in these mice. This phenotype was produced in the absence 
of a systemic increase in ADMA concentrations indicating that a local increase in 
ADMA within the adipose tissue is sufficient to cause adipocyte hypertrophy in vivo. 
After a high fat diet any phenotypic differences between the two cohorts was lost. 
This was due to the exaggerated increase in ADMA concentrations in both control 
and DDAH1Ad-/- far beyond that caused by DDAH1 deletion alone.  
 
7.1.4 DDAH1En-/- reduces angiogenesis, reduces adipocyte DDAH1 expression 
and causes adipocyte hypertrophy 
Nitric oxide is an important signalling molecule in angiogenesis and ADMA has 
previously been shown to reduce vessel growth in vitro. Deleting DDAH1 in the 
endothelium reduced angiogenesis in expanding adipose tissue during a high fat 
diet.  
Hypoxia has previously been shown to down-regulate DDAH1 expression. As 
reduced angiogenesis would lead to a hypoxia environment DDAH1 expression in 
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primary adipocytes from these mice was investigated and found to be reduced; 
leading to a small increase in intracellular ADMA. DDAH1En-/- mice demonstrated the 
same phenotype as DDAH1Ad-/- mice including increased fat mass and adipocyte 
hypertrophy. Hypoxia itself changes many signalling pathways and may contribute to 
the phenotype of hypertrophy; however the elevation in ADMA concentrations within 
adipocytes is consistent with the signalling seen in DDAH1Ad-/-.    
 
7.2 ADMA, mTOR and obesity 
7.2.1 Intracellular adipocyte ADMA 
Circulating ADMA is increased in human obesity (Eid et al., 2004; Koc et al., 2010), 
and here it is demonstrated that ADMA concentrations in adipocytes increases eight 
fold in mice after high fat feeding compared to those on a normal chow diet. This 
would suggest that elevated adipose ADMA concentrations are a factor in obesity; 
although whether this is due to an increase in ADMA production or decreased 
metabolism is still unknown. Our data presented here would suggest that in mice 
production is the major driver resulting in elevated ADMA concentrations as total 
abolition of DDAH1 in adipocytes does not have such an pronounced affect on 
intracellular concentrations.  
A possible next step would be to determine the role of arginine methylation by 
PRMT’s in normal adipocyte physiology and whether this alters in the development 
of obesity. Presently, little is known about PRMT expression and activity in 
adipocytes or obesity and therefore it is unknown whether increased arginine 
methylation occurs. However, an early indication that PRMT’s may be important is 
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that global deletion of PRMT2 results in lean mice which are resistant to diet induced 
obesity (Iwasaki, 2012).  
The third control point for ADMA concentrations is the level of catabolism within 
adipocytes. In obesity there is extensive adipose and adipocyte remodelling to 
accommodate for the expanding tissue (Lee et al., 2010b), particularly in pre-
adipocytes as they differentiate into mature cells (Rigamonti et al., 2011). This 
adipocyte turnover correlates with an increase in protein turnover, which has been 
associated with ADMA concentrations in the plasma of obese individuals (Marliss et 
al., 2006). Therefore, this increased breakdown of proteins and therefore production 
of free methylarginines may be enough to swamp DDAH1 resulting in raised 
intracellular ADMA concentrations that can effect adipocyte function.   
7.2.2 The expression of mTOR in obesity 
Although the in vivo source of ADMA is unknown, and plasma ADMA concentrations 
probably reflect the contribution of many individual cell types and tissues, it has been 
shown in this thesis that ADMA can exert significant biological effects on adipocyte 
function. In 3T3-L1 cells increased exposure to ADMA was found to upregulate the 
transcription and activity of mTOR (figure 7.1). Two protein complexes of mTOR 
exist (Jacinto et al., 2004) and increased mTORC1 activity, as evidenced by an 
increased transcription of the lipid synthesis genes acetyl-CoA carboxylase and fatty 
acid synthase, was associated with adipocyte hypertrophy. ADMA exposure was 
also linked with increased phosphorylation of Akt and eNOS both of which are 
downstream of mTORC2 signalling. However, Akt phosphorylation can also be 
downstream of PI3-Kinase signalling (Burgering and Coffer, 1995) and this pathway 
would need further investigation to exclude its involvement in ADMA driven eNOS 
phosphorylation.       
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An increase in mTOR activity has been noted in a number of other tissues in obesity. 
Hyperactive mTOR is seen in both the liver and skeletal muscle in obesity in 
response to hyperinsulinemia (Khamzina et al., 2005). This high insulin state 
increased phosphorylation of mTOR is thought play a part in insulin resistance due 
to increased phosphorylation of IRS-1 (Haruta et al., 2000; Khamzina et al., 2005). ,It 
would be interesting to assess whether mTOR phosphorylation increases in 
response to ADMA in 3T3-L1 and the mouse models on a normal diet where there is 
no obvious change in glucose handling. In the obese mice there is elevated 
adipocyte ADMA, increased mTOR transcription and insulin resistance is therefore it 
would be of interesting to explore the effect of ADMA on the insulin signalling 
pathway.  
In sarcopenic obesity where muscle mass is lost as fat mass is increased 
hyperactive mTOR has been described in the skeletal muscle (Miller et al., 2008). 
This is perhaps the situation that most closely resembles that seen here in 
adipocytes where increased protein turnover could raise local ADMA concentrations 
thereby increasing mTOR activity. To investigate this, the muscle cell line C2C12 or 
skeletal muscle specific DDAH1-/- mice could be used to determine whether ADMA 
can increase mTOR signalling in this cell type or whether this pathway is restricted to 
adipocytes.   
 
7.3 NO-Independent actions of ADMA 
A novel finding of this thesis is that the affects of ADMA on adipocyte hypertrophy 
and mTOR upregulation could not be reproduced by the chemical NOS inhibitors L-
NAME and PB-ITU. Due to time limitations the studies in this thesis were limited to 
the downstream effects of mTOR upregulation and how this altered in vivo 
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physiology and therefore the mechanism by which ADMA increases mTOR 
expression and activity was not explored.  
Amino acids are known regulators of mTOR activity and the presence of arginine is 
thought to be vital for in the activation of mTOR independent of any other upstream 
regulators (Hara et al., 1998). Withdrawal of amino acids from a culture system leads 
to the inactivation of mTOR and its downstream signalling molecules; in contrast the 
addition or removal of amino acids had no affect on the PI3Kinase, MAPK, and 
Insulin receptor pathways. Amino acids increase mTOR activity by causing its 
translocation to the lysosome (Laplante and Sabatini, 2012), and excess ADMA 
concentrations may be able to cause this translocation due to its structural similarity 
to arginine.  
However, the above mechanism increases mTOR activity independent to 
expression, whereas although ADMA may be able to increase activity through this 
mechanism it also increased mTOR mRNA and protein expression levels. mTOR 
itself is a major regulator of transcription and translation but little is known about the 
regulation of its own transcription. There are a number of amino acid sensitive 
transcription factors including CHOP (Bruhat et al., 2000), C/EBPβ (Fafournoux et 
al., 2000) and AFT2 and AFT3 (Chaveroux et al., 2009) that may be involved in its 
regulation. However, most known signalling pathways respond to amino acid 
starvation rather than concentrations in excess of physiological levels. As a result, 
future experiments would be needed to explore the effect of ADMA on mTOR 
expression. By utilising a promoter reporter assay ADMA sensitive regions of 
mTOR’s promoter could be established which may identify a particular transcription 
binding site. Furthermore, if ADMA treatment was performed in the presence of an 
inhibitor of translation it could be determined whether the action of ADMA was 
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directly on mTOR or via the upregulation of a secondary at present unknown protein 
that could regulate mTOR expression.    
7.3.1 ADMA/Arginine Ratio 
Until now the only action of ADMA was thought to be through the inhibition of nitric 
oxide production. As ADMA is a competitive inhibitor blockade at the active site 
relies on the ratio between arginine and ADMA shifting in favour of ADMA. However, 
the concentration of arginine rarely falls below at ~100μM (depending on the cell 
type) while ADMA is found in the low micromolar range (Cardounel and Zweier, 
2002). As a result the concentration of ADMA may not always be sufficient to block 
NOS with a Ki of around 0.9μM whereas arginine concentrations are maintained well 
above its Km for NOS at 3.14μM. As a result the extent of the association between 
ADMA and pathology is perhaps surprising.   
ADMA driven mechanisms independent of nitric oxide inhibition could help explain 
the extent of ADMA’s effects. Here ADMA significantly upregulated mTOR 
expression at only 1μM in cell culture that contained 300 μM arginine. In vivo similar 
effects on mTOR were apparent with only a modest increase in adipocyte ADMA 
concentrations. Therefore it would be interesting to explore the lower limit of this 
upregulation as it is much closer to those concentrations seen in disease states. 
Currently it is unknown whether ADMA’s action on mTOR occurs in any other cell 
type and therefore the importance of this pathway globally is still in question. Never 
the less, induction of adipocyte mTOR signalling leading to adipocyte hypertrophy 
has widespread, whole body effects in vivo illustrating the importance of this 
signalling pathway. The identification of the first NO-independent effect of ADMA 
pathway leads to the possibility that ADMA may have a number of other actions that 
still to be discovered. 
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7.4 Circulating ADMA concentrations 
In many diseases associated with elevated ADMA concentrations it has been 
assumed that this is due to a dysregulation of DDAH activity. This is further 
supported by the fact that a number of human polymorphisms in DDAH1 have been 
identified and again associated with increased concentrations of circulating ADMA 
(Abhary et al., 2010; Caplin et al., 2010).  
In mice the link between DDAH1 dysregulation and ADMA concentrations was 
further established through the global deletion of DDAH1 which caused a significant 
increase in plasma ADMA (Hu et al., 2011), and in fact a 50% reduction in global 
DDAH1 activity is sufficient to alter ADMA (Leiper et al., 2007). However, here two 
mouse models of a tissue specific DDAH1 deletion did not alter circulating ADMA; 
when intracellular ADMA concentrations were elevated. Furthermore, deletion of 
DDAH1 in the either the kidney proximal tubule or in hepatocytes does not alter 
systemic ADMA levels (unpublished data). This was particularly surprising in 
hepatocytes due to the very high levels of DDAH1 expression within the liver (Tran et 
al, 2000) and the fact that it has previously been thought of as the major site of 
ADMA metabolism (Nijveldt et al., 2003; Siroen et al., 2005). In fact the only other 
knockout mouse to alter circulating concentrations of ADMA is the global AGXT2 
deletion (Caplin et al., 2012). Although genetically developed as a global knockout 
AGXT2 is only expressed in the kidney and therefore the loss of AGXT2-mediated 
ADMA metabolism in the medulla of the kidney seems to achieve what as of yet only 
a global deletion of DDAH1 can accomplish. 
The above data suggests that mice may handle ADMA clearance differently from 
previously thought and that not all tissues are equal when it comes to ADMA 
production or metabolism.  As of yet there are a range of tissues including skeletal 
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muscles and the lungs in which the extent of ADMA production and metabolism has 
not yet been established. Perhaps the most significant of these is the brain where 
DDAH1 expression has previously been shown to be very high (Tran et al., 2000). 
Furthermore, in the heterozygous global deletion of DDAH1 ADMA concentration in 
the brain was increased very significantly (Leiper et al., 2007). A synapsin cre driven 
neuronal specific DDAH1 deletion is currently being developed to determine whether 
the brain is indeed a major site of ADMA production and whether this specific 
deletion will alter systemic concentrations of ADMA.  
A second possibility is that ADMA production within single cell types or systems is 
not enough alone to alter the circulating concentration of ADMA but rather it is an 
additive effect of DDAH1 deletion in all tissues that causes the resultant increase in 
ADMA. Finally, the small increases in intracellular ADMA seen in these tissue 
specific DDAH1 knockouts may be modulated by an increase in DDAH2 or AGXT2. 
Although DDAH2 expression did not change in adipocytes this was not investigated 
in endothelial cells and AGXT2 was not assessed in either mice. The increase in 
their activity may keep global concentrations, which can have profound affects on 
blood pressure and vascular reactivity and therefore need to be carefully regulated, 
within healthy boundaries. As a result, only local changes in NO and ADMA 
signalling occur limiting the effect of DDAH1 dysregulation.  
 
7.5 Hypoxia 
Angiogenesis in adulthood is important in adipose expansion and revascularisation 
after injury and ischemia. The growth of new vessels is important in maintaining 
oxygen pressure within cells otherwise a fall in oxygen, known as hypoxia, triggers a 
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number of signalling pathways that are aimed at maintaining the energy balance of a 
cell but can have a wide range of detrimental effects.  
Deletion of DDAH1 in endothelial cells reduced adipose capillary density. This 
reduction in vessel growth is likely to cause hypoxia in DDAH1En-/- which could be 
confirmed by investigating HIF-1 signalling (Ye et al., 2007).  A down-regulation in 
DDAH1 expression was identified in DDAH1En-/- adipocytes again suggesting a 
hypoxic environment. Although adipocyte DDAH1 expression was lower in  
DDAH1En-/- mice compared to controls on a normal diet, DDAH1 expression in these 
mice after high fat feeding was not investigated and therefore it is unknown whether 
DDAH1 expression falls in obesity alone.  
Poor vessel growth is not the only cause of hypoxia in obese adipose tissue. As 
adipocytes become enlarged in obesity they can become up to 200μm in diameter; 
this is beyond the accepted distance that oxygen is capable of diffusing across and 
therefore parts of an adipocyte may be in a microscopic hypoxic environment 
(Brahimi-Horn and Pouyssegur, 2007; Skurk et al., 2007). Adipokine and cytokine 
secretion is known to be altered in adipocytes this large (Skurk et al., 2007); 
however, this also suggests that DDAH1 expression may be down-regulated in very 
large adipocytes due to the level of internal hypoxia. This may in part account for the 
increase in adipocyte ADMA concentrations in control mice which have been fed a 
high fat diet.  
The expression of DDAH1 in neither adipocytes nor endothelial cells has been 
investigated in human obesity. Endothelial dysfunction is known to occur in human 
obesity with a loss in NO signalling; however, the role of ADMA and DDAH1 in this 
endothelial dysfunction is unknown. Human adipose tissue in obesity is thought to be 
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hypoxic (Hosogai et al., 2007; Ye et al., 2007) and therefore it is possible that 
DDAH1 expression in these cells is reduced and therefore ADMA concentrations 
may be increased. Therefore an important next step in confirming the importance of 
ADMA in obesity is to assess these pathways in humans and determine whether 
adipocyte intracellular ADMA increases with an effect on mTOR signalling.  
Hypoxia occurs in other disease states and DDAH1 down-regulation has been 
demonstrated in ischemia and hypoxia-induced pulmonary hypertension; and over-
expression of the gene is thought to improve outcome (Jacobi et al., 2005; Millatt et 
al., 2003). This suggests that DDAH1 may be a good target to improve outcome in 
low oxygen environments where increased ADMA could have detrimental effects. 
However, designing a DDAH1 agonist has currently proved difficult as there is no 
known site for allosteric activation of the enzyme. Furthermore, when normal oxygen 
levels are re-established as in ischemia-reperfusion they are often associated with a 
detrimental increase in NO production by iNOS (Wildhirt et al., 1999). Here the 
presence of ADMA may be seen as positive by limiting the amount of NO produced.  
Therefore, increasing DDAH1 activity in hypoxia has to be balanced with appropriate 
levels of NO production.    
 
7.5.1 Visceral obesity in eNOS-/- 
 As discussed in the introduction eNOS dysfunction itself has been associated with 
visceral obesity and adipocyte hypertrophy (Nakata et al., 2008). This seems at odds 
to the discovery here that ADMA’s role in causing adipocyte hypertrophy in 3T3-L1 
cells was independent of NO inhibition.  
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Although the inhibition of NO in vivo is likely to inhibit mitochondrial biogenesis and 
beta-oxidation (Le Gouill et al., 2007; Nisoli et al., 2003) therefore reducing 
metabolism and increasing fat storage the major contributor to eNOS-/- obesity may 
be poor vascularisation in expanding adipose tissue. Nitric oxide is a known 
regulator of angiogenesis and eNOS-/- mice have significantly reduced capacity for 
vessel growth (Lee et al., 1999). A proposed mechanism by which ADMA causes 
adipocyte hypertrophy within eNOS-/- mice is shown in figure 7.2 below; poor 
vascularisation due to a NO-dependent loss of angiogenesis leads to hypoxic 
adipose tissue, here DDAH1 expression is down-regulated increasing adipocyte 
ADMA concentrations thereby upregulating mTOR expression and lipid synthesis.  
An important step in confirming the NO-independent action of ADMA and the role of 
hypoxia in adipocyte hypertrophy is to investigate eNOS-/- mice.  Investigating the 
epididymal fat pads of eNOS-/- mice would establish whether there is an increase in 
hypoxic signalling leading to decreased DDAH1 expression and increased ADMA 
production within adipocytes. Conservation of ADMA upregulation of mTOR and lipid 
synthesis in these ADMA rich adipocytes would suggest that the same mechanism 






Figure 7.2:  Proposed mechanism underlying NO-independent adipocyte 
hypertrophy in eNOS-/- mice. Deletion of eNOS restricts vessel growth within 
adipose tissue causing local hypoxia. Hypoxia is known to down-regulate DDAH1 
expression and therefore ADMA concentrations increase within adipocytes 




7.6 ADMA and mouse models of human disease 
Many human diseases have been associated with an increase in systemic ADMA 
concentrations, even if the disease itself occurs in a specific cell type or tissue. Here 
a model of obesity was studied, a disease in humans that has previously been 
related to plasma ADMA concentrations (Koc et al., 2010; McLaughlin et al., 2006). 
However, in mice with diet induced obesity, whether wildtype, DDAH1Ad-/- or 
DDAH1En-/-, no change in ADMA concentration was detected at the end of the study. 
This suggests that either the model doesn’t fully replicate obesity as seen in human 
subjects or that mice handle ADMA metabolism more efficiently that humans.  
Very few mouse studies have determined whether ADMA concentrations alter in a 
diseased state independent of genetic modification. Of the few studies that does 
investigate this is inflammation which appears to have a major impact on ADMA 
(Nandi et al., 2012; Scott et al., 2011; Sharma et al., 2010). Furthermore, ADMA is 
associated with markers of chronic inflammation in humans (van der Zwan et al., 
2011). Therefore a confounding factor in comparing human and mouse studies is 
that many clinical studies assess human individuals after the disease has reached a 
chronic stage often associated with an increased level of systemic inflammation. 
Obesity is an example of this as it is thought to propagate a state of long term low-
grade inflammation which may be a regulator of ADMA concentrations. However, 
although the mice on a high fat diet do have increased inflammation the duration of 
the model studied here cannot mimic chronic human inflammation. 
 Obesity and the metabolic syndrome is a lesser known risk factor for chronic kidney 
disease. Both the Framingham Offspring study and the Hypertension detection and 
Follow-Up programme found that being overweight or obese causes a 20% to 40% 
increase in the likelihood of developing chronic kidney disease (Fox et al., 2004; 
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Kramer et al., 2005). As methylarginines are excreted by the kidney, kidney disease 
is a known regulator of methylarginine concentrations (Vallance et al., 1992) and 
therefore if there is a shift towards poor kidney function in obese subjects the 
increase in plasma ADMA may in part be due to poor clearance or metabolism by 
the kidney rather that obesity itself. Mice are highly resistant to kidney disease 
maintaining normal levels of creatinine clearance even after a considerable portion of 
the kidneys have been removed; as a result mice may be more resistant to an 
increase in circulating methylarginines based upon a higher level of clearance 
through the kidney.   
Therefore, mouse models of disease should be considered as an early marker in 
disease development and used to investigate the cellular changes that occur early in 
a disease process that are unavailable in human studies. As a model of obesity 16 
weeks high fat feeding is sufficient to develop visceral obesity and to initiate 
macrophage infiltration and a small increase in cytokine production. However, to 
more closely model human obesity and determine whether plasma ADMA in mice 
alters a study of longer duration would be needed.   
 
7.7 Project Summary 
This thesis aimed to address the unknown action of the NOS inhibitor ADMA and its 
metabolising enzyme DDAH1 in the normal function of adipocytes and adipose 
tissue. As elevated plasma ADMA has been associated with obesity this thesis also 
aimed to ascertain how increased ADMA concentrations may be detrimental in the 
development of obesity. 
Initial studies were carried out in the 3T3-L1 cell line where it was established for the 
first time that both isoforms of DDAH are expressed and that this cell type produces 
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ADMA. Treatment of fully differentiated 3T3-L1 cells with ADMA resulted in 
adipocyte hypertrophy which was driven by the mTOR signalling pathway through an 
increased expression of lipid synthesis genes. Importantly the upregulation of this 
pathway could not be achieved by NOS inhibitors suggesting that ADMA has actions 
independent of NO inhibition. 
To determine whether the action of ADMA on adipocyte hypertrophy was conserved 
in vivo a novel adipocyte specific DDAH1 knockout mouse was developed where 
intracellular ADMA concentrations were raised. These mice developed visceral 
obesity with enlarged adipocytes compared to control mice. Within these primary 
adipocytes the upregulation of mTOR was conserved confirming its importance in 
vivo. 
To investigate DDAH1 in adipose vascularisation a further mouse model was 
developed with the specific deletion of DDAH1 in endothelial cells. This model 
confirmed the importance of DDAH1 and ADMA in angiogenesis by limiting adipose 
expansion in obesity. However, this model also highlighted the importance of 
hypoxia in the regulation of DDAH1 and adipocyte function.  
In summary, DDAH1 and particularly ADMA are important modulators of adipocyte 
function that can occur independently to ADMA’s inhibition of nitric oxide production. 
A better understanding of how ADMA concentrations become elevated in obesity 
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